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A B S T R A C T
Background
Bipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes
of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the initial aim
of rapid control of agitation, aggression and dangerous behaviour. Aripiprazole, an atypical antipsychotic, is used in the treatment of
mania both as monotherapy and combined with other medicines. The British Association of Psychopharmacology guidelines report
that, in monotherapy placebo-controlled trials, the atypical antipsychotics, including aripiprazole, have been shown to be effective for
acute manic or mixed episodes.
Objectives
To assess the efficacy and tolerability of aripiprazole alone or in combination with other antimanic drug treatments, compared with
placebo and other drug treatments, in alleviating acute symptoms of manic or mixed episodes. Other objectives include reviewing
the acceptability of treatment with aripiprazole, investigating the adverse effects of aripiprazole treatment, and determining overall
mortality rates among those receiving aripiprazole treatment.
Search methods
The Cochrane Depression, Anxiety and Neurosis Group’s Specialised Register (CCDANCTR-Studies and CCDANCTR-References)
was searched, all years to 31st July 2013. This register contains relevant randomised controlled trials from: The Cochrane Library (all
years), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date). We also searched Bristol-Myers Squibb
clinical trials register, the World Health Organization (WHO) trials portal (ICTRP) and ClinicalTrials.gov (to August 2013).
Selection criteria
Randomised trials comparing aripiprazole versus placebo or other drugs in the treatment of acute manic or mixed episodes.
Data collection and analysis
Two review authors independently extracted data, including adverse effect data, from trial reports and assessed bias. The drug manu-
facturer or the trial authors were contacted for missing data.
1Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Ten studies (3340 participants) were included in the review. Seven studies compared aripiprazole monotherapy versus placebo (2239
participants); two of these included a third comparison arm-one study used lithium (485 participants) and the other used haloperidol
(480 participants). Two studies compared aripiprazole as an adjunctive treatment to valproate or lithium versus placebo as an adjunctive
treatment (754 participants), and one study compared aripiprazole versus haloperidol (347 participants). The overall risk of bias was
unclear. A high dropout rate from most trials (> 20% for each intervention in eight of the trials) may have affected the estimates
of relative efficacy. Evidence shows that aripiprazole was more effective than placebo in reducing manic symptoms in adults and
children/adolescents at three and four weeks but not at six weeks (Young Mania Rating Scale (YMRS); mean difference (MD) at three
weeks (random effects) -3.66, 95% confidence interval (CI) -5.82 to -2.05; six studies; N = 1819, moderate quality evidence) - a
modest difference. Aripiprazole was compared with other drug treatments in three studies in adults-lithium was used in one study and
haloperidol in two studies. No statistically significant differences between aripiprazole and other drug treatments in reducing manic
symptoms were noted at three weeks (YMRS MD at three weeks (random effects) 0.07, 95% CI -1.24 to 1.37; three studies; N =
972, moderate quality evidence) or at any other time point up to and including 12 weeks. Compared with placebo, aripiprazole caused
more movement disorders, as measured on the Simpson Angus Scale (SAS), on the Barnes Akathisia Scale (BAS) and by participant-
reported akathisia (high quality evidence), with more people requiring treatment with anticholinergic medication (risk ratios (random
effects) 3.28, 95% CI 1.82 to 5.91; two studies; N = 730, high quality evidence). Aripiprazole also led to more gastrointestinal
disturbances (nausea (high quality evidence), and constipation) and caused more children/adolescents to have a prolactin level that
fell below the lower limit of normal. Significant heterogeneity was present in the meta-analysis of movement disorders associated with
aripiprazole and other treatments and was most likely due to the different side effect profiles of lithium and haloperidol. At the three-
week time point, meta-analysis was not possible because of lack of data; however, at 12 weeks, haloperidol resulted in significantly
more movement disorders than aripiprazole, as measured on the SAS, the BAS and the Abnormal Involuntary Movement Scale (AIMS)
and by participant-reported akathisia. By 12 weeks, investigators reported no difference between aripiprazole and lithium (SAS, BAS,
AIMS), except in terms of participant-reported akathisia (RR 2.97, 95% CI 1.37 to 6.43; one study; N = 313).
Authors’ conclusions
Aripiprazole is an effective treatment for mania in a population that includes adults, children and adolescents, although its use leads to
gastrointestinal disturbances and movement disorders. Comparative trials with medicines other than haloperidol and lithium are few,
so the precise place of aripiprazole in therapy remains unclear.
P L A I N L A N G U A G E S U M M A R Y
Aripiprazole alone or in combination with other drugs for treating the acute mania phase of bipolar disorder
Bipolar disorder is a mental disorder that is seen as periods of high mood called mania, or hypomania if less severe, and periods of low
mood (depression).
Medication is the main treatment for mania, with the first aim to decrease agitation, aggression and dangerous behaviour.
Antipsychotics and other antimanic medicines are included in guidelines for treating mania. This review considers the antipsychotic,
aripiprazole, and assesses how effective it is in the treatment of acute mania. It also examines the side effects of aripiprazole and discusses
whether people find aripiprazole to be an acceptable treatment for themselves.
Ten studies are included (3340 participants). Most studies compared aripiprazole versus placebo, but some researchers compared
aripiprazole versus haloperidol (two studies) and versus lithium (one study). Two studies examined the effect of adding aripiprazole to
another treatment (valproate or lithium) and compared this combination versus placebo combined with these other treatments. We
assessed the overall risk of bias in the ten studies as unclear.
The main measure of effect was the mean change on the Young Mania Rating Scale from the start to the end of the trial; this tool is used
by clinicians to assess the severity of mania. After three weeks of treatment, aripiprazole was better than placebo at reducing the severity
of mania when used on its own or when added to other mood stabilisers. The effect was modest. However, aripiprazole caused more
inner restlessness (akathisia), nausea, and constipation than placebo. Aripiprazole was similarly effective in reducing the symptoms of
mania when compared with other drug treatments (haloperidol and lithium). Aripiprazole caused fewer movement disorders and less
raised prolactin (a hormone secreted by the pituitary gland) than haloperidol. People taking aripiprazole were more likely to remain on
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treatment than those taking haloperidol but were no more or less likely than those taking placebo or lithium. The main reason for the
difference in dropouts between aripiprazole and haloperidol groups was the adverse effects associated with haloperidol.
In summary, aripiprazole is an effective treatment for mania when compared with placebo. This finding is based on studies that included
mixed populations (i.e. children, adolescents and adults). For the adult population, studies have directly compared aripiprazole versus
haloperidol, lithium and placebo, but evidence obtained for treatment of the child and adolescent population is available only from
placebo-controlled studies. Given the lack of evidence obtained by comparing aripiprazole versus other drugs, its exact place in therapy
is unclear. Further studies focused on particular populations are needed to determine whether this treatment is equally effective in
different age groups.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Aripiprazole versus placebo for an acute manic or mixed episode
Patient or population: patients with an acute manic or mixed episode
Settings: inpatients and outpatients
Intervention: aripiprazole
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Aripiprazole versus
placebo
Mean change in YMRS
from baseline at three
weeks
Young Mania Rating
Scale (YMRS): an 11-
item questionnaire to as-
sess the severity of
core symptoms of mania.
Scale from 0 to 60
Follow-up: three weeks
Mean change in YMRS
from baseline at three
weeks ranged across
control groups from
-3.4 to -10.12 points
Mean change in YMRS
from baseline at three
weeks in the intervention
groups was
3.66 lower
(5.28 to 2.05 lower)
1819
(six studies)
⊕⊕⊕©
moderate1
≥ 50% decrease in total
YMRS from baseline at
three weeks
Young Mania Rating
Scale (as above)
Follow-up: three weeks
Study population RR 1.70
(1.23 to 2.34)
1230
(four studies)
⊕⊕⊕©
moderate1
263 per 1000 446 per 1000
(323 to 614)
Moderate
243 per 1000 413 per 1000
(299 to 569)
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Numbers completing
double-blind treatment
Number of participants
Follow-up: three to 12
weeks
Study population RR 1.03
(0.95 to 1.12)
2216
(eight studies)
⊕⊕⊕©
moderate2
610 per 1000 628 per 1000
(579 to 683)
Moderate
744 per 1000 766 per 1000
(707 to 833)
Requirement for anti-
cholinergics
number of participants re-
quiring medication for ex-
trapyramidal side effects
Follow-up: four to six
weeks
Study population RR 3.28
(1.82 to 5.91)
730
(two studies)
⊕⊕⊕⊕
high
46 per 1000 152 per 1000
(85 to 274)
Moderate
40 per 1000 131 per 1000
(73 to 236)
Akathisia
Participant report
Follow-up: three to 12
weeks
Study population RR 3.16
(2.25 to 4.43)
2305
(seven studies)
⊕⊕⊕⊕
high
41 per 1000 128 per 1000
(91 to 180)
Moderate
22 per 1000 70 per 1000
(50 to 97)
Nausea
Participant report
Follow-up: three to 12
weeks
Study population RR 1.50
(1.2 to 1.88)
2305
(seven studies)
⊕⊕⊕⊕
high
101 per 1000 152 per 1000
(122 to 191)
Moderate
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118 per 1000 177 per 1000
(142 to 222)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Not all the study confidence intervals overlapped, moderately high I2 value, and low P value. Heterogeneity may be explained by
differences in study design-variable-dose aripiprazole versus fixed-dose aripiprazole.
2High I2 value, low P value. Heterogeneity might be explained by differences in study design-one study discontinued non-responders
from the trial at the end of week two and offered open-label aripiprazole, excluding them from the analysis.
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B A C K G R O U N D
Description of the condition
Bipolar disorder is a mental disorder characterised by episodes of
elevated or irritable mood (manic or hypomanic episodes) and
episodes of low mood and loss of energy (depressive episodes).
Depressive and manic symptoms may occur at the same time in
some people (mixed episode). Bipolar disorder can be divided into
different forms, including bipolar I disorder and bipolar II dis-
order. Bipolar I disorder is characterised by manic and depres-
sive episodes, and bipolar II disorder by hypomanic and depres-
sive episodes. Psychotic symptoms, such as delusions or hallucina-
tions, can occur in mania and often are considered a severity mea-
sure rather than evidence of a comorbid psychotic disorder. Some
authorities do not accept this position, and arguably non-mood
congruent psychotic symptoms should be examined separately, al-
though they occur in a minority of patients (EMEA 2001). Those
people who meet the diagnostic criteria for bipolar disorder and
schizophrenia at the same time are given a diagnosis of schizoaf-
fective disorder.
The lifetime prevalence of mania in the general population is ap-
proximately 1% (Waraich 2004). The costs of manic episodes are
high both for patients and for health services. For patients, in ad-
dition to the period of acute illness, manic episodes often leave
an aftermath of psychological, social and financial problems (APA
2002; de Zelicourt 2003; Olie 2002). Direct medical costs are
high because admission to a psychiatric unit is often necessary.
Description of the intervention
The overall objective when treating patients with acute mania is
to control symptoms such that psychosocial functioning returns
to normal; the initial aim is to achieve rapid control of agitation,
aggression and dangerous behaviour. Drug treatment is the first-
line treatment for acute mania. Several different drugs are used as
monotherapy or in combination. Antipsychotics have been used
for many years, particularly when mania is accompanied by psy-
chosis. Evidence-based guidelines for the treatment of bipolar dis-
order provided by the British Association for Psychopharmacology
(BAP) recommend that for severe manic or mixed episodes, an
oral antipsychotic or valproate should be initiated because of its
rapid antimanic effect, and that atypical antipsychotics should be
considered because of “their generally more favourable short term
adverse effect profile, especially in relation to motor side effects
and the evidence of their efficacy as anti-manic agents” (Goodwin
2009). When symptoms are inadequately controlled with an op-
timised dose of a first-line agent and/or mania is very severe, com-
bination treatment is recommended, such as that provided when
lithium or valproate is combined with an antipsychotic. Atypical
antipsychotics are similarly recommended as appropriate first-line
treatment by several other recent guidelines (Nivoli 2012).
All antimanic drug treatments are potentially associated with
adverse effects. The adverse effect profiles of these agents dif-
fer, and this is an important factor for the clinician to con-
sider when selecting acute treatment, in particular when assess-
ing the acceptability of long-term treatment. Antipsychotic med-
ications, also sometimes known as neuroleptics or major tran-
quillisers, are associated with a wide range of potential adverse
effects. These include extrapyramidal side effects (EPS) (parkin-
sonian tremor, dystonia, akathisia and tardive dyskinesia), car-
diovascular problems (hypotension, tachycardia, arrhythmias and
other electrocardiographic (ECG) changes), anticholinergic effects
(dry mouth, blurred vision), endocrine changes, including eleva-
tions in serum prolactin levels (which can lead to sexual dysfunc-
tion, gynaecomastia, hypogonadism and amenorrhoea) and ab-
normalities of lipid and glucose metabolism. Rare, but potentially
life-threatening, effects include neutropenia and neuroleptic ma-
lignant syndrome. The newer atypical antipsychotics are associ-
ated with reduced frequency of EPS, although their use may lead
to increased weight gain and additional metabolic complications
(Geddes 2000).
Lithium has several common adverse effects, including tremor,
thirst and weight gain. Other, less frequently occurring, adverse
effects include hypothyroidism, hypercalcaemia and other elec-
trolyte disturbances (Dunner 2000). Lithium has a narrow thera-
peutic index (Keck 2002), which means that it has the potential
to produce toxicity at doses not much greater than those required
for a therapeutic effect, making regular plasma lithium level mon-
itoring necessary.
Valproate is associated with adverse effects, including gastroin-
testinal disturbances, tremor, sedation and weight gain and, less
commonly, with platelet disorders, pancreatitis and liver toxicity
(APA 2002; Perucca 2002).
The risk of depression following mania is widely acknowledged. It
has been suggested that this risk may be increased by the use of an-
tipsychotics (Segal 2000; Yatham 2002), but it is also a component
of the natural history of the disorder. Indeed effective treatment of
mania rather than the antipsychotic may be the cause of a subse-
quent depressive phase. In practice, these possible mechanisms are
difficult to disentangle, and it has not yet been established whether
any drugs used in the treatment of mania increase the likelihood
of depression.
How the intervention might work
It has been proposed that dopamine abnormalities are involved
in the hyperactivity associated with severe stages of mania (Manji
2000). Aripiprazole is an antipsychotic drug that is a partial agonist
atD2 receptors (Taylor 2003). The intrinsic activity of aripiprazole
atD2 receptors is less than the activity of endogenous dopamine, so
in the presence of an excess of endogenous dopamine, aripiprazole
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acts as an antagonist (Argo 2004). Because of its intrinsic proper-
ties, when all D2 receptors are occupied by aripiprazole, the effect
is about a 30% reduction in receptor-mediated activity (Taylor
2003). In low dopamine states, aripiprazole has been shown to
act as an agonist, causing increases in dopaminergic transmission
(Grunder 2003). Aripiprazole is also a potent antagonist at 5HT2A
and is a partial agonist at 5HT1A receptors (Jordan 2002), which
may offer protection against EPS (Taylor 2003). All other cur-
rently available antipsychotics are antagonists at dopamine D2 re-
ceptors. Occupancy of typical antipsychotic drugs at striatal D2
receptors of between 60% and 80% has been suggested as the
optimum for treatment response, with occupancy above 80% as-
sociated with EPS. The same is true for most of the atypical an-
tipsychotics (Grunder 2003). In contrast to other antipsychotics,
clinically effective doses of aripiprazole occupy about 80% to 95%
of striatal dopamine D2 receptors (Grunder 2003), but at these
levels of occupancy, the incidence of EPS is no greater than with
placebo (Grunder 2003; Taylor 2003). It has been suggested that
aripiprazole has a favourable side effect profile. Rates of EPS were
similar to those seen with placebo (Marder 2003). It has also been
shown that aripiprazole is not associatedwith hyperprolactinaemia
(Carson 2002) or QTc prolongation (Stock 2002). However, it
has been associated with minimal weight increases similar to those
seen with haloperidol (Jody 2002) and may be associated in the
short term with nausea, vomiting, dyspepsia, insomnia, somno-
lence, constipation, headache and akathisia (Taylor 2003).
Why it is important to do this review
The BAP guidelines report that, in monotherapy placebo-con-
trolled trials, the atypical antipsychotics, including aripiprazole,
have been shown to be effective in the treatment of acute manic
or mixed episodes (Goodwin 2009). A systematic review of 13
randomised placebo-controlled trials (including two of aripipra-
zole) concluded that antipsychotics andmood stabilisers are signif-
icantly more effective than placebo in treating acute mania (Smith
2007). Two recent reviews of aripiprazole in bipolar disorder con-
cluded that aripiprazole is clinically effective in managing acute
mania and in preventing relapse (De Fazio 2010; Fountoulakis
2009). A recent meta-analysis (Fountoulakis 2011) of aripipra-
zole monotherapy that included data from six trials supports the
usefulness of aripiprazole, although the effect sizes reported were
not impressive, and the meta-analysis was not performed in accor-
dance with the methodology of The Cochrane Library.
This systematic review assesses evidence obtained for the efficacy
and tolerability of aripiprazole, given alone or in combination
with other antimanic drug treatments, comparedwith placebo and
other drug treatments (excluding treatments included in separate
reviews of mood stabilisers), in the treatment of acute manic or
mixed episodes. It will be added to the portfolio of Cochrane re-
views on antipsychotic drugs (haloperidol (Cipriani 2006); olan-
zapine (Rendell 2003); and risperidone (Rendell 2006)) for acute
mania.
O B J E C T I V E S
To assess the efficacy and tolerability of aripiprazole alone or in
combination with other antimanic drug treatments, compared
with placebo and other drug treatments, in alleviating acute symp-
toms of manic ormixed episodes. Other objectives include review-
ing the acceptability of treatment with aripiprazole, investigating
the adverse effects of aripiprazole treatment, anddetermining over-
all mortality rates among those receiving aripiprazole treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials comparing aripiprazole alone or in
combination with other antimanic drug treatments, placebo or
other drug treatments. Trials thatwere not stated to be randomised,
or for which the allocation method was unknown but was not
strictly random (e.g. quasi-randomised), or that were cluster-ran-
domised were not included. It was planned that for trials that used
a cross-over design, only results from the first randomisation pe-
riod would be considered; however, no cross-over trials were iden-
tified.
Types of participants
Patients of both sexes and all ages with a diagnosis of bipolar or
schizoaffective disorder, manic or mixed episode, however diag-
nosed, with or without psychotic symptoms.
Diagnostic classifications fromDiagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) (APA 1994) or Inter-
national Classification of Diseases, Tenth Revision (ICD-10) (WHO
1992) criteria, as well as from ICD-9, DSM-III/DSM-IIIRor other
diagnostic systems, were considered.
Studies of acute treatment with aripiprazole that recruited patients
with diagnoses other than bipolar disorder or schizoaffective dis-
order and did not stratify randomisation according to diagnosis
were not included in this review.
Types of interventions
Experimental intervention
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Aripiprazole as monotherapy or added to other antimanic agents
(e.g. lithium, valproate).
Comparator intervention
1. Placebo
2. Other drug treatment (e.g. antipsychotics, anticonvulsants,
lithium)
Types of outcome measures
Primary outcomes
Efficacy in treatment of manic or mixed episode
The primary measure of efficacy for this review is change in manic
symptom ratings at three weeks, as change data are more clinically
interpretable and are less likely to be skewed than total scores. The
Young Mania Rating Scale (YMRS) was used.
Secondary outcomes
1. Efficacy
As measured by:
1. achievement of response (defined as a decrease in score on
the YMRS of ≥ 50% from baseline) or remission of manic
symptoms (defined as a YMRS score of ≤ 12);
2. change in depression rating scales (e.g. Hamilton
Depression Rating Scale, Montgomery-Åsberg Depression
Rating Scale) and achievement of response or remission of
depressive symptoms in all participants;
3. change in psychotic symptom rating scales (e.g. Brief
Psychiatric Rating Scale (BPRS));
4. any use of rescue medication;
5. time to onset of symptom reduction (a statistically
significant improvement on the symptom rating scale used) or
response; and
6. requirement for inpatient care (e.g. length of stay).
2.General health and social functioning
As measured by:
1. rating scales of severity of psychiatric symptoms (e.g.
BPRS);
2. rating scales of functioning (e.g. Global Assessment of
Functioning (GAF)); and
3. quality of life scales (e.g. 36-item short form health survey
(SF-36)).
3. Acceptability of treatment
As measured by completion of the trial.
4. Specific adverse effects
As measured by participants experiencing:
1. extrapyramidal side effects-parkinsonian symptoms,
dystonia, akathisia, tardive dyskinesia (e.g. Abnormal
Involuntary Movement Scale, Dyskinesia Identification System:
Condensed User’s Scale, Simpson-Angus Scale, Barnes Akathisia
Rating Scale);
2. cardiovascular side effects-hypotension (blood pressure
measurement), tachycardia (pulse measurement), ECG changes
(ECG measurements);
3. treatment-emergent depression (Hamilton Depression
Rating Scale);
4. weight gain;
5. sedation;
6. GI disturbance (e.g. nausea, vomiting, constipation); or
7. other adverse effects.
5. Mortality
As measured by the number of deaths that occurred during the
study.
Timing of outcome assessment
Outcomes were measured at four days, three weeks, four weeks,
six weeks and 12 weeks.
Inclusion of the four-day outcome assessment point was a post
hoc decision made so that review authors could examine whether
there was an early treatment effect.
Search methods for identification of studies
CCDAN’s Specialized Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN) maintains two clinical trial registers at its editorial base in
Bristol, UK: a references register and a studies-based register. The
CCDANCTR-References Register contains over 33,000 reports
of randomised controlled trials in depression, anxiety and neu-
rosis. Approximately 65% of these references have been tagged
to individual, coded trials. The coded trials are held in the CC-
DANCTR-Studies Register, and records are linked between the
two registers through the use of unique Study ID tags. Coding of
trials is based on the EU-Psi Coding Manual. Please contact the
CCDANTrials SearchCo-ordinator for further details. Reports of
trials for inclusion in theGroup’s registers are collated from routine
(weekly), generic searches ofMEDLINE (1950 to date), EMBASE
(1970 to date) and PsycINFO (1960 to date); quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL);
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and review-specific searches of additional databases. Reports of
trials are also sourced from international trials registers (ICTRP),
ClinicalTrials.gov, drug companies, the handsearching of key jour-
nals, conference proceedings andother (non-Cochrane) systematic
reviews and meta-analyses. Details of CCDAN’s generic search
strategies can be found on the Group’s website.
Electronic searches
TheCCDANCTR (Studies and References Register) was searched
all years to 31 July 2013, using the termAripiprazole (intervention
alone).
The review authors supplemented the search of the CCDANCTR
by performing the following searches:
MEDLINE (1951 to July 2013)-see Appendix 1 for search strat-
egy.
EMBASE (1974 to July 2013)-see Appendix 2 for search strategy.
PsycINFO (1887 to July 2013)-see Appendix 3 for search strategy.
CINAHL (1982 to July 2013)-see Appendix 4 for search strategy.
No language restrictions were applied within the limitations of the
search tools.
Searching other resources
The WHO trials portal (ICTRP) and ClinicalTrials.gov was
searched using terms for mania and aripiprazole, all years to Au-
gust 2013.
Bristol-Myers Squibb clinical trials resultswebsite (BMS 2012)was
also searched to February 2012 to identify all trials investigating
the use of Abilify® (aripiprazole).
Reference checking
We checked reference lists of all identified randomised controlled
trials, other relevant papers and major textbooks of affective dis-
order written in the English language.
Personal communication
We contacted the authors of three papers to ask for additional
information relevant to the review. Bristol-Myers Squibb and Ot-
suka Pharmaceuticals, the pharmaceutical companies that market
aripiprazole, were asked to provide relevant published and unpub-
lished data.
Data collection and analysis
Selection of studies
Two review authors (RB and MJT) examined the titles and ab-
stracts of citations obtained from the searches. Any article indicat-
ing that a relevant randomised controlled trial may be described
was retrieved for assessment. Obviously irrelevant articles were dis-
carded.
Retrieved articles were assessed independently by the two review
authors for inclusion, according to the previously defined inclusion
criteria.
Data extraction and management
Two review authors (RB and MJT) independently extracted from
all included studies data concerning participant characteristics, in-
tervention details (including whether the study was of discontin-
uation design) and outcome measures. Subgroup analyses were
recorded in cases where the subgroups were defined a priori. Any
disagreements were resolved by consensus discussions with a third
member of the review team.
Main comparisons
1. Aripiprazole (as monotherapy or as add-on treatment to other
antimanic agents) versus placebo. (A post hoc decision was made
to stratify the trials by aripiprazole dosage.)
2. Aripiprazole (as monotherapy or as add-on treatment to other
antimanic agents) versus other drug treatment. (A post hoc de-
cision was made to stratify the trials by three main comparator
groups-antipsychotics, mood stabilisers and lithium.)
Assessment of risk of bias in included studies
Two review authors (RB and MJT) assessed risk of bias according
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and a judgement was assigned to each trial of low,
high or unclear risk.
The following six domains were used to assess bias: selection bias
(random sequence generation and allocation concealment), per-
formance bias (blinding of participants and personnel), detection
bias (blinding of outcome assessment), attrition bias (incomplete
outcome data), reporting bias (selective reporting) and any other
biases that might be present (particularly as most of the trials were
sponsored by a drug company).
Measures of treatment effect
One review author (RB) entered data into Review Manager 5
software. Intention-to-treat (ITT) data were used when available.
Analysis of continuous data
1. For continuously distributed outcomes, the mean difference
or the standardised mean difference (when different
measurement scales were used) was calculated as appropriate
using a fixed-effect model and a random-effects model.
2. When standard deviations were not reported and could not
be calculated from available data, we asked study authors or
Bristol-Myers Squibb to supply the data.
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3. We anticipated that in some studies, to do an ITT analysis,
the method of last observation carried forward (LOCF) would be
used. As with all methods of imputation used to deal with
missing data, LOCF introduces uncertainty about the reliability
of the results. When LOCF data were used in the analysis, we
have indicated this in the review.
Analysis of dichotomous data
For binary efficacy outcomes, risk ratios (with 95% confidence
intervals) were calculated using a fixed-effectmodel and a random-
effects model.
Unit of analysis issues
Studies with multiple treatment groups
For studies with multiple intervention groups, we split the shared
comparison group into two or more groups of a smaller sample
size. The smaller comparison groupswere then comparedwith two
or more intervention groups. For dichotomous outcomes, both
the numbers of events and the total numbers of participants were
divided up, but for continuous outcomes, only the total numbers
of participants were divided, and the means and the standard de-
viations remained the same. Selection of this approach allowed
for approximate investigation of heterogeneity across intervention
arms (Higgins 2011).
Cross-over studies
In future updates, if cross-over trials are identified, we will use
only data from the first phase of the trial. This will eliminate any
concerns about the risk of a carry-over effect, which is seen when
an effect from treatment given during the first phase is carried over
into the second phase despite the use of a washout period.
Dealing with missing data
When ITT data were not available, endpoint data for trial com-
pleters were used.
When dichotomous data were missing, we assumed that the neg-
ative outcome was experienced at the end of the trial (e.g. no re-
sponse).
Assessment of heterogeneity
We assessed heterogeneity between studies using the Chi2 test
(with a P value of less than or equal to 0.1 taken to indicate
heterogeneity). We also examined the I2 value using as a guide the
following overlapping bands provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: may represent considerable heterogeneity.
When significant heterogeneity was identified, the reasons for het-
erogeneity were explored but were interpreted cautiously, as stud-
ies differ in many ways, and it may be incorrect to attribute a dif-
ference in results to any single factor.
Assessment of reporting biases
As only 10 studies were included in the meta-analysis, we did not
test for funnel plot asymmetry because when so few studies are
included, the power of the test is too low to distinguish chance
from real asymmetry (Higgins 2011).
Data synthesis
In addition to a random-effects model, a fixed-effect analysis was
routinely performed on our primary analyses to investigate the
effect of these two statistical methods on the estimates calculated.
Random-effects analyses (and fixed-effect analyses, when used) are
presented within the text of the effects of interventions section.
A large number of analyses were included. As 5% of analyses will
be significant by chance, with a large number of analyses in the
review it is likely that some results were statistically significant
purely by chance. For this reason, the analyses were divided into
those that were the main analyses important for answering our
main review question and all others, which were considered as
exploratory analyses.
Subgroup analysis and investigation of heterogeneity
Data were insufficient for performance of subgroup analyses to as-
sess whether participants with psychotic mania responded differ-
ently to aripiprazole than participants with non-psychotic mania.
Sensitivity analysis
If the proportion of participants withdrawing from treatment was
substantial (> 20%), we planned to perform sensitivity analyses to
investigate the effects of the possible different outcomes of those
participants who withdrew in each group. However, this was not
possible.
Summary of findings table
This review addresses more than one major comparison; therefore
separate Summary of findings tables were prepared for each of
the two comparisons using GRADE profiler. The range, which
consisted of the highest and the lowest estimate of scores in the
control groups, was used as the source of the assumed risk scores.
The GRADE framework was used for assessment of the quality of
evidence.
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R E S U L T S
Description of studies
Results of the search
The search of electronic databases produced the following hits:
CCDANCTR-studies: 22 studies (44 references); CCDANCTR-
references: 105; BMS: 63; ICTRP: 12; EMBASE: 1984; MED-
LINE: 423; PsychINFO: 1510; CINAHL: 304. Examination of
titles and abstracts led to the identification of 19 studies of arip-
iprazole used for the treatment of acute mania (see PRISMA di-
agram, Figure 1). After obtaining 12 references in published full
text, three as clinical report synopses and four as reports on the
international clinical trials registry portal (ICTRP), we excluded
eight studies (see Excluded studies for details).
12Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. PRISMA diagram
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The remaining 11 studies met our inclusion criteria. Nine were
published randomised controlled trials, and some had been pre-
sented at conferences. The tenth study was an unpublished study
that was originally identified from the text of one of the pub-
lished studies. Information and data for this study (protocol
CN138-007) were kindly supplied by Bristol-Myers Squibb/Ot-
suka Pharmaceuticals. In 2010, some details from this study were
published (ElMallakh 2010); it primarily focuses on post hoc anal-
yses of subpopulations.We refer to protocol CN138-007 through-
out. The 11th study was a report that was found on the ICTRP
website.
Additional data for some of the published studies were requested
and received from Bristol-Myers Squibb. An author of one of the
manufacturer-sponsored studies (Sachs 2006) and an author of
the independently conducted study (Tramontina 2009) kindly
supplied us with additional data. Additional data were requested
from the authors of one of the published studies (Kanba 2012)
and from the sponsor, Otsuka Pharmaceuticals. Until we receive
these data, the study remains as one awaiting classification, and it
has not been included in the meta-analysis.
Included studies
In total, we included 10 studies in the review (see Characteristics
of included studies).
Design
All of the included studies were double-blind randomised con-
trolled trials (RCTs). Nine of the ten studies were company spon-
sored. The duration of the studies ranged from three weeks to 12
weeks.
Sample sizes
The total number of participants from these 10 studies was 3340
(347 (Vieta 2005), 272 (Sachs 2006), 262 (Keck 2003), 480 (Keck
2009), 384 (Vieta 2008), 485 (Young 2009), 43 (Tramontina
2009), 296 (Findling 2009), 401 (protocol CN138-007) and 370
(NCT00665366)).
Setting
Participants in most of the adult studies were treated in hospital
with the requirement that they remained in hospital for at least
the first two weeks (CN138-007; Keck 2003; Keck 2009; Sachs
2006; Young 2009). At the end of week two, treatment could
be continued on an outpatient basis provided that the Clinical
Global Impression-Bipolar Disorder (CGI-BP) severity (mania)
score was ≤ 3 and the CGI-BP improvement (mania) score was
≤ 2. One study allowed participants to be treated as inpatients
or as outpatients (Vieta 2005). The precise setting is unclear in
Vieta 2008; however, patients were not enrolled if they had been
in hospital for their current episode of mania for longer than three
weeks. The precise setting is also unclear in NCT00665366. One
of the studies in children/adolescents included outpatients and
hospitalised and partially hospitalised patients (Findling 2009);
the other (Tramontina 2009) included those who were treated as
outpatients.
Except for one small study conducted at a single centre in Brazil
(Tramontina 2009), all studies were multicentre studies. Four re-
cruited participants from US centres-29, 38, 49 and 59 centres,
respectively (Findling 2009; Keck 2003; Keck 2009; Sachs 2006);
two recruited from 76 and 59 international centres, respectively
(Vieta 2005; Young 2009); one recruited from 56 centres in the
United States, Argentina andMexico (protocol CN138-007); one
recruited from 73 centres in Europe, South Africa and Russia
(NCT00665366); and one was stated as multicentre (Vieta 2008)
with no further details included.
Participants
Eight studies were conducted in adults, and twowere conducted in
children/adolescents (Findling 2009; Tramontina 2009). A fairly
even split ofmales and femaleswas described inmost of the studies.
In the adult studies, participants had amean age of late 30s to early
40s, and in the child/adolescent studies, mean ages were around
12 to 13.
In nine studies, DSM-IV criteria were used to diagnose bipolar
I disorder, manic or mixed episode. The report on the ICTRP
website for NCT00665366 provides no details about which di-
agnostic criteria were used. With the exception of two studies
(NCT00665366; Vieta 2008), all participants were required to
have a YMRS ≥ 20 at randomisation. In NCT00665366 and
Vieta 2008, patients were included if they had a YMRS total score
of ≥ 16. Four of the studies in adults specified that the current
episode of mania must have been no longer than four weeks in
duration, and two studies excluded patients with episodes requir-
ing hospitalisation for longer than three weeks.
Those with significant risk of suicide were stated as having been
excluded from the studies, as were those with a substance use dis-
order. Full exclusion criteria were specified in each of the published
studies.
Interventions
Seven RCTs compare aripiprazole monotherapy versus placebo
(CN138-007; Findling 2009; Keck 2003; Keck 2009; Sachs 2006;
Tramontina 2009; Young 2009). Twoof these studies also included
additional active comparator arms of lithium (Young 2009) and
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haloperidol (Keck 2009), and two others were fixed-dose studies-
onewith doses of aripiprazole of 10mgand30mg (Findling 2009),
and the other with doses of 15 mg and 30 mg (CN138-007).
One study compared aripiprazole monotherapy versus haloperidol
monotherapy (Vieta 2005), and two other studies used aripipra-
zole or placebo as adjunctive treatment with valproate or lithium
(NCT00665366; Vieta 2008).
Benzodiazepine use was allowed in seven studies. The following
schedule was used in three studies (CN138-007; Keck 2003; Sachs
2006): lorazepam (or equivalent) only on days one to four (≤ 6
mg/d), five to seven (≤ 4 mg/d) and eight to 10 (≤ 2 mg/d).
Similar dose-tapering regimens were used in Keck 2009 (days one
to four ≤ 4 mg/d, days five to 10 ≤ 2 mg/d, days 11 to 14 ≤ 1
mg/d) and in Young 2009 (tapering from ≤ 4 mg/d at days one
to four to 0 mg/d at day 15). In Vieta 2008, during the double-
blind phase, lorazepam ≤ 2 mg/d for a maximum of 10 days
was allowed during the first four weeks only. In Findling 2009,
benzodiazepines were permitted, but no details were provided of
the regimens used. In NCT00665366, it is not known whether
benzodiazepines were permitted because this information was not
included in the report. The use of anticholinergics was allowed in
all studies except two in which it was not allowed (CN138-007;
Tramontina 2009) and one for which this information is unknown
because it is not provided in the report (NCT00665366).
Outcomes
The primary efficacy measure in all but one of the studies (Vieta
2005) was mean change in YMRS total score from baseline; this
was measured in five of the studies at three weeks (CN138-007;
Keck 2003; Keck 2009; Sachs 2006; Young 2009), in one study
at four weeks (Findling 2009), in two studies at six weeks
(Tramontina 2009; Vieta 2008) and in one study at 12 weeks
(NCT00665366). In one of the 12-week studies (Vieta 2005), the
primary endpoint was response, defined as those who remained
in therapy at week 12 and showed a ≥ 50% reduction in YMRS
score from baseline.
Secondary outcome measures included mean change in YMRS
and response at other time points, remission, mean change in total
and subscale scores on the CGI-BP and the Positive and Negative
Syndrome Scale (PANSS), mean change in the Montgomery-As-
berg Depression Rating Scale (MADRS) and time to discontinu-
ation of study medication.
Excluded studies
The following eight studies were excluded for the reasons stated
below.
Zimbroff 2007, a study comparing intramuscular aripiprazole
with placebo in participants with bipolar disorder, was excluded
because the indication for treatment was immediate relief of acute
agitation (rapid tranquillisation).
CN138189, a relapse prevention study, included three phases:
phase one consisted of two weeks of treatment with lithium or val-
proate, phase two was a single-blind phase during which aripipra-
zole was added to lithium or valproate for participants who had
confirmed partial non-response and phase three was the double-
blind portion, during which those who had maintained response
for 12weeks during phase twowere randomly assigned to continue
with aripiprazole and the mood stabiliser or to switch to placebo
and the mood stabiliser for 52 weeks. The reason for exclusion
was that data from phase two of the study could not be used as
the trial did not include a comparison arm.
NCT00484471, a relapse prevention study, included a five- to
six-week aripiprazole plus valproate acute treatment phase, which
was open-label. This was followed by a 22-week double-blind
phase, during which participants were randomly assigned to re-
ceive placebo plus valproate or to continue with aripiprazole plus
valproate. The trial was excluded because it was not possible to
use data from the acute phase, as it included no comparison arm
and was open-label.
Woo 2011, a relapse prevention study, included a six-week arip-
iprazole plus valproate acute treatment phase, which was open-
label. This was followed by a 24-week double-blind phase, during
which participants were randomly assigned to receive placebo plus
valproate or to continue with aripiprazole plus valproate. The trial
was excluded because it was not possible to use data from the acute
phase, as it included no comparison arm and was open-label.
Limited details are provided in the report of NCT00606229. The
study investigated the safety and efficacy of aripiprazole in com-
bination with a mood stabiliser (lithium or valproate) over 24
weeks in participants with bipolar disorder who were experiencing
a manic or mixed episode. As the entire study was open-label, it
was excluded from the meta-analysis.
Intramuscular depot aripiprazole is used in NCT01567527, a re-
lapse prevention study in patients experiencing a manic episode.
The study included four treatment phases: a conversion to oral
aripiprazole monotherapy phase, an oral aripiprazole stabilisation
phase, a single-blind aripiprazole intramuscular depot stabilisation
phase and a double-blind placebo-controlled maintenance phase
lasting 52 weeks. The acute phases of treatment were open-label
or single-blind; therefore, data from this study were not included
in the meta-analysis.
A cross-over study ofmethylphenidate combinedwith aripiprazole
in children and adolescents with bipolar disorder and attention-
deficit/hyperactivity disorder (Zeni 2009) was excluded, as partic-
ipants had to have been already stable on aripiprazole (from two
previous studies). Therefore, this study did not assess the effect of
aripiprazole on acute mania.
A synoptic clinical study report (CN138077), available on the
Bristol-Myers Squibb website, describes a study that appears to
meet our inclusion criteria. However, Bristol-Myers Squibb dis-
continued enrolment and closed the study early, citing that suffi-
cient data were already available from other studies to support the
safety and efficacy of aripiprazole in the treatment of acute mania.
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A sample size of 250 was planned, and the study was discontin-
ued after randomisation of only 56 participants. Further details
and data were requested from Bristol-Myers Squibb but were not
supplied. It is not clear whether any usable data were reported.
Therefore, we were not able to include this study in our meta-
analysis.
Risk of bias in included studies
The overall risk of bias was unclear. The assignment of an unclear
risk was due mainly to the lack of specific information provided
on the methodology used. See Characteristics of included studies
for additional details, and for a risk of bias summary, see Figure 2
and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All trials were described as randomised. Most study authors gave
no details as to the methods used to achieve random allocation or
allocation concealment. Only one study stated that a computer-
derived algorithm was used to randomly assign participants and
that an independent third party performed the group allocation
(Tramontina 2009). Therefore, most of the trials were rated as
unclear in accordance with the Cochrane bias assessment tool.
Blinding
Some studies provided incomplete details on blinding methods
used, and others merely stated that the study was blinded. There-
fore, we rated the blinding of all studies as “unclear”.
Incomplete outcome data
Most studies include CONSORT diagrams (or similar) to show
the paths of participants through the study (CN138-007; Findling
2009; Keck 2009; Tramontina 2009; Vieta 2005; Vieta 2008;
Young 2009), numbers allocated to treatment, reasons for discon-
tinuations and numbers included in the analysis.
All of the published studies provided details of which, if any, par-
ticipants were excluded from the analysis on the basis that they
had not taken any study medication or that they had completed
no postbaseline efficacy ratings.
All of the published studies state that LOCF analysis was car-
ried out with all efficacy and safety data, and five of these stud-
ies (CN138-007; Keck 2009; Vieta 2005; Vieta 2008; Young
2009) state that observed case (OC) analysis, where only data
from participants whose results are known, was also performed.
In NCT00665366, not all data presented represent LOCF. Some
OC data are presented in cases where LOCF information is not
given.
In some studies, the total number of participants included in the
LOCF analysis was sometimes less than the ITT data set minus
those stated to have been excluded. No explanation is given in
these trials for this difference. It therefore appears that a “true”
LOCF analysis has not always been conducted.
In this review, the denominator for dichotomous efficacy outcome
measures that we have used is the number randomly assigned to
receive that treatment, leading to the assumption that those who
had been excluded (with and without an explanation provided)
had failed to respond to treatment. For all other outcomes, we
have used the denominators provided in the trials stated as being
LOCF, although some are not “true” LOCF.
Selective reporting
Risk of reporting bias was unclear. Most of the studies reported
results for the outcomes stated in the published reports; however,
without published protocols, it was not possible to assign a low
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risk.
Other potential sources of bias
Overall, it was unclear whether other biases were present, primarily
because most of the trials were manufacturer sponsored.
Effects of interventions
See:Summary of findings for themain comparisonAripiprazole
versus placebo for an acute manic or mixed episode; Summary of
findings 2 Aripiprazole versus other drug treatment for an acute
manic or mixed episode
See Summary of findings for themain comparison for aripiprazole
versus placebo and Summary of findings 2 for aripiprazole versus
other treatments.
With the exception of the two studies in children/adolescents (
Findling 2009; Tramontina 2009), the proportion of participants
who withdrew from treatment in the studies exceeded 20% for
each intervention. Unfortunately, no detailed data were available
on participants who had completed the study and responded to
treatment that would have allowed us to conduct a sensitivity
analysis.
Comparison 1. Aripiprazole versus placebo
The unpublished study (protocol CN138-007) compared placebo
versus fixed doses of aripiprazole (15 mg and 30 mg), and the
Findling 2009 study compared fixed doses of 10 mg and 30 mg
versus placebo, so we set the following comparison subcategories:
placebo versus variable aripiprazole dosing (as used in Keck 2003;
Keck 2009; Sachs 2006; Young 2009; and Tramontina 2009),
placebo versus 10 mg aripiprazole, placebo versus 15 mg aripipra-
zole and placebo versus 30 mg aripiprazole. To avoid double data
entry from protocol CN138-007 and Findling 2009, the denom-
inator used for the placebo arm of the study trial was halved, as
described in the Methods section. In addition, a comparison sub-
category was set up for aripiprazole versus placebo as an add-on
to lithium or valproate (NCT00665366; Vieta 2008).
The main analyses that help to answer our review question of
whether aripiprazole is an effective and safe treatment for mania
are change in manic symptoms on YMRS, response, remission,
acceptability of treatment and emergence of side effects such as
EPS, cardiac complications and metabolic side effects. These anal-
yses therefore are the primary analyses (marked with an *), and all
others are secondary data exploration analyses.
Primary outcomes
1 Change in manic symptoms on YMRS (at three weeks)*
With the exception of one study, which used response as the pri-
mary outcome (Vieta 2005), all other trials report, defined a priori,
the mean change in YMRS total score from baseline to endpoint
as the primary outcome measure. On this measure, using random-
effects analysis, evidence shows that aripiprazole was more effica-
cious than placebo at the end of week three; however, the differ-
ence was relatively modest (Analysis 1.1; Figure 4 six studies, N
= 1819; random-effects mean difference (MD) -3.66, 95% confi-
dence interval (CI) -5.28 to -2.05; P < 0.00001; Tau2 = 3.20, Chi
2 for heterogeneity = 17.57, df = 7 (P = 0.01), I2 = 60%). Evidence
remained in favour of aripiprazole on fixed-effect analysis (fixed-
effect MD -3.62, 95% CI -4.62 to -2.62; P < 0.00001). The dif-
ference in study design (fixed vs variable dosing) may explain the
significant heterogeneity that was present. However, heterogeneity
was also present between the two studies that used a fixed dose of
30 mg aripiprazole (protocol CN138-007; Findling 2009). These
studies used different age groups (adults vs children/adolescents),
and this may have contributed to the heterogeneity observed.
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Figure 4. Forest plot of comparison: 1 Aripiprazole versus placebo, outcome: 1.1 Mean change in YMRS
from baseline at three weeks.
Secondary outcomes
2.1 Change in manic symptoms on YMRS at other time
points and on other rating scales
Evidence in favour of aripiprazole was also apparent at the end of
week four (Analysis 1.3: one study (two fixed doses), N = 294;
fixed-effect MD -7.16, 95% CI -9.44 to -4.88; P < 0.00001; Chi2
= 0.98, df = 1 (P = 0.32), I2 = 0%) but not at week 6 (Analysis 1.4:
two studies, N = 420; random-effects MD -4.38, 95% CI -9.13
to 0.37; P = 0.07; Tau2 = 8.30, Chi2 = 2.78, df = 1 (P = 0.10),
I2 = 64%). The I2 value indicates the possibility of heterogene-
ity, which might be due to differences in study design (aripipra-
zole monotherapy vs aripiprazole as add-on therapy) or in study
populations (adults vs children/adolescents). It was not possible
to meta-analyse data from NCT00665366 at the 12-week time
point. However, the extracted data showed no statistically signifi-
cant difference between aripiprazole and placebo on change from
baseline on the YMRS at 12 weeks.
When manic symptoms were measured using the CGI scale, arip-
iprazole was superior to placebo at three weeks (Analysis 1.10:
seven studies (including two studies with two fixed doses), N =
2262; CGI severity (mania) random-effects MD -0.41, 95% CI -
0.66 to -0.16; P = 0.001; Tau2 = 0.11, Chi2 = 38.01, df = 8 (P =
<0.00001), I2 = 79%; and Analysis 1.12: five studies, N = 1529;
CGI improvement (mania) random-effects MD -0.41, 95% CI -
0.62 to -0.21; P < 0.0001; Tau2 = 0.03, Chi2 = 10.01, df = 5 (P
= 0.07), I2 = 50%) and at four weeks (Analysis 1.11: one study
(two fixed doses), N = 287; CGI severity (mania) fixed-effect MD
-1.05, 95% CI -1.34 to -0.76; P < 0.00001; Chi2 = 2.84, df = 1
(P = 0.09)).
2.2 Response*
A significant difference in favour of aripiprazole was noted in
achieving response at endpoint (defined as ≥ 50% decrease in to-
tal YMRS from baseline) in the studies with usable data at three
weeks (Analysis 1.6: four studies, N = 1230; three-week random-
effects RR 1.70, 95%CI 1.23 to 2.34; P = 0.001; Tau2 = 0.10, Chi
2 = 16.23, df = 5 (P = 0.006), I2 = 69%). On fixed-effect analysis,
the difference in favour of aripiprazole remained (fixed-effect RR
1.67, 95% CI 1.41 to 1.97; P < 0.00001); however, the I2 value
20Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
indicates that significant heterogeneity was present in these results.
Evidence in favour of aripiprazole was also obtained at four weeks
(Analysis 1.7: one study (two fixed doses), N = 295; fixed-effect
RR 2.18, 95% CI 1.50 to 3.16; P < 0.0001) and at six weeks (two
studies, N = 420; Analysis 1.8: random-effects RR 1.40, 95% CI
1.09 to 1.80; P = 0.008; Tau2 = 0.01, Chi2 = 1.45, df = 1 (P =
0.23), I2 = 31%).
2.3 Remission*
Remission rates were not looked at in all of the studies. We were
able to use data fromonly three of the studies that did report remis-
sion rates (NCT00665366; Tramontina 2009; Vieta 2008).Meta-
analysis using a random-effects model suggests that at six weeks,
no statistically significant difference was seen between aripiprazole
and placebo (Analysis 1.9: three studies, N = 782; random-effects
RR 1.28, 95% CI 0.98 to 1.69; P = 0.07; Tau2 = 0.03, Chi2 =
5.86, df = 2 (P = 0.05), I2 = 66%). With fixed-effect analysis, more
people taking aripiprazole were in remission than those taking
placebo, but significant heterogeneity was evident in these results
(fixed-effect RR 1.22, 95% CI 1.06 to 1.39; P = 0.005). The three
studies differ in their design (adults vs children/adolescents and
also monotherapy vs add-on therapy), and this may contribute to
the heterogeneity.
2.4 Change in depression rating scales
One study (Sachs 2006) assessed depressive symptoms using
MADRS and reported that although a trend in favour of aripipra-
zole was noted, it did not reach statistical significance. However,
the data could not be analysed. Some evidence from two other tri-
als (Keck 2009; Young 2009) also tended towards favouring arip-
iprazole on the MADRS scale at three weeks; however, the con-
fidence interval included zero, and heterogeneity was significant
(two studies, N = 635; Analysis 1.19: random-effects MD -0.43,
95% CI -2.08 to 1.22; P = 0.61; Tau2 = 0.92, Chi2 = 2.78, df = 1
(P = 0.10), I2 = 64%). Depressive symptoms were not prominent
at baseline in either study, but differences between the studies in
baselineMADRS scores could have contributed to the heterogene-
ity.
With the exception of Tramontina 2009, all other studies mea-
sured changes in depressive symptoms using the CGI-BP depres-
sive scale; however, not all studies reported data that could be used
in the meta-analysis. Some evidence in favour of aripiprazole was
seen on this scale for a reduction in symptoms at the three- and
four-week endpoint; however, the confidence intervals included
zero (CGI severity (depression) at three weeks; six studies; N =
1905; Analysis 1.13: random-effects MD -0.09, 95% CI -0.18 to
0.01; P = 0.07; Tau2 = 0.00, Chi2 = 7.00, df = 7 (P = 0.43, I
2 = 0%; and at four weeks; Analysis 1.14: one study (two fixed
doses), N = 287; fixed-effectMD -0.30, 95%CI -0.61 to 0.01; P =
0.06). Some evidence was found showing a difference in favour of
aripiprazole in terms of change from the preceding phase at three
weeks; however, the lower end of the confidence interval included
zero (Analysis 1.15: two studies, N = 632; CGI improvement (de-
pression) random-effects MD -0.19, 95% CI -0.45 to 0.07; P =
0.16; Tau2 = 0.02, Chi2= 3.43, df = 2 (P = 0.18), I2 = 42%).
In the study by Tramontina 2009, two rating scales for depressive
symptoms were used. These were the Brazilian version of the Chil-
dren’s Depression Rating Scale (a 17-item clinician-administered
scale) and the Kutcher Adolescent Depression Scale. The authors
state that no significant between-group difference were noted in
these measures for depression.
2.5 Change in psychotic symptoms rating scales
Five studies reported change in psychotic symptoms (protocol
CN138-007; Keck 2009; Sachs 2006; Vieta 2008; Young 2009).
Symptoms were measured using the PANSS scale.
Aripiprazole was more efficacious than placebo for an overall re-
duction in psychotic symptoms: mean change in PANSS total
score at week three (three studies, N = 863; Analysis 1.20: ran-
dom-effects MD -3.22, 95% CI -5.62 to -1.19; P = 0.002; Tau2 =
0.00, Chi2 = 2.07, df = 3 (P = 0.56), I2 = 0%). It was not possible
to meta-analyse data from the positive or negative subscales, as
each of these scales was reported on in only one study; however,
aripiprazole was more efficacious than placebo on the hostility
and cognitive subscales (hostility; Analysis 1.21: three studies, N
= 827; random-effects MD -1.17, 95% CI -1.68 to -0.66; P <
0.00001; Tau2 = 0.00, Chi2 = 0.23, df = 2 (P = 0.89), I2 = 0%);
cognitive; Analysis 1.22: three studies, N = 863; random-effects
MD - 0.77, 95% CI -1.38 to - 0.15; P = 0.01; Tau2 = 0.00, Chi2
= 2.68, df = 3 (P = 0.44), I2 = 0%).
2.6 Any use of rescue medication
Only two studies reported usable data on the numbers of partici-
pants requiring benzodiazepines (Keck 2003; Vieta 2008). There
was no statistically significant difference between aripiprazole and
placebo in the requirement for lorazepam during the first couple of
weeks of treatment (Analysis 1.24: two studies, N = 638; random-
effects RR 0.99, 95% CI 0.88 to 1.12; P = 0.93; Tau2 = 0.00, Chi
2 = 1.06, df = 1 (P = 0.30), I2 = 6%).
Two studies provided usable data (Findling 2009; Vieta 2008) on
use of anticholinergics. Evidence showed that the use of aripipra-
zole was associated with a greater requirement to use anticholin-
ergics for the treatment of EPS (Analysis 1.23: two studies, N =
730; random-effects RR 3.28, 95% CI 1.82 to 5.91; P < 0.0001;
Tau2 = 0.01, Chi2= 2.07, df = 2 (P = 0.36), I2 = 3%).
2.7 Time to onset of symptom reduction or response
Although none of the trials were specifically designed to detect
changes early in treatment, meta-analysis of two published trials
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(Keck 2003; Sachs 2006) indicates that an effect favouring arip-
iprazole may occur as early as day four, as measured by mean
change in YMRS total score (two studies, N = 510; Analysis 1.2:
random-effects MD -2.83, 95% CI -4.52 to -1.14; P = 0.001; Tau
2 = 0.00, Chi2 = 0.00, df = 1 (P = 0.96), I2 = 0%). Although statis-
tically significant, the difference is small and may not be clinically
significant.
2.8 Requirement for inpatient care (e.g. length of stay)
Meta-analysis of two studies with usable data (Keck 2003; Sachs
2006) indicates that aripiprazole treatment allowed more partici-
pants to be treated as outpatients in the third week than placebo
(Analysis 1.28: two studies, N = 534; random-effects RR 1.67,
95% CI 1.19 to 2.34; P = 0.003; Tau2 = 0.02, Chi2 = 1.36, df =
1 (P = 0.24), I2 = 26%).
2.9 General health and social functioning
2.9.1 Rating scales of severity of psychiatric symptoms
CGI-BP overall severity was measured in all studies, but data for
meta-analysis were not available in two of them (Sachs 2006; Vieta
2005). Aripiprazole was more efficacious at reducing the overall
severity of bipolar symptoms at three weeks (Analysis 1.16: five
studies, N = 1549; random-effects MD -0.52, 95% CI -0.75 to -
0.29; P < 0.0001; Tau2 = 0.39, Chi2 = 1.76, df = 4 (P = 0.42), I2
= 67%). At six weeks, meta-analysis of data from two studies was
not statistically significant (Analysis 1.17: two studies, N = 419;
random-effects MD -0.08, 95% CI -0.72 to 0.56; P = 0.81; Tau
2 = 0.39, Chi2 = 2.21, df = 1 (P = 0.14), I2 = 55%). I2 values
indicate heterogeneity in the results.
2.9.2 Rating scales of functioning
Functioning was assessed and reported in one study (
NCT00665366). No statistically significant difference was found
at 12 weeks between aripiprazole and placebo on the Longitudinal
Interval Follow-up Evaluation-Range of Impaired Function Tool
(LIFE-RIFT), (a brief assessment of functional impairment), or
the Functional Assessment Short Test (FAST), (an interview-ad-
ministered instrument used to assess the main functioning prob-
lems that patients with bipolar disorder experience). Other studies
did not assess functioning; therefore, meta-analysis was not possi-
ble.
2.9.3 Quality of life scales
Only one study used a quality of life assessment scale (Findling
2009). It is stated that no significant difference between placebo
and aripiprazole was noted at week four, although the data are not
reported.
2.10 Acceptability of treatment, as measured by completion
of the trial*
No statistical difference was noted in terms of numbers of partici-
pants completing double-blind treatment based on data from eight
studies (Findling 2009; Keck 2003; Keck 2009; NCT00665366;
Sachs 2006; Tramontina 2009; Vieta 2008; Young 2009) (Analysis
1.25: eight studies, N = 2216; random-effects RR 1.03, 95% CI
0.95 to 1.12; P = 0.46; Tau2 = 0.01, Chi2 = 18.08, df = 8 (P =
0.02), I2 = 56%). This remained the case when a fixed-effect anal-
ysis was performed (fixed-effect RR 1.04, 95% CI 0.98 to 1.11;
P = 0.18). However, the I2 indicates statistical heterogeneity. The
study that appears to contribute primarily to the heterogeneity
is Keck 2003, which had some methodological differences from
other included studies. In all other studies, participants were con-
tinued and analysed in the treatment groups to which they were
assigned to the end of week three (or week six in the case of Vieta
2008 and Tramontina 2009, week four in Findling 2009 and week
12 in NCT00665366); however, in the Keck 2003 study, par-
ticipants were dropped out of double-blind treatment and were
allowed to enter open-label treatment at the end of week two if
they did not meet specified criteria for having responded. Another
study that may be contributing towards the heterogeneity is Vieta
2008, which employed a slightly different design. During phase
two of the study, partial non-response to lithium or valproate was
confirmed before participants entered phase three. Phase three was
the double-blind phase and was six weeks in duration.
Removing the data from Keck 2003 and Vieta 2008 from the
analysis did not result in a significant change in the results with a
random-effects or a fixed-effect model (random-effects RR 1.03,
95% CI 0.96 to 1.11; P = 0.35; Tau2 = 0.00, Chi2 = 1.48, df = 5
(P = 0.92), I2 = 0%; fixed-effect RR 1.04, 95% CI 0.96 to 1.13;
P = 0.33).
Adverse effects were cited as a reason for discontinuing more often
with aripiprazole than with placebo, just reaching statistical signif-
icance on both random-effects and fixed-effect analysis (Analysis
1.26: eight studies, N = 2621; random-effects RR 1.26, 95% CI
0.97 to 1.63; P = 0.08; Tau = 0.00, Chi2 = 7.82, df = 9 (P = 0.55),
I2 = 0%; fixed-effect RR 1.30, 95% CI 1.01 to 1.67; P = 0.04).
More participants dropped out because of lack of efficacy with
placebo (Analysis 1.27: eight studies, N = 2609; RR 0.61, 95%
CI 0.44 to 0.84; P = 0.002; Tau = 0.10, Chi2 = 15.18, df = 9 (P =
0.09), I2 = 41%). Results were similar with a fixed-effect analysis
(RR 0.60, 95% CI 0.48 to 0.75; P < 0.0001).
Adverse effects
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3.1 Extrapyramidal side effects*
A statistically significant difference in favour of placebo was found
in terms of movement disorders as measured on the Simpson An-
gus Scale (Analysis 1.29: four studies, N = 1233; random-effects
MD 0.75, 95% CI 0.20 to 1.30; P = 0.007; Tau2 = 0.38, Chi2
= 27.27, df = 5 (P < 0.0001), I2 = 82%). The presence of signif-
icant heterogeneity might be explained by the use of fixed doses
in some studies and variable dosing (allowing for dose reduction
based on tolerability) in others. However, by removing the studies
using the highest fixed dose of aripiprazole (30 mg), the difference
between aripiprazole and placebo was no longer statistically signif-
icant. A statistically significant difference in favour of placebo on
the Barnes Akathisia Scale was noted (Analysis 1.30: five studies,
N = 1498; random-effects MD 0.20, 95% CI 0.09 to 0.31; P =
0.0006; Tau2 = 0.01, Chi2 = 8.22, df = 6 (P = 0.22), I2 = 27%),
and statistically significantly more patients treated with aripipra-
zole reported akathisia (Analysis 1.38: seven studies, N = 2305;
random-effects RR 3.16, 95% CI 2.25 to 4.43; P < 0.00001; Tau
2 = 0.00, Chi2 = 4.03, df = 8 (P = 0.85), I2 = 0%). No difference
between placebo and aripiprazole was found as measured on the
Abnormal Involuntary Movement Scale (Analysis 1.31: four stud-
ies, N = 1068; random-effects MD 0.02, 95% CI -0.10 to 0.15;
P = 0.70; Tau2 = 0.00, Chi2 = 1.43, df = 5 (P = 0.92), I2 = 0%).
Six of the studies state that anticholinergics were allowed (Findling
2009; Keck 2003; Keck 2009; Sachs 2006; Vieta 2008; Young
2009); however, data on usage were available in only two of these
(Findling 2009; Vieta 2008), and evidence indicates that partici-
pants were more likely to require treatment with anticholinergics
if they were taking aripiprazole (Analysis 1.23: two studies, N =
730; random-effects RR 3.28, 95% CI 1.82 to 5.91; P < 0.0001;
Tau2 = 0.01, Chi2 = 2.07, df = 2 (P = 0.36), I2 = 3%).
3.2 Cardiovascular side effects*
Most studies included the measurement of ECGs at baseline and
at one ormore time point during the study (CN138-007; Findling
2009; Keck 2003; Keck 2009; Sachs 2006; Vieta 2008). In no
study was a significant difference in ECG results noted between
treatment groups; however, meta-analysis was not possible.
One participant in the Keck 2003 study had a clinically signifi-
cant increase in QTc from baseline when Bazett’s correction fac-
tor was used. This participant was receiving placebo. The authors
report that this normalised when the FDA Neuropharmacologi-
cal Division correction factor was used. Four participants treated
with aripiprazole (2.7%) and five treated with haloperidol (3.0%)
had QTc values ≥ 450 ms when Bazett’s correction factor was
used, but the authors state that when the FDA correction fac-
tor was used, no participant in either group had a raised QT in-
terval (Vieta 2005). In the Findling 2009 study of children/ado-
lescents, abnormal QTc values (using Bazett’s correction factor)
were seen in four (4.4%) participants receiving aripiprazole 10mg,
in two (2.3%) participants receiving aripiprazole 30 mg and in
seven (8.4%) participants receiving placebo. ECGs weremeasured
during the CN138-007 study; however, the time points at which
measurements were taken are not stated. QTc intervals of > 450
ms were reported in each group when Bazett’s correction factor
was used (placebo 1/133, aripiprazole 15 mg 3/131, aripiprazole
30 mg 1/135), but again, it is reported that when the FDA Neu-
ropharmacological Division correction factor was used, all of the
intervals normalised.
Vital signs were stated as having beenmeasured in all studies except
two (NCT00665366; Tramontina 2009), and it was reported in
most that no significant differences were observed between treat-
ment groups (Findling 2009; Keck 2003; Keck 2009; Sachs 2006;
Vieta 2005; Vieta 2008; Young 2009); however, with the excep-
tion of blood pressure, no specific data for inclusion in the meta-
analysis are available. Only two studies report data on rates of
hypertension (CN138-007; Keck 2003). The difference between
aripiprazole and placebo was not statistically significant on meta-
analysis; however, a trend suggested that participants receiving
aripiprazole were more likely to have hypertension than those re-
ceiving placebo (Analysis 1.33: two studies, N = 663; random-
effects RR 3.17, 95% CI 0.83 to 12.14; P = 0.09; Tau2 = 0.00,
Chi2 = 0.11, df = 2 (P = 0.94), I2 = 0%). Had data been obtained
from the other studies, it would have been interesting to see what
effect this would have had on the meta-analysis result.
3.3 Treatment-emergent depression
Only one study (NCT00665366) recorded participant-reported
depression as a side effect. Significantly more aripiprazole-treated
participants than placebo-treated participants reported depression
over this 12-week study (RR 2.94, 95% CI 1.08 to 8.00; P =
0.03). However, the study report does not include information on
the presence of depressive symptoms at baseline and whether this
differed between groups. Other studies did not report depression
as a side effect, so meta-analysis was not possible.
3.4 Weight gain*
Body weight was measured in all studies. Mean weight change
was reported as not significantly different between groups in any
study; however, sufficient data were not available to allow meta-
analysis. No difference was seen between aripiprazole and placebo
in terms of a body weight gain of ≥ 7% compared with baseline
weight (Analysis 1.48: five studies, N = 1596; RR 0.72, 95% CI
0.47 to 1.10; P = 0.13; Tau2 = 0.00, Chi2 = 2.80, df = 4 (P =
0.59), I2 = 0%).
In one of the studies in children/adolescents, body mass index
(BMI) was also measured. No difference was reported between
aripiprazole 10 mg or 30 mg and placebo in the number of partic-
ipants with a change from normal BMI at baseline to an abnormal
BMI (> 95th percentile) at endpoint (Findling 2009).
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3.5 Sedation
The incidence of somnolence was no different between aripipra-
zole and placebo on meta-analysis of three studies (CN138-007;
Findling 2009; Sachs 2006), two of which were fixed-dose studies
(Analysis 1.45: three studies, N = 970; random-effects RR 1.85,
95% CI 0.94 to 3.65; P = 0.08; Tau2 = 0.33, Chi2 = 9.50, df
= 4 (P = 0.05), I2 = 58%). The presence of heterogeneity might
be explained by the difference in study design (fixed vs variable
dosing or studies of children and adolescents vs adults).
3.6 Gastrointestinal disturbance
Random-effects analysis yielded very similar results to those ob-
tained by fixed-effect analysis. Aripiprazole was associated with
statistically significantly more nausea (Analysis 1.39: seven stud-
ies, N = 2305; random-effects RR 1.50, 95% CI 1.20 to 1.88; P =
0.0004; Tau2 = 0.00, Chi2 = 3.05, df = 8 (P = 0.93), I2 = 0%), and
more constipation (Analysis 1.42: four studies, N = 1255; fixed-
effect RR 1.75, 95% CI 1.23 to 2.49; P = 0.002; Tau2 = 0.00, Chi
2 = 0.57, df = 4 (P = 1.00), I2 = 0%).
No statistically significant difference between aripiprazole and
placebo was found in the occurrence of dyspepsia (Analysis 1.40:
three studies, N = 930; random-effects RR 1.31, 95% CI 0.89 to
1.92; P = 0.17; Tau2 = 0.05, Chi2 = 4.41, df = 3 (P = 0.22), I2 =
32%), vomiting (Analysis 1.41: four studies, N = 1232; random-
effects RR 1.47, 95% CI 0.87 to 2.48; P = 0.15; Tau2 = 0.13, Chi
2 = 7.37, df = 5 (P = 0.19), I2 = 32%), or diarrhoea (Analysis 1.43:
four studies, N = 1319; random-effects RR 0.82, 95% CI 0.58 to
1.17; P = 0.28; Tau2 = 0.00, Chi2= 1.77, df = 4 (P = 0.78), I2 =
0.00) .
In one study (Sachs 2006), gastrointestinal adverse effects were
analysed further and were reported to have occurred primarily
during the first week and to have resolved within seven days.
3.7 Other adverse effects
Prolactin levels were measured in all studies except for
NCT00665366 and one of the studies in children/adolescents
(Tramontina 2009). The study in children/adolescents in which
prolactin was measured (Findling 2009) had missing data that
were not accounted for. Data from any of these studies were insuf-
ficient for meta-analysis. The authors of Findling 2009 reported
that at the four-week endpoint, significantly more male and fe-
male adolescents receiving aripiprazole had a prolactin level that
was below the lower end of the normal range, and they comment
that it is important to be mindful of a potential for lowered pro-
lactin levels in children taking aripiprazole, and that although the
clinical relevance is not known, some adverse consequences may
occur. This is an area that probably warrants further investigation.
Mean prolactin levels in the aripiprazole and placebo groups in all
other studies also fell; it is reported in two of them (CN138-007;
Sachs 2006) that the levels did not go below the lower end of
normal.
Of 23 other adverse effects, no difference between aripiprazole and
placebo was observed for the following 19 (see meta-analysis and
adverse effects, Table 1): manic reaction, overdose of sedatives,
agitation, chest discomfort, syncope, urticaria, headache, anxi-
ety, insomnia, light-headedness, asthenia, tremor, fatigue, blurred
vision, salivary hypersecretion, decreased appetite, increased ap-
petite, dizziness and dystonia.
The following four adverse effects were significantly more likely
to occur in participants taking aripiprazole on fixed-effect and
random-effects analysis: akathisia (Analysis 1.38: seven studies,
N = 2305; random-effects RR 3.16, 95% CI 2.25 to 4.43; P <
0.00001; Tau2 = 0.00, Chi2 = 4.03, df = 8 (P = 0.85), I2 = 0%),
EPS (Analysis 1.47: three studies, N = 1001; random-effects RR
2.24, 95% CI 1.47 to 3.42; P = 0.0002; Tau2 = 0.05, Chi2 = 4.18,
df = 3 (P = 0.24), I2 = 28%), painful extremity (Analysis 1.44: two
studies, N = 673; random-effects RR 2.01, 95% CI 1.07 to 3.78;
P = 0.03; Tau2 = 0.00, Chi2 = 0.76, df = 2 (P = 0.68), I2 = 0%)
and accidental injury (Table 1).
4 Mortality
Deaths: No deaths were reported in the aripiprazole and placebo
groups.
Comparison 2. Aripiprazole versus other drug
treatments
Three studies compared aripiprazole versus other drug treatment.
In one 12-week study, aripiprazole was compared with haloperidol
(Vieta 2005). Two other studies used placebo and active compara-
tor arms. In one study, the active comparator was lithium (Keck
2009), and in the other, the active comparator was haloperidol
(Young 2009). Both of these studies were 12 weeks long; however,
only the aripiprazole and active comparator arms were contin-
ued beyond week three. Comparison subcategories were set up for
aripiprazole versus haloperidol and for aripiprazole versus lithium,
and data at three and 12 weeks were included in the meta-anal-
ysis. Again a large number of analyses are included, and to an-
swer our main review question of whether aripiprazole is an ef-
fective and safe treatment for mania, change in manic symptoms
on the YMRS, response, remission, acceptability of treatment and
emergence of side effects such as EPS, cardiac complications and
metabolic side effects are considered as the primary analyses (and
are marked with an *). All others are secondary data exploration
analyses.
Primary outcomes
1 Change in manic symptoms on YRMRS (at three weeks)*
No statistical difference between aripiprazole and other drug treat-
ment was seen in themean change in YMRS from baseline at week
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three, with random-effects analysis and fixed-effect analysis yield-
ing the same result (Analysis 2.1: three studies, N = 972; random-
effects MD 0.07, 95% CI -1.24 to 1.37; P = 0.92; Tau2 = 0.00,
Chi2 = 0.85, df = 2 (P = 0.65), I2 = 0%).
Secondary outcomes
2.1 Change in manic symptoms on YMRS at other time
points and on other rating scales
No statistical difference between aripiprazole and other drug treat-
ment was observed at any time point; however, a steady trend
moved from favouring other drug treatment initially to favouring
aripiprazole by week 12, although this finding did not quite reach
statistical significance (week 12) (Analysis 2.2, Figure 5 two stud-
ies, N = 645; random-effects MD -1.75, 95% CI -3.60 to 0.11; P
= 0.06; Chi2 = 0.00, df = 1 (P = 0.97), I2= 0%).
Figure 5. Forest plot of comparison: 2 Aripiprazole versus other drug treatment, outcome: 2.2 Mean
change in YMRS from baseline at week 12.
Similarly, no difference between aripiprazole and other drug treat-
ment was seen at any time point in the mean change in severity of
manic symptoms, including week three (Analysis 2.4: three stud-
ies, N = 971; CGI bipolar version severity (mania), random-effects
MD -0.04, 95% CI -0.20 to 0.13; P = 0.68; Tau2 = 0.00, Chi2 =
1.91, df = 2 (P = 0.38), I2 = 0%); however, a gradual trend towards
favouring aripiprazole was evident by week 12, although at this
time point, the upper CI was zero (Analysis 2.5: two studies, N =
644; CGI bipolar version severity (mania); random-effects MD -
0.22, 95% CI -0.44 to 0.00; P = 0.05; Tau2 = 0.00, Chi2 = 0.37,
df = 1 (P = 0.55), I2 = 0%).
2.2 Response*
In one study (Vieta 2005), response was the primary outcome
measure and was defined a priori as those remaining on treatment
at week 12 and with a≥ 50% decrease in YMRS total scores from
baseline. In the other two studies, response was a secondary out-
come at 12 weeks, and it was a secondary outcome in all studies
at three weeks. At three weeks, the difference in response was not
significantly different between other drug treatments and aripipra-
zole, with very similar results obtained on fixed-effect and ran-
dom-effects analyses (Analysis 2.3: three studies, N = 990; ran-
dom-effects RR 1.12, 95% CI 0.77 to 1.63; P = 0.54; Tau2 =
0.08, Chi2 = 8.73, df = 2 (P = 0.01) I2 = 77%; fixed-effect RR
1.12, 95% CI 0.94 to 1.33; P = 0.20). The presence of significant
heterogeneity does not appear to be explained by the difference
in drug treatments used (lithium and haloperidol), and when the
two comparator drug treatments were looked at separately, no dif-
ference was noted between aripiprazole and either drug treatment:
aripiprazole versus haloperidol (two studies, N = 675; random-
effects RR 1.26, 95% CI 0.73 to 2.16; P = 0.41; Tau2 = 0.13,
Chi2 = 6.68, df = 1 (P = 0.010), I2 = 85%) or aripiprazole versus
lithium (RR 0.89, 95% CI 0.64 to 1.25; P = 0.50).
Only one study (Vieta 2005) had usable data at the 12-week time
point, so meta-analysis was not possible. However, more people in
this study achieved a response with aripiprazole than with other
treatment (haloperidol).
2.3 Remission*
Remission rates were looked at in all three studies; however, as
sufficient data were available in only one study (Keck 2009), meta-
analysis was not possible.
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2.4 Change in depression rating scales
Depressive symptoms were assessed using MADRS and CGI-BP
depressive scales.
Only one study reported a 50% reduction in MADRS (Vieta
2005), so meta-analysis was not possible. Baseline MADRS scores
were similar in each group in this study, significantly more peo-
ple in the aripiprazole group had a 50% or greater reduction in
mean scores from baseline than those in the other drug treatment
(haloperidol) group at three weeks and at 12 weeks.
At three weeks, no difference was observed between aripiprazole
and other drug treatment on meta-analysis of all three studies
for a change in MADRS scores, but significant heterogeneity was
present (Analysis 2.9: three studies, N = 971; total mean change in
MADRS, random-effectsMD-0.55, 95%CI -2.03 to 0.92;Tau2 =
1.20 (P=0.36),Chi2 =0.72, df = 1 (P=0.40), I2 =71%). Although
depressive symptoms were not prominent in any of these studies
at baseline, differences between studies were noted in baseline
MADRS scores. Removing the study with the lowest MADRS
scores (Young 2009) resulted in a significant difference favouring
aripiprazole; however, all of these results should be viewed with
caution and as data exploration.
At week 12,MADRS data from two studies were analysed. No 12-
week data from Young 2009 were available to include in the meta-
analysis. Although the evidence favoured aripiprazole, findings
remained not statistically significant (Analysis 2.10: two studies,
N = 644; random-effects MD -1.05, 95% CI -2.93 to 0.30; P =
0.13; Tau2 = 1.20, Chi2 = 0.15, df = 1 (P = 0.70), I2 = 0%).
At 12 weeks, no significant difference was observed between arip-
iprazole and other drug treatments in mean change in the severity
of depression, as measured on the CGI-BP subscale (Analysis 2.6:
two studies, N = 644; 12-week random-effects MD -0.08, 95%
CI -0.25 to 0.09; P = 0.34; Tau2 = 0.00, Chi2 = 0.03, df = 1 (P =
0.87), I2 = 0%).
2.5 Change in psychotic symptoms rating scales
Nostatistically significant differenceswere noted between aripipra-
zole and other drug treatment groups on PANSS total or subscale
scores at threeweeks or at 12weeks.OnPANSS total scores atweek
three, a trend favoured haloperidol when the “other drug treat-
ment” was haloperidol, and a trend favoured aripiprazole when
the “other drug treatment” was lithium. However, on meta-anal-
ysis of all treatments together, the difference was not significant
(Analysis 2.11: two studies, N = 582; random-effects MD -0.64,
95% CI -3.62 to 2.34; Tau2 = 1.85 (P = 0.70), Chi2 = 1.62, df
= 1 (P = 0.20), I2 = 38%). Similar trends were observed for the
PANSS cognitive and hostility subscales (Analysis 2.12; Analysis
2.13).
2.6 Any use of rescue medication
The use of benzodiazepines was permitted up to day 10 in one
study (Vieta 2005) and up to day 14 in the other two studies (Keck
2009; Young 2009); however, data were not presented or were not
usable.
Two studies (Keck 2009; Young 2009) permitted the use of anti-
cholinergics; however, data were not sufficient for meta-analysis.
2.7 Time to onset of symptom reduction or response
No data were reported.
2.8 Requirement for inpatient care (e.g. length of stay)
No data were reported.
2.9 General health and social functioning
2.9.1 Rating scales of severity of psychiatric symptoms
Evidence was seen to favour aripiprazole at 12 weeks compared
with other drug treatment for reducing overall severity of bipo-
lar symptoms (Analysis 2.7: two studies, N = 644; lithium and
haloperidol; fixed-effect MD -0.29, 95% CI -0.50 to -0.07; P =
0.008; Chi2 = 0.90, df = 1 (P = 0.34)).
2.9.2 Rating scales of functioning
Data were reported in one study (Young 2009) as showing similar
improvement across groups at three weeks (aripiprazole, haloperi-
dol and placebo) and at 12 weeks (aripiprazole and haloperidol)
on the LIFE-RIFT scale. Other studies did not assess functioning;
therefore, meta-analysis was not possible.
2.9.3 Quality of life scales
No data were reported.
2.10 Acceptability of treatment, as measured by completion
of the trial*
Meta-analysis of data at three weeks showed no difference in the
number of people remaining on aripiprazole comparedwith “other
drug treatments” (Analysis 2.20: three studies, N = 994; random-
effects RR 1.12, 95% CI 0.90 to 1.39; P = 0.31; Tau2 = 0.03,
Chi2 = 10.36, df = 2 (P = 0.06), I2 = 81%). When a fixed-effect
analysis was performed, a difference favouring aripiprazole only
just reached statistical significance (fixed-effect RR 1.13, 95% CI
1.03 to 1.24; P = 0.01). However, the I2 value indicates significant
heterogeneity. Looking at the drugs individually reveals no differ-
ence between aripiprazole and haloperidol or between aripiprazole
and lithium.
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No difference in dropouts due to lack of efficacy was reported
between aripiprazole and “other drug treatments” (Analysis 2.22:
two studies, N = 647; random-effects RR 0.51, 95% CI 0.19 to
1.40; P = 0.19; Tau2 = 0.33, Chi2 = 2.69, df = 1 (P = 0.10), I2 =
63%). However, when a fixed-effect analysis was performed, more
participants were seem to drop out because of lack of efficacy with
“other drug treatments” than with aripiprazole (RR 0.48, 95% CI
0.27 to 0.86; P = 0.01). Again, significant heterogeneity is present.
Similarly, no difference in dropouts due to adverse effects was ob-
served between aripiprazole and “other drug treatments” (Analysis
2.23: three studies, N = 994; three-week random-effects RR 0.79,
95% CI 0.22 to 2.76; P = 0.71; Tau2 = 1.09, Chi2 = 19.23, df =
2 (P < 0.0001), I2 = 90%). However, on fixed-effect analysis, it
was noted that more people dropped out because of adverse effects
with “other drug treatments” (fixed-effect RR 0.63, 95% CI 0.43
to 0.90; P = 0.01). Looking at the drugs separately on random-
effects analysis revealed no difference between aripiprazole and
either drug (lithium or haloperidol); however, with fixed-effect
analysis, more dropouts were seen with haloperidol but not with
lithium. Significant heterogeneity does not appear to be explained
by the differences in drug treatments compared (haloperidol and
lithium).
At 12 weeks, the number of people completing treatment was not
statistically significant between aripiprazole and “other drug treat-
ments” on fixed-effect or random-effects analysis (Analysis 2.21:
three studies, N = 994; random-effects RR 1.12, 95% CI 0.73 to
1.71; P = 0.60; Tau2 = 0.12, Chi2 = 15.65, df = 2 (P = 0.0004), I
2 = 87%; fixed-effect RR 1.13, 95% CI 0.98 to 1.30; P = 0.09).
Again, a look at these drugs separately reveals that more people
remained on aripiprazole than on haloperidol on fixed-effect anal-
ysis but not on random-effects analysis (random-effects RR 1.30,
95% CI 0.74 to 2.31; P = 0.36; Chi2 = 11.89, df = 1 (P = 0.0006),
I2 = 92%), with no difference reported between aripiprazole and
lithium. The very high level of heterogeneity between the two
haloperidol studies might be explained by differences in study de-
sign.
3 Adverse effects
Adverse effect data were available or inclusion in the meta-anal-
ysis only from the 12-week aripiprazole versus haloperidol study
(Vieta 2005) and from the placebo and lithium controlled study
(Keck 2009). Additional adverse effects data were requested for
the haloperidol and placebo controlled study (Young 2009) but
were not received.
3.1 Extrapyramidal side effects*
Data were available fromonly one study on the incidence of move-
ment disorders (as measured on the Simpson Angus Scale (SAS),
the Barnes Akathisia Rating Scale (BARS) and the Abnormal In-
voluntary Movement Scale (AIMS)) at the three-week time point
and therefore were not meta-analysable.
Meta-analysis of 12-week data from the two studies with adverse
effects data (Keck 2009; Vieta 2005) suggests that no statistically
significant difference exists between aripiprazole and “other drug
treatments” onSAS, BARSorAIMSwhen random-effects or fixed-
effect analysis was performed. However, significant heterogeneity
was present, which may be due to the different side effect profiles
of lithium and haloperidol; therefore, meta-analysis may not have
been appropriate. Data fromVieta 2005 alone show that haloperi-
dol was associated with a statistically significantly higher incidence
of movement disorders at 12 weeks compared with aripiprazole,
as measured on SAS (Analysis 2.14: one study, N = 333; fixed-
effect MD -4.68, 95% CI -5.87 to -3.49; P < 0.00001), BARS
(Analysis 2.15: one study N = 333; fixed-effect MD -0.48, 95%
CI -0.73 to -0.23; P = 0.0002) and AIMS (Analysis 2.16: one
study, N = 321; fixed-effectMD -0.67, 95%CI -1.07 to -0.27; P =
0.001), and based on the reported incidence of akathisia (Analysis
2.17: one study, N = 344; RR 0.50, 95% CI 0.30 to 0.81; P =
0.005) and EPS (Table 1). No difference at 12 weeks was noted
between aripiprazole and lithium on SAS, BARS or AIMS; how-
ever, more participants taking aripiprazole were likely to report
akathisia (Analysis 2.17: one study, N = 313; RR 2.97, 95% CI
1.37 to 6.43; P = 0.006).
No difference between groups was observed in the incidence of
tremor at three weeks (lithium vs aripiprazole; see table) or at 12
weeks when other drug treatments were meta-analysed (Analysis
2.19: two studies, N = 657; random-effects RR 0.67, 95% CI
0.41, 1.09; P = 0.11; Tau2 = 0.00, Chi2 = 0.01, df = 1 (P = 0.93),
I2 = 0%) and when they were looked at separately (aripiprazole vs
lithium and aripiprazole vs haloperidol).
3.2 Cardiovascular side effects
Only the 12-week study comparing haloperidol versus aripiprazole
(Vieta 2005) provided data on the effect on the QT interval. No
difference was seen between aripiprazole and haloperidol in the
incidence of prolonged QTc interval (≥ 450 ms or a ≥ 10%
increase from baseline) (Table 1). ECG measurements were not
taken in the haloperidol and placebo-controlled study (Young
2009). In Keck 2009, no data are presented, but it is stated that no
clinicallymeaningful differences were observed between treatment
groups in ECG results.
3.3 Treatment-emergent depression
Only one study measured treatment-emergent depression (Vieta
2005). This was defined post hoc as a CGI-BP depression sub-
score worsening by≥ two points, with no difference seen between
aripiprazole- and haloperidol-treated participants (Table 1).
3.4 Weight gain*
Meta-analysis was not possible because data were insufficient.
However, it is reported that LOCF mean weight change from
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baseline to 12 weeks was not statistically different between arip-
iprazole (+0.27 kg) and haloperidol (-0.10 kg) (Vieta 2005) and
that no significant difference was observed between aripiprazole
and haloperidol (Young 2009) or between aripiprazole and lithium
(Keck 2009) in mean weight change or in numbers of participants
with a clinically relevant weight gain on both OC and LOCF anal-
ysis at 12 weeks.
3.5 Sedation
No difference between aripiprazole and lithium was observed in
rates of sedation (Table 1) (Keck 2009).
3.6 Gastrointestinal disturbance
Rates of nausea and constipation were reported in the placebo/
lithium-controlled study (Keck 2009). No differences were re-
ported between lithium- and aripiprazole-treated participants in
the rate of either of these adverse effects (Table 1).
3.7 Other adverse effects
Prolactin was measured in all three studies; however, data are in-
sufficient for inclusion in the meta-analysis. Authors report that
fewer participants taking aripiprazole experienced a change in pro-
lactin level to above the upper limit of normal when compared
with lithium (Keck 2009) and haloperidol (Vieta 2005; Young
2009). It is also reported in all studies that a decrease in mean pro-
lactin levels was noted in participants taking aripiprazole. In the
lithium-controlled study (Keck 2009), a mean decrease in levels
was noted in the group taking lithium; however, the decrease in
the aripiprazole group was significantly greater. The haloperidol
groups in both of the other studies (Vieta 2005; Young 2009) saw
mean increases in prolactin levels.
Aripiprazole-treated participants were more likely than those tak-
ing haloperidol to experience insomnia (Table 1) (Keck 2009).
No statistically significant differences were observed between arip-
iprazole- and lithium-treated participants at three weeks (Table
1) or between aripiprazole and other treatments (haloperidol and
lithium) at 12 weeks (Analysis 2.18: two studies, N = 657; ran-
dom-effects RR 1.01, 95%CI 0.72 to 1.42; P = 0.94; Chi2 = 0.16,
df = 1 (P = 0.69), I2 = 0%) for the occurrence of headache.
4 Mortality
Deaths: No deaths were reported in the aripiprazole or other treat-
ment groups.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Aripiprazole versus other drug treatment for an acute manic or mixed episode
Patient or population: patients with an acute manic or mixed episode
Settings: inpatients and outpatients
Intervention: aripiprazole
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Aripiprazole versus
other drug treatment
Mean change in YMRS
from baseline at week
three
Young Mania Rating
Scale: an 11-item ques-
tionnaire to assess the
severity of the core symp-
toms of mania. Scale
from 0 to 60
Follow-up: 12 weeks
Mean change in YMRS
from baseline at week
three ranged across con-
trol groups from
-15.65 to -12.03 points
Mean change in YMRS
from baseline at week
three in the intervention
groups was
0.07 higher
(1.24 lower to 1.37
higher)
972
(three studies)
⊕⊕⊕©
moderate1
≥ 50% decrease in
YMRS from baseline at
week three
Young Mania Rating
Scale (YMRS): as above
Follow-up: 12 weeks
Study population RR 1.12
(0.77 to 1.63)
990
(two studies)
⊕⊕⊕©
moderate1
320 per 1000 359 per 1000
(247 to 522)
Moderate
81 per 1000 91 per 1000
(62 to 132)
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Numbers completing the
trial (at end of week
three)
Number of participants
Follow-up: 12 weeks
Study population RR 1.13
(1.03 to 1.24)
994
(three studies)
⊕⊕©©
low1,2
592 per 1000 668 per 1000
(609 to 734)
Moderate
338 per 1000 382 per 1000
(348 to 419)
Barnes Akathisia Scale
LOCF at week 12
A physician-assessed
rating scale to assess the
severity of drug-induced
akathisia Scale from 0 to
14
Follow-up: 12 weeks
Mean Barnes Akathisia
Scale LOCF at week 12
ranged across control
groups from
0.06 to 0.8
Mean Barnes Akathisia
Scale LOCF at week 12
in the intervention groups
was
0.17 lower
(0.76 lower to 0.41
higher)
646
(two studies)
⊕⊕©©
low1,3
Abnormal Involuntary
Movement Scale LOCF
at week 12
A physician-administered
rating scale with 12 items
to measure tardive dyski-
nesia Scale from 0 to 40
Follow-up: 12 weeks
Mean Abnormal Invol-
untary Movement Scale
LOCF at week 12 ranged
across control groups
from
-0.06 to 0.81
Mean Abnormal Invol-
untary Movement Scale
LOCF at week 12 in the
intervention groups was
0.31 lower
(0.97 lower to 0.36
higher)
634
(two studies)
⊕⊕©©
low1,3
Simpson Angus Scale
LOCF at week 12
A physician-administered
rating scale to measure
drug-induced Parkinson-
ism Scale from 0 to 40.
Follow-up: 12 weeks
Mean Simpson Angus
Scale LOCF at week 12
ranged across control
groups from
0.18 to 5.7
Mean Simpson Angus
Scale LOCF at week 12
in the intervention groups
was
2.09 lower
(7.11 lower to 2.93
higher)
646
(two studies)
⊕⊕©©
low1,3
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Wide confidence intervals and minimal quantity of directly comparative data.
2Significant heterogeneity present. Differences in study design could explain the heterogeneity-the lithium comparator and one of the
haloperidol comparator studies were placebo and active drug controlled. Also a difference in the average dose of haloperidol at the 12-
week endpoint- 11.2 mg/d in one study and 7.4 mg/d in the other.
3Heterogeneity might be explained by the different side effect profiles of lithium and haloperidol.
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D I S C U S S I O N
Summary of main results
The primary measure of efficacy for this review was change in
manic symptom ratings using the YMRS, and overall, evidence
showed that aripiprazolewas superior to placebo in reducingmanic
symptoms measured using this scale (mean change in YMRS from
baseline at three weeks in the intervention groups was 3.66 points
lower (5.28 to 2.05)-a modest difference; Summary of findings for
themain comparison) and evidence showed no difference between
aripiprazole and other drug treatments (mean change in YMRS
from baseline in the intervention groups was 0.07 higher (1.24
lower to 1.37 higher; Summary of findings 2).
Aripiprazole-treated participants were also more likely than
placebo-treated participants to achieve a clinical response (see
Summary of findings for the main comparison); however, no sta-
tistically or clinically significant differences were observed between
aripiprazole and other drug treatments in terms of reduction in
clinical symptoms or in the rate of response (see Summary of
findings 2). Aripiprazole-treated participants were no more likely
to achieve remission than placebo-treated participants.
Dropout rates were high in all but two trials. Many factors can
influence a person’s decision to continue taking medication, in-
cluding perceived efficacy and side effects, and in a patient popu-
lation with bipolar disorder, compliance with medication is gen-
erally poor.
Overall dropout rates did not differ significantly between aripipra-
zole and placebo (see numbers completing treatment in Summary
of findings for the main comparison), although exploratory anal-
ysis suggests that adverse effects resulted in more dropouts with
aripiprazole, and that lack of efficacy resulted in more dropouts
with placebo. No significant difference in dropout rates or in rea-
sons for dropping out was observed between aripiprazole and other
drug treatments (haloperidol and lithium) (see numbers complet-
ing treatment in Summary of findings 2), although significant het-
erogeneity was noted in these results, which did not appear to be
fully explained by the differences in comparative treatments used.
Exploratory analyses were also performed as part of the review.
When other scales such as the CGI-BP were analysed, aripipra-
zole appeared superior to placebo. Exploratory analysis of the data
for depressive symptoms suggested that aripiprazole was not sta-
tistically significantly better than placebo at reducing depressive
symptoms. Also, no significant difference between aripiprazole
and other drug treatments was observed in the change in CGI-
BP depressive scale scores and MADRS scores. However, as de-
pressive symptoms were not particularly prominent at baseline in
any of the studies, further research is needed to explore the effect
of aripiprazole on depressive symptoms in patients with bipolar
disorder.
Further exploratory analysis provides evidence to suggest that arip-
iprazole was superior to placebo in reducing psychotic symptoms,
but no statistically significant differences were reported between
aripiprazole and any other drug treatments for psychotic symp-
tom reduction. Lack of meta-analysable data makes this finding
preliminary.
No significant difference between aripiprazole and placebo was
seen in the numbers of participants requiring treatment with ben-
zodiazepines. However, as no details indicated which individuals
in each group required this treatment, it is difficult to further in-
terpret this finding. Meta-analysis of aripiprazole compared with
other drug treatments on this measure was not possible.
The requirement for anticholinergics was included in the sum-
mary of findings tables as an indication of the propensity for arip-
iprazole and comparison treatments to cause extrapyramidal side
effects. Aripiprazole was associated with a greater requirement to
use anticholinergics, suggesting thatmore aripiprazole-treated par-
ticipants than placebo-treated participants experienced these side
effects (Summary of findings for the main comparison); however,
this finding was based on meta-analysis of data from only two
studies because other studies lacked usable data. No usable data
were obtained from the studies comparing aripiprazole with other
drug treatments (Summary of findings 2).
The greater need to use anticholinergic medication was confirmed
by evidence that aripiprazole was associated with a higher in-
cidence of movement disorders than placebo, as measured on
the SAS scale, on the BARS scale and by participant-reported
akathisia. Significant heterogeneity was present in the meta-analy-
sis of movement disorders with aripiprazole and other drug treat-
ments; this is most likely a result of the different side effect pro-
files of lithium and haloperidol. Aripiprazole was more likely to
cause movement disorders than lithium earlier in treatment, as
measured on SAS and BARS scales, but later on (by week 12), no
difference on any measure was apparent. Haloperidol was more
likely to cause movement disorders than aripiprazole on all mea-
sures apart from tremor.
Aripiprazolewas not significantly different fromplacebo in causing
significant weight gain in adults (≥ 7% increase in body weight)
or change from a normal to an abnormal BMI (> 95th percentile)
in adolescents. No significant differences in cardiovascular adverse
effects were seen between aripiprazole and placebo, and very lim-
ited data suggest no significant differences in ECG results between
aripiprazole and other drug treatments. Treatment-emergent de-
pression was examined in only one study; this suggests that arip-
iprazole might be associated with a greater incidence of depres-
sion than placebo, and post hoc analysis in one study revealed
no difference between aripiprazole and haloperidol on this mea-
sure; however, this is an area for further research. No treatment
was associated with significantly more sedation than any other,
but aripiprazole was more likely to cause insomnia than haloperi-
dol. Gastrointestinal disturbance, including nausea, dyspepsia and
constipation, was more of a problem with aripiprazole than with
placebo; however, limited evidence suggests that these problems
may be short-lived. A lower incidence of raised prolactin with arip-
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iprazole than with haloperidol is reported by authors of these stud-
ies, who indicate that mean prolactin levels fall with aripiprazole
and increase with haloperidol. However, as insufficient data meant
that meta-analysis was not possible, these findings need further
confirmation. In the child/adolescent population, study authors
reported that aripiprazole caused more prolactin levels to fall be-
low the lower limit of normal (in both males and females). The
long-term consequences of this effect have not been investigated,
but it is suggested that low levels could be associated with adverse
outcomes (Findling 2009). This area warrants further research.
No details were reported in these trials regarding the severity of
side effects reported or time to onset or resolution, with the excep-
tion of one trial, which further analysed gastrointestinal adverse
effects and reported that they usually occurred in the first week
and resolved within seven days.
Aripiprazole was superior to placebo in reducing overall severity
of psychiatric symptoms, but it was not different from other drug
treatments. Most studies did not investigate general health, social
functioning or quality of life.However, one studymeasured quality
of life but provided no usable data, and another study measured
functioning by using two separate functioning assessment scales,
both of which revealed no differences between aripiprazole and
placebo.
Overall completeness and applicability of
evidence
The overall aim of the review was to assess the efficacy and tol-
erability of aripiprazole, alone or in combination with other an-
timanic drug treatments, compared with placebo and other drug
treatments in the treatment of acute manic or mixed episodes.
Most studies were carried out in an adult population, with a fairly
equal split between male and female participants, who were pri-
marily inpatients, but some outpatients were included. Standard
diagnostic criteria were used, andmost studies employed a placebo
comparison. Supporting evidence is sufficient to show that arip-
iprazole is an effective treatment for mania, but as it was compared
only with haloperidol and lithium in the adult population, and as
no active comparison was made in the child/adolescent popula-
tion, the evidence does not lead us to determine the place of arip-
iprazole in current therapy. Further comparative work is needed
to address this question. Relatively limited evidence is available in
the child/adolescent population, and the unanswered question re-
mains regarding the potential consequences of lowering prolactin
levels in this age group. Significant heterogeneity was present in
many of the analyses, and for future updates of this review, it may
be appropriate to analyse the data differently, in particular, to con-
sider setting up additional comparisons, so that aripiprazole can be
compared against different classes of antimanic agents separately
rather than by combining them together.
Quality of the evidence
Results from 10 trials (3340 participants) were included in the
review; two of these were trials in children/adolescents. Only one
was an independently conducted study, and nine trials were con-
ducted by the manufacturer of aripiprazole. This is a potential
limitation, and data should therefore be interpreted cautiously.
Overall, no trial report provided adequate information to allow a
proper assessment of trial quality.
The overall risk of bias was assigned as “unclear”, mainly specific
details were lacking in the published reports (e.g. simply stating
that the trial was randomised but providing no other information).
In the summary of findings tables, risk of bias was not additionally
marked down, as trials had well-balanced baseline characteristics,
and it was believed that marking down would not provide a fair
reflection of the overall grade of the evidence.
In view of the low number of studies and wide confidence in-
tervals for results from outcomes relevant to the comparison be-
tween aripiprazole and other drugs, we downgraded the quality
of evidence for all the outcomes in Summary of findings 2 due to
imprecision.
Statistical heterogeneity was observed between studies on a num-
ber of comparisons. Explanations for this heterogeneity may in-
clude the differences in dose regimens used-variable versus fixed-
dose regimens, differences in study design-monotherapy verus
add-on therapy, differences in populations-adults versus children/
adolescents and differences in comparison drug treatments used-
lithium versus haloperidol.
All trials used the LOCF method. This method uses the last avail-
able data point for all subsequent missing observations after a per-
son has dropped out of the study. Assuming that a participant
gradually improves during the study means that carrying a value
forward from part-way through the study will result in a conser-
vative estimate by underestimating what value data would have
had if these participants had completed the study (Streiner 2008).
LOCF is a method frequently used in clinical trials, but it intro-
duces uncertainty about the reliability of the results. LOCF as-
sumes that no further change will occur, and it does not take into
account whether the participant was improving or deteriorating.
The dropout rate was high in most of the studies included in this
review. Without knowing what subsequently happened to indi-
vidual participants who dropped out of these studies, it is difficult
to know exactly what effect this may have had on the results.
We have not formally investigated sources of heterogeneity by
using meta-regression as data were sparse.
Potential biases in the review process
Robust search strategies were employed, and it is highly likely that
all relevant studies were identified. Bristol-Myers Squibb and the
authors of some studies supplied uswith requested additional data;
however, additional data were not available on all outcomes of in-
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terest, and this could have introduced somebias. It was not possible
to obtain additional data for one large study (Kanba 2012), which
prevented its inclusion in the meta-analysis; however, it is hoped
that it may still be possible to obtain the requested data, and this
would inform an update of the review. The review included trials
conducted in all age groups and analysed the findings together.
This may have introduced bias; therefore, for future updates, it
may be more appropriate to carry out two reviews to look at the
adult population and the child/adolescent population separately.
In practice, a clinician will be faced with manic patients who are
already taking other mood stabilisers, as well as those who are not.
As these clinical situations lead to the same question (i.e. Will
aripiprazole treat the manic symptoms that my patient has?), the
decision was made to combine monotherapy studies (i.e. those in
which aripiprazole was compared with placebo and those in which
it was compared with other treatments) with add-on studies (i.e.
those comparing the addition of aripiprazole to lithium/valproate
versus placebo or other treatments added to lithium/valproate)
and to stratify by these groups in the analyses. It is possible that
dealing with these different studies may have introduced bias, and
for future updates, we may consider analysing the different studies
separately. In the Results section, it was specified which analyses
help to answer the review question of whether aripiprazole is an
effective and safe treatment for mania; these were considered the
primary analyses and were marked with an *. The inclusion of a
number of other analyses (dealt with as secondary data exploration
analyses) may introduce bias in the conclusions drawn from the
data presented.
Agreements and disagreements with other
studies or reviews
A systematic review of 13 randomised placebo-controlled trials
concluded that antipsychotics (including aripiprazole) and mood
stabilisers are significantly more effective than placebo in treating
acute mania (Smith 2007). This systematic review included two of
the studies that we have included in our review (Keck 2003; Sachs
2006). A recently published meta-analysis (Fountoulakis 2011) of
aripiprazole monotherapy data in acute mania/mixed episodes, in
acute bipolar depression and as maintenance treatment reported a
moderate effect size of 0.34 for aripiprazole versus placebo against
acute mania. The authors include the same six acute mania/mixed
monotherapy trials in adults that we have included in our meta-
analysis (CN138-007; Keck 2003; Keck 2009; Sachs 2006; Vieta
2005; Young 2009). The monotherapy trials in children/adoles-
cents (Findling 2009; Tramontina 2009) and the combination
treatment study (Vieta 2008) are not included.
A recently published multiple treatments meta-analysis (MTM)
comparing (directly and indirectly) the efficacy and acceptabil-
ity (based on the number of participants who discontinued treat-
ment for any reason) of antimanic drugs in acute mania (Cipriani
2011) found aripiprazole to be significantly more effective than
placebo and haloperidol to be significantly more effective than
aripiprazole. Haloperidol and lithiumwere considered less accept-
able treatments based on the numbers of participants who left the
study early for any reason during the first three weeks. This MTM
and the reviews and analyses mentioned above are consistent with
our finding that aripiprazole is an effective treatment for mania;
however, our review suggests that no significant difference exists
between aripiprazole and haloperidol (based on mean change in
YMRS). The MTM suggests that risperidone and olanzapine are
the best available options in terms of both efficacy and acceptabil-
ity (based on dropouts). No direct comparisons are available with
these drugs, so our review is unable to suggest a place in therapy
for aripiprazole.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is moderate quality evidence that aripiprazole is an effective
treatment for mania compared with placebo in studies of children/
adolescents and adults. There is also moderate quality evidence
that indicates that aripiprazole is better than placebo in producing
a clinical response but imprecise evidence that it is comparable
to other drug treatments. Overall, therefore, the evidence in this
review is sufficient to support aripiprazole as an option for treating
manic symptoms. However its place in therapy is unclear from
this review, as very few directly comparative data on efficacy or
tolerability were obtained and the quality of the evidence of its
effects relative to other antimanic drugs is low. Direct compar-
isons between other antipsychotics and mood stabilisers such as
risperidone and olanzapine may help to confirm the exact place of
aripiprazole in therapy.
Although people taking aripiprazole were no more or less likely
to remain on treatment than those taking placebo or other drug
treatments, differences in side effect profiles may influence treat-
ment choice. Aripiprazole is more likely than lithium (although
less likely than haloperidol) to cause movement disorders, in par-
ticular, parkinsonism and akathisia. It remains unknown how arip-
iprazole directly compares with antipsychotics and mood stabilis-
ers (other than haloperidol and lithium) in terms of tolerability in
the treatment of mania.
In the child/adolescent population, comparison studies with treat-
ments other than placebo are lacking. In our analysis, we did not
consider studies in children/adolescents separately from those in
adults, and this could have introduced a source of heterogeneity.
Also, the potential adverse consequences of lowering prolactin lev-
els to below the lower limit of normal in this age group remain
unstudied.
When initiating treatment for acute mania, clinicians are likely
to be considering the requirement for longer-term treatment of
34Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the illness. Evidence for aripiprazole as a treatment for relapse
prevention has not been obtained in this review.
Implications for research
Studies involving large numbers of participants in a naturalistic
setting are required. Studies comparing aripiprazole with other
antipsychotics and mood stabilisers should also be conducted to
further our understanding about the potential place of aripipra-
zole in the treatment of mania. In addition, these studies should
address the issue of the comparative efficacy of aripiprazole in the
long-term prevention of relapse. Quality of life and functioning
are highly relevant measures for both patients and clinicians, for
which we require good quality data. Adverse effects of medication
are a key contributing factor to poor compliance with medication;
therefore, more detailed assessment of emergent side effects, in-
cluding comparative side effects with other medicines, is an im-
portant requirement in future research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CN138-007
Methods Randomised controlled trial
Multinational (56 centres in US, Argentina and Mexico)
Three weeks
16.3.2000 to 13.7.2001
Participants N = 401
Age: 18 to 74 years old (mean age not stated)
Males 48%, females 52%
Bipolar I disorder, manic or mixed (DSM-IV criteria) with YMRS total score of ≥ 20
and in acute relapse
Participants were hospitalised for at least the first two weeks of treatment
Exclusion criteria: delirium, dementia, amnestic or other cognitive disorder, schizophre-
nia, schizoaffective disorder, first manic episode or current episode longer than four
weeks, substance abuse disorder, non-response to clozapine, suicide or homicide risk,
unstable thyroid pathology, history of neuroleptic malignant syndrome
Interventions Aripiprazole 15 mg fixed dose (N = 136), aripiprazole 30 mg fixed dose (N = 134),
placebo (N = 134)
Outcomes Primary: mean change from baseline on YMRS total score
Secondary: CGI-bipolar version, PANSS,MADRS, response (> 50% decrease in YMRS)
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details, merely stated as randomised
(synopsis page 1)
Allocation concealment (selection bias) Unclear risk No details of method
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some missing data, without explanation/
details. Likely low impact
Selective reporting (reporting bias) Unclear risk Not all outcomes were included in the un-
published clinical report synopsis, but thy
were supplied upon request. However, we
did not have access to a published protocol
Other bias Unclear risk No suggestion of other biases from the data
and content of the synopsis report; how-
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CN138-007 (Continued)
ever, assigned as anunclear risk, as the study
has not been published andwas kept as data
on file
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details of method
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of method
Findling 2009
Methods Randomised controlled trial
Multicentre (59 US centres)
Four weeks
March 2005 and February 2007
Participants N = 296
Age: 10 to 17 years old (mean age 13.4, SD 2.2)
Males 53.7%, females 46.3%
Bipolar I, current episode manic or mixed with or without psychotic features (DSM-IV
criteria) and YMRS total score of ≥ 20
Participants were outpatients, hospitalised or partially hospitalised
Comorbid ADHD, conduct disorder, oppositional defiant disorder or anxiety disorder
(except PTSD) allowed
Exclusion criteria: bipolar II, bipolarNOS, PDD, schizophrenia, schizoaffective disorder,
substance misuse, pregnancy, suicide risk
Interventions Aripiprazole fixed dose 10 mg (N = 98), aripiprazole fixed dose 30 mg (N = 99), placebo
(N = 99)
After screening and washout, aripiprazole 10 mg or 30 mg or placebo for four weeks
Aripiprazole initiated as 2 mg/d (day one and day two), 5 mg/d (day three and day four)
, 10 mg/d (day five), and if in 30 mg group, titration continued as 10 mg/d (day five and
day six), 15 mg/d (day seven and day eight), 20 mg/d (day nine and day 10), 25 mg/d
(day nine and day 10) and 30 mg/d (day 13 onwards)
Outcomes Primary: mean change on YMRS total score from baseline
Secondary: response (≥ 50% decrease in total YMRS), CGI-bipolar version (severity
of mania, depression and overall bipolar illness), CGAS, CDRS-R, GBI (abbreviated
version), parent questionnaire on home behaviours version of the ADHD Rating Scale-
Version IV (ADHD-RS-VI), Pediatric Quality of Life Enjoyment and Satisfaction Ques-
tionnaire (P-LES-Q)-all assessed at weeks one, two, three, and four (apart from P-LES-
Q, which was administered at baseline and at week four) and time to discontinuation
Notes Manufacturer sponsored
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Findling 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details, merely stated as randomised
(page 1442)
Allocation concealment (selection bias) Unclear risk No details of method
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some missing data because rating scales
were not completed. Likely low impact
Selective reporting (reporting bias) Unclear risk All stated outcomes are reported on, with
the exception of P-QLES-Q, a secondary
outcome. It is commented on that no sig-
nificant difference was seen at week four,
but data are not presented (page 1444).
However, we did not have access to a pub-
lished protocol
Other bias Unclear risk No suggestion of other biases (baseline
characteristics balanced; table 1, page
1445); however, this was a manufacturer-
sponsored study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind, but no details of
method provided (page 1442)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of method
Keck 2003
Methods Randomised controlled trial
Multicentre (38 US centres)
Three weeks
Study dates not stated
Participants N = 262
Age: ≥ 18 years old (range not stated); mean age: 40.5, SD 12.2
Males 44%, females 56%
Bipolar I, manic or mixed episode (DSM-IV criteria) with YMRS≥ 20 and experiencing
an acute relapse requiring hospitalisation
Participants were hospitalised for at least the first two weeks of treatment. At end of week
two, discharged if CGI-bipolar version: severity of illness score ≥ 3 and change from
preceding phase ≥ two. If not meeting these criteria, patients remained hospitalised for
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Keck 2003 (Continued)
the remaining week
Participants not responding at end of week two (change from preceding phase score
of four to seven) were discontinued from double-blind treatment and were offered the
option of open-label aripiprazole during week three
Exclusion criteria: pregnant or lactating women, delirium, dementia, amnestic, other
cognitive disorders, schizophrenia or schizoaffective disorder, experiencing first manic
episode, duration of current mania > four weeks, non-response to clozapine, probable
need for prohibited concomitant treatment, psychoactive substances/substance use dis-
order, at screening: lithium > 0.6 mmol/L and/or divalproex sodium > 50 microgram/
mL (therapeutic levels), suicide or homicide risk, history of NMS or seizure disorder,
clinically significant abnormal lab results, vitals, ECG, previous enrolment in an arip-
iprazole trial
Interventions Aripiprazole variable dose (N = 130) and placebo (N = 132)
After a one- to seven-day screening period to assess patient eligibility and to allow for
elimination of existing psychotropics, participants were allocated to 30mg aripiprazole or
placebo for three-week treatment period. Aripiprazole was initiated at 30 mg/d-reduced
if needed to 15 mg/d. Average dose at endpoint 27.9 mg
Outcomes Primary: mean change in total YMRS
Secondary: response (≥ 50%decrease in total YMRS),CGI-bipolar version scale (severity
and change from preceding phase) for mania, depression and overall illness, time to
discontinuation due to lack of efficacy or entry into open-label aripiprazole treatment
All assessed at days four, seven, 10, 14 and 21
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Merely states that participants were “ran-
domly assigned” (page 1652)
Allocation concealment (selection bias) Unclear risk No details of methods
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not all participants allocated treatment
were included in the analysis. Likely low
impact. Table included that lists reasons
and numbers of participants discontinuing
(table 2, page 1653). LOCFusedwhenpos-
sible
Selective reporting (reporting bias) Unclear risk Stated outcomes reported on; however, we
did not have access to a published protocol
Other bias Unclear risk No suggestion of other biases-baseline
characteristics balanced (table 1, page
1653); however, this was a manufacturer-
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Keck 2003 (Continued)
sponsored study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind (page 1652), no de-
tails of methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
Keck 2009
Methods Randomised controlled trial
Multicentre (49 US centres)
12 weeks
April 2004 and July 2006
Participants N = 488
18- to 65-year-olds (mean ages: placebo 39.8 (SD 11.3), lithium 39.6 (SD 10.5), arip-
iprazole 39.6 (SD 10.6))
Males 52%, females 48%
Bipolar I disorder (DSM-IV criteria), acute manic or mixed episode with or without
psychotic features and YMRS ≥ 20 requiring hospitalisation
Exclusions include cognitive or psychotic disorders other than mania, bipolar II, bipolar
NOS, rapid cycling, known non-response to antimanic agents, substance or alcohol
abuse, medical conditions exposing to undue harm
Interventions Aripiprazole (N = 155), lithium (N = 160) or placebo (N = 165)
Three parallel groups
Following washout period, participants were allocated 1:1:1 to aripiprazole, lithium or
placebo
Participants requiring hospitalisation beyond three weeks were discontinued
After three weeks, participants in the placebo group were switched to aripiprazole for
remaining nine weeks of the study but were excluded from the analysis beyond week
three
After 12 weeks, participants could enter a 40-week extension phase
Outcomes Primary: mean change from baseline on YMRS total score (days two and four, weeks
one, two, three, four, five, six, eight, 10 and 12)
Secondary: response (≥ 50% decrease in total YMRS), remission (YMRS ≤ 12) at three
weeks and at 12weeks, CGI-bipolar version severity of illness (mania, depression, overall)
and change from preceding phase (mania) (days two and four, weeks one, two, three,
four, five, six, eight, 10 and 12), PANSSmean change (total, cognitive, hostility) at three
weeks and at 12 weeks,MADRSmean change (days two and four, weeks one, two, three,
four, five, six, eight, 10 and 12)
Notes Manufacturer sponsored
Third phase of study is still ongoing. Participants could continue double-blind on arip-
iprazole or lithium for additional 40 weeks
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details-merely stated as randomised
(page 38)
Allocation concealment (selection bias) Unclear risk No details of method
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Figure 1 (page 41) provides the disposition
of participants during the study but some
missing data. Likely low impact. LOCF
used
Selective reporting (reporting bias) Unclear risk Stated outcomes are reported on; however,
we did not have access to a published pro-
tocol
Other bias Unclear risk No suggestion of other biases-baseline
characteristics balanced (table 1, page 40)
; however, this was a manufacturer-spon-
sored study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Details/methods lacking
Sham lithium levels are stated as hav-
ing been reported in the aripiprazole and
placebo arms, but the exact method is un-
clear (page 38) (e.g. Were blood samples
taken, How were sham levels given?)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of method
NCT00665366
Methods Randomised controlled trial
Multicentre (73 sites in Europe, South Africa and Russia)
12 weeks
June 2008 to October 2011
Participants N = 370
18 years and older-age range not stated (mean age: 44.65 ± 12.57)
Males 46%, females 54%
Bipolar I mania, manic or mixed with or without psychotic features
Current ongoing treatment with lithium or valproate
Therapeutic lithium or valproate levels and YMRS ≥ 16
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Exclusions include women of child-bearing potential; delirium, dementia, amnesia or
other cognitive disorder, or a psychotic disorder; bipolar II or NOS, or any other primary
psychiatric disorder other than bipolar I mania; thyroid pathology; cocaine abuse; history
of NMS; refractory manic symptoms; previous non-response to aripiprazole; significant
risk of suicide
Interventions Aripiprazole (N = 181) or placebo (N = 189) in combination with valproate or lithium
Participants partially non-responsive (YMRS ≥ 16) to therapeutic levels of lithium or
valproate entered 12 weeks of double-blind treatment, during which they were allocated
aripiprazole or placebo in a 1:1 ratio. Aripiprazole was given at 5 mg daily (week one)
, then at 10 mg daily (weeks two and three), then at 15 mg daily (weeks four to six).
Flexible dosing of 15 mg or 30 mg daily was administered during weeks seven to 12.
The dose could be reduced during weeks seven to 12 to 10 mg daily if necessary for
tolerability
Outcomes Primary: mean change from baseline on YMRS total score at week 12
Secondary: response (≥ 50% decrease in total YMRS), remission (YMRS < 12), CGI-
bipolar version scale (severity) for mania, depression and overall illness, FAST-change
from baseline in total and subscale scores, LIFE-RIFT-change from baseline in total
score, PGI-I
Measurements taken at three, six, nine and 12 weeks
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details-merely stated as randomised
Allocation concealment (selection bias) Unclear risk No details of methods
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not all participants allocated treatment
were included in all the analyses. Likely
low impact. Table included that lists rea-
sons and numbers of participants discon-
tinuing. LOCF used when possible
Selective reporting (reporting bias) Unclear risk Stated outcomes reported on; however, we
did not have access to a published protocol
Other bias Unclear risk No suggestion of other biases (baseline
characteristics balanced-participant flow
table); however, this was a manufacturer-
sponsored study
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NCT00665366 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind, no details of meth-
ods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
Sachs 2006
Methods Randomised controlled trial
Multicentre (29 US centres)
Three weeks
Study dates not stated
Participants N = 272
Age: ≥ 18 years (age range not stated), mean age: 38.8 (SE 0.7)
Males 49%, females 51%
Bipolar I disorder (DSM-IV criteria), acute manic or mixed episode requiring hospitali-
sation with baseline YMRS ≥ 20
Exclusion criteria: delirium, dementia, amnestic or other cognitive disorders, schizophre-
nia or schizoaffective disorder, experiencing first manic episode, duration of episode >
four weeks, unresponsive to clozapine, possibility that the patient would require pro-
hibited concomitant medication, use of psychoactive substances, substance use disorder,
lithium > 0.6 mmol/L or divalproex sodium > 50 microgram/mL (therapeutic levels)
at screening, suicide or homicide risk, history of neuroleptic malignant syndrome or
seizure disorder, clinically significant laboratory test results, vital signs, ECG, or previous
enrolment in aripiprazole trial
Interventions Aripiprazole variable dose (N = 137) and placebo (N = 135)
Following a one- to seven-day screening period, participants were allocated to aripiprazole
30 mg daily (with option to reduce to 15 mg for tolerability) or to placebo for three
weeks
Participants remained hospitalised for a minimum of two weeks. 85% remained on 30-
mg dose at endpoint
Outcomes Primary: YMRS mean change from baseline
Secondary: response (≥ 50% decrease in YMRS), CGI-bipolar version severity of illness
and change from preceding phase for mania, depression and overall illness, mean change
in PANSS-total and hostility subscale, MADRS and rate of discontinuation due to lack
of efficacy
All assessed at days two, four, seven, 10, 14 and 21
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
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Sachs 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details-merely stated as randomised
(page 537)
Allocation concealment (selection bias) Unclear risk No details of methods
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 272 randomly assigned, three did not take
medication and were excluded from anal-
ysis, one discontinued early (page 538).
Likely low impact. LOCF used
Selective reporting (reporting bias) Unclear risk Stated outcomes are reported on; however,
we did not have access to a published pro-
tocol
Other bias Unclear risk No suggestion of other biases-baseline
characteristics balanced (table 1, page 539)
; however, this was a manufacturer-spon-
sored study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind (page 537), no de-
tails of methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
Tramontina 2009
Methods Randomised controlled trial
One centre in Brazil
Six weeks
January 2005 to November 2007
Participants N = 43
Eight- to 17-year-olds (mean ages: aripiprazole 11.72 (SD 2.71), placebo 12.16 (SD 2.
75))
Males 46.5%, females 53.5%
Bipolar I or II disorder (DSM-IV criteria), acute manic or mixed state (YMRS ≥ 20)
Comorbid with DSM-IV ADHD (clear reports of ADHD symptom onset preceding
any mood symptoms)
Outpatients
Exclusions include IQ < 70, medication use during the previous four weeks, PDD <
schizophrenia, substance abuse, suicide/homicide risk, previous aripiprazole use, preg-
nancy, acute/chronic diseases that may interfere with the study
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Interventions Aripiprazole variable dose (N = 18) or placebo (N = 25)
Starting dose > 50 kg = 5 mg/d, < 50 kg = 2 mg/d
Dose increased according to response/adverse effects to a max 20 mg/d
Outcomes Primary: mean change in YMRS
Secondary: response (≥ 50% decrease in YMRS), remission (YMRS≤ 12), CGI severity
of illness, Child Mania Rating Scale-parent version, Brazilian version of Child’s Depres-
sion Rating Scale, Kutcher Adolescent Rating Scale
Assessed at weeks one, two, three, four, five and six
Notes Not manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived sequence algorithm-
Epi-Info (page 757)
Allocation concealment (selection bias) Unclear risk Independent third party performed group
allocation. No further details (page 737)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, ITT analysis
and none excluded/missing (figure 1, page
760)
Selective reporting (reporting bias) Unclear risk All outcomes reported in the published
study; however, we did not have access to a
published protocol
Other bias Low risk No suggestion of other biases-baseline
characteristics balanced (table 1, page 761)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as blind (page 757), no details of
methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
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Vieta 2005
Methods Randomised controlled trial.
Multicentre (76 international centres).
12 weeks
Study dates not stated.
Participants N = 347
Age range: 18 to 68 years (mean age: 41.8 (SD 0.6))
Males 38%, females 62%
Bipolar I disorder (DSM-IV criteria), acute manic or mixed episode and YMRS baseline
≥ 20
Inpatients or outpatients
Exclusion criteria: rapid cycling bipolar I, current manic episode of > four weeks, Proven
substance misuse, unresponsive to antipsychotics, significant risk of suicide, recent treat-
ment with long-acting antipsychotics, lithium or divalproate, use of psychotropic medi-
cations (other than benzodiazepines) within one day of randomisation, use of fluoxetine
within past four weeks, previous enrolment in an aripiprazole study
Interventions Aripiprazole variable dose (N = 175) or haloperidol variable dose (N = 172)
After a one- to three-day washout period, participants were allocated to aripiprazole 15
mg daily (with an option to increase to 30 mg if poor response at end of week one or
two) or haloperidol 10 mg daily (with an option to increase to 15 mg if poor response at
end of week one or two). Average aripiprazole dose: at three weeks = 22.6 mg and at 12
weeks = 21.6 mg. Average haloperidol dose: at three weeks = 11.6 mg and at 12 weeks
= 11.1 mg.
At the end of week three, if CGI-BP (mania) severity scale ≥ 4 or MADRS ≥ 18,
participants were discontinued from the study
Participants remaining from four to 12 weeks continued on the dose prescribed in week
three (dose decreases were allowed for tolerability)
Outcomes Primary: response (≥ 50% decrease in YMRS from baseline)
Secondary: remission (YMRS≤ 12), mean change in YMRS, CGI-bipolar version-sever-
ity of illness for mania, depression and overall illness, MADRS, time to discontinuation
for any reason
All assessed at days four and seven and 10 and at weeks two, three, four, five, six, eight,
10 and 12
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as a fixed randomisation schedule in
a 1:1 ratio between treatment arms, but no
details of methods provided (page 235)
Allocation concealment (selection bias) Unclear risk No details of method
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk CONSORT diagram (figure 1, page 236)
and numbers balanced across intervention
groups. LOCF used. One participant ran-
domly assigned to haloperidol but treated
with aripiprazole. Likely low impact
Selective reporting (reporting bias) Unclear risk Results for all stated outcomes appear in
the text; however, we did not have access to
a published protocol
Other bias Unclear risk No suggestion of other biases-baseline
characteristics balanced (table 1, page 237)
. However, this was a manufacturer-spon-
sored study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind (page 235), no de-
tails of methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
Vieta 2008
Methods Randomised controlled trial
Multicentre (number not stated)
Six weeks
Study dates not stated
Participants N = 384
Age: 18 years or older (mean ages: aripiprazole 42.2 (SD 11.6), placebo 41.7 (SD 12.1))
Males 46%, females 54%
Bipolar I (DSM-IV criteria),manic ormixed episodewith orwithout psychotic symptoms
Participants were required to have lithium levels of 0.6 to 1.0 mmol/L or valproate levels
of 50 to 125 microg/mL
Exclusion criteria include hospitalisation for current episode of longer than three weeks,
previous non-response to antimanics, bipolar II, rapid cycling, substance use, suicide
risk, use of long-acting antipsychotics
Interventions Aripiprazole (N = 253) or placebo (N = 131) in combination with valproate or lithium
Phase one: three-day to four-week washout of medication other than lithium or valproate
Phase two: Participants not already taking lithium or valproate were started on one of
these treatments, then a two-week period followed to confirm whether participants were
partially non-responsive to lithium or valproate
If partially non-responsive (YMRS ≥ 16), participants entered phase three, which was
a six-week double-blind phase during which they were allocated aripiprazole or placebo
in a 2:1 ratio. Aripiprazole was started at 15 mg daily and could be increased from day
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seven to a max of 30 mg if required
Outcomes Primary: mean change in YMRS
Secondary: response (≥ 50% decrease in YMRS frombaseline), remission (YMRS≤ 12),
CGI-bipolar version-mean change in severity of illness and change from preceding phase
for mania, depression and overall illness, MADRS, PANSS total and positive, negative,
cognitive and hostility subscales, Time to discontinuation for any reason
All assessed at day four, weeks one, two, three, four, five and six
Notes Manufacturer sponsored
Fourth phase of study: Participants could enter a 46-week open-label extension with
aripiprazole and lithium or valproate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Merely stated as randomised (page 1317),
no details of methods provided
Allocation concealment (selection bias) Unclear risk No details of methods
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk LOCF data used, but some data missing.
Likely low impact. CONSORT diagram
included (figure 1, page 1318)
Selective reporting (reporting bias) Unclear risk Stated outcomes are reported on; however,
we did not have access to a published pro-
tocol
Other bias Unclear risk Unclear how study personnel allocated
participants in phase two to lithium or
valproate. Unclear how drug levels were
blinded and how they were dealt with dur-
ing the double-blind phase. Also, manufac-
turer sponsored
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Phases one and two were open-label; phase
three stated as double-blind, but no details
of methods (page 1317)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
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Young 2009
Methods Randomised controlled trial
Multicentre (59 international centres)
Three weeks
Study dates not stated
Participants N = 485
Age: 18 years or older (range not stated); mean age: 40.8
Males 44%, females 56%
Bipolar I (DSM-IV) with an acute manic or mixed episode with or without psychotic
features requiring hospitalisation with YMRS ≥ 20 (< 25% increase from screening to
baseline) andMADRS total≤ 17 at end of phase one (nomore than a four-point increase
between screening and baseline with measures at least two days apart)
Exclusions include delirium, dementia, amnestic or other cognitive disorders, schizophre-
nia, schizoaffective disorder, first manic/mixed episode, personality disorder, serious un-
stable medical illness, hospitalisation for current episode of > three weeks, previously
unresponsive to antimanics, bipolar II, rapid cycling, substance misuse, suicide risk,
long-acting antipsychotics, antidepressants during the previous two to four weeks, ECG
during three previous weeks, long-acting antipsychotics
Interventions Aripiprazole (N = 167), haloperidol (N = 165), placebo (N = 153)
Phase one: two- to 14-day screening and washout
Phase two: double-blind treatment with aripiprazole, haloperidol or placebo in a 1:1:1
ratio for three weeks. After three weeks, those receiving placebo were offered open-label
aripiprazole. All participants continued until week 12
Aripiprazole was started at 15 mg on day one of phase two. On day four, it was increased
to 30 mg if required (mean dose at three weeks = 23.6 mg/d, at 12 weeks = 22.0 mg/d)
. Haloperidol was started at 5 mg/d on day one. Dose could increase to 10 mg on day
four and 15 mg on day seven if required (mean dose at three weeks = 5.8 mg/d, 12 weeks
= 7.4 mg/d)
Outcomes Primary: mean change from baseline in YMRS total score
Secondary: response (≥ 50% decrease in YMRS from baseline), response (YMRS ≤ 12)
, mean change in CGI-bipolar version-severity and change from preceding phase for
mania, CGI-BP severity of illness, mean change in PANSS total and cognitive, hostility,
positive and negative subscales, MADRS total mean change, LIFE-RIFT
All assessed at days two, four, seven, 10, weeks two, three, four, five, six, eight, 10 and
12
Notes Manufacturer sponsored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Merely stated as randomisedwith nodetails
of methods (page 40)
Allocation concealment (selection bias) Unclear risk No details of methods
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk LOCF used. Some missing data (figure
1, page 42 gives the flow of participants
through the study and includes reasons for
discontinuing). Likely low impact
Selective reporting (reporting bias) Unclear risk Prespecified outcomes have been reported
on; however, we did not have access to a
study protocol
Other bias Unclear risk Baseline characteristics are stated as similar
between groups, but this information was
not available, and it is stated as reported
online in a table (DS2) separately from the
published report (page 41). Manufacturer
sponsored
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind but no details of
methods (page 40)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details of methods
YMRS = Young Mania Rating Scale: consists of 11 items that assess the core symptoms of mania. The severity of four items (irritability,
speech (rate and amount), content and disruptive/aggressive behaviour) is graded from zero (best) to eight (worst), while the severity
of the seven other items (elevatedmood, increasedmotor activity/energy, sexual interest, sleep, language/thought disorder, appearance
and insight) is graded from zero (best) to four (worst). The YMRS is the sum of all items with a possible score from 0 to 60.
CGI-BP = Clinical Global Impression Scale-Bipolar Version: The scale comprises three major categories rating the severity of illness,
the change from preceding illness and the change from the worst phase of the illness in the domains of mania, depression and overall
illness, rating on each of these domains using seven-point Likert scales.
CGAS = Children’s Global Assessment Scale: a 100-point rating scale to assess the emotional and behavioural functioning of a child in
the past three months, with one being the worst score and 100 the best.
CDRS-R = Children’s Depression Rating Scale - Revised: a brief rating scale based on a semi-structured interview (modelled on the
Hamilton Rating Scale for Depression) to diagnose depression and determine its severity. Seventeen symptom areas are rated, most of
them on a seven-point scale and giving a single summary score.
GBI = General Behaviour Inventory: a 73-item self-reported questionnaire to identify individuals at risk for serious affective disorders.
The 73 clinical symptoms are rated on a four-point scale.
PANSS = Positive and Negative Syndrome Scale: assesses the presence of positive and negative syndromes within schizophrenia. Thirty
symptoms or signs within the categories of positive, negative and general psychopathology are assessed by the clinician and graded by
severity on a seven-point Likert scale from absent to extreme.
MADRS =Montgomery Asberg Depression Rating Scale: a clinician-rated 10-item scale used to assess depressive symptoms, particularly
change following treatment with antidepressant medication. Items are rated on a zero to six scale with a total possible score of 60 and
higher scores indicating greater depressive symptoms.
LIFE-RIFT = Longitudinal Interval Follow-up Evaluation-Range of Impaired Function Tool: a brief assessment of functional impair-
ment. Total score = four to 20 and is the sum of four items: work, interpersonal relations, satisfaction and recreation. A negative score
indicates improvement.
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FAST = Functional Assessment Short Test: an interview-administered instrument used to assess the main functioning problems that
patients with bipolar disorder experience. The FAST consists of 24 items that assess impairment or disability in six specific areas
of functioning (autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure
time). All items are rated using a four-point scale. Global score ranges from zero to 96, with higher scores indicating higher levels of
impairment.
PGI-I = Patient Global Impression Improvement Scale: self-administered seven-point scale with scores ranging from one (very much
improved) to seven (very much worse).
ADHD = Attention-deficit hyperactivity disorder.
PDD = pervasive developmental disorder.
PTSD = post-traumatic stress disorder.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
CN138077 Did not produce any results
CN138189 Data could not be used from phase two of the study, as it did not include a comparison arm
NCT00484471 It was not possible to use data from the acute phase, as it had no comparison arm and was open-label
NCT00606229 Open-label study
NCT01567527 Acute phases of treatment were open-label or single-blind
Woo 2011 Not possible to use data from the acute phase, as it had no comparison arm and was open-label
Zeni 2009 Not a study assessing the effect of aripiprazole on acute mania
Zimbroff 2007 Indication for treatment was immediate relief of acute agitation (rapid tranquillisation)
Characteristics of studies awaiting assessment [ordered by study ID]
Kanba 2012
Methods A multicentre, randomised, double-blind, placebo-controlled, parallel-group comparison trial
Participants Patients aged 18 to 65 who meet DSM-IV-TR criteria for manic or mixed episodes
Interventions Aripiprazole 24 mg per day versus placebo
Outcomes Primary: Young Mania Rating Scale (YMRS); secondary: Clinical Global Impression-Bipolar Version (CGI-BP)
Notes Manufacturer sponsored
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D A T A A N D A N A L Y S E S
Comparison 1. Aripiprazole versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in YMRS from
baseline at three weeks
6 1819 Mean Difference (IV, Random, 95% CI) -3.66 [-5.28, -2.05]
1.1 Aripiprazole variable dose
versus placebo as monotherapy
4 1146 Mean Difference (IV, Random, 95% CI) -3.69 [-5.01, -2.38]
1.2 Aripiprazole 10 mg versus
placebo as monotherapy
1 142 Mean Difference (IV, Random, 95% CI) -5.80 [-8.88, -2.72]
1.3 Aripiprazole 15 mg versus
placebo as monotherapy
1 192 Mean Difference (IV, Random, 95% CI) 0.11 [-3.17, 3.39]
1.4 Aripiprazole 30 mg versus
placebo as monotherapy
2 339 Mean Difference (IV, Random, 95% CI) -3.82 [-9.92, 2.27]
2 Mean change in YMRS from
baseline at day four
2 510 Mean Difference (IV, Random, 95% CI) -2.83 [-4.52, -1.14]
2.1 Aripiprazole variable dose
versus placebo as monotherapy
2 510 Mean Difference (IV, Random, 95% CI) -2.83 [-4.52, -1.14]
3 Mean change in YMRS from
baseline week four
1 287 Mean Difference (IV, Fixed, 95% CI) -7.16 [-9.44, -4.88]
3.1 Aripiprazole 10 mg versus
placebo as monotherapy
1 142 Mean Difference (IV, Fixed, 95% CI) -6.0 [-9.24, -2.76]
3.2 Aripiprazole 30 mg versus
placebo as monotherapy
1 145 Mean Difference (IV, Fixed, 95% CI) -8.3 [-11.51, -5.09]
4 Mean change in YMRS from
baseline at week six
2 420 Mean Difference (IV, Random, 95% CI) -4.38 [-9.13, 0.37]
4.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 377 Mean Difference (IV, Random, 95% CI) -2.61 [-4.25, -0.97]
4.2 Aripiprazole versus
placebo as monotherapy
1 43 Mean Difference (IV, Random, 95% CI) -7.70 [-13.45, -1.95]
5 Mean change in YMRS from
baseline to week 12
1 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Response (≥ 50% decrease in
total YMRS from baseline) at
three weeks
4 1230 Risk Ratio (M-H, Random, 95% CI) 1.70 [1.23, 2.34]
6.1 Aripiprazole variable dose
versus placebo
2 534 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.43, 2.34]
6.2 Aripiprazole 10 mg versus
placebo as monotherapy
1 147 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.24, 4.81]
6.3 Aripiprazole 15 mg versus
placebo
1 198 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.73, 1.55]
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6.4 Aripiprazole 30 mg versus
placebo
2 351 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.64, 5.45]
7 Response (≥ 50% decrease in
total YMRS from baseline) at
four weeks
1 295 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.50, 3.16]
7.1 Aripiprazole 10 mg versus
placebo
1 147 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.04, 3.08]
7.2 Aripiprazole 30 mg versus
placebo
1 148 Risk Ratio (M-H, Random, 95% CI) 2.60 [1.55, 4.34]
8 Response (≥ 50% decrease in
total YMRS from baseline) at
six weeks
2 420 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.09, 1.80]
8.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 377 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.06, 1.58]
8.2 Aripiprazole versus
placebo as monotherapy
1 43 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.13, 2.58]
9 Remission (YMRS total score ≤
12) at six weeks
3 782 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.98, 1.69]
9.1 Aripiprazole versus
placebo as monotherapy
1 43 Risk Ratio (M-H, Random, 95% CI) 2.26 [1.19, 4.28]
9.2 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 739 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.96, 1.44]
10 CGI-Bipolar Version: severity
(mania)-mean change at three
weeks
7 2262 Mean Difference (IV, Random, 95% CI) -0.41 [-0.66, -0.16]
10.1 Aripiprazole variable dose
versus placebo as monotherapy
4 1142 Mean Difference (IV, Random, 95% CI) -0.43 [-0.61, -0.25]
10.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 188 Mean Difference (IV, Random, 95% CI) -0.60 [-0.92, -0.28]
10.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 190 Mean Difference (IV, Random, 95% CI) -0.12 [-0.55, 0.31]
10.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 385 Mean Difference (IV, Random, 95% CI) -0.64 [-1.56, 0.28]
10.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 357 Mean Difference (IV, Random, 95% CI) 0.04 [-0.18, 0.26]
11 CGI-Bipolar Version: severity
(mania)-mean change at four
weeks
1 287 Mean Difference (IV, Random, 95% CI) -1.05 [-1.54, -0.56]
11.1 Aripiprazole 10 mg
versus placebo
1 142 Mean Difference (IV, Random, 95% CI) -0.8 [-1.21, -0.39]
11.2 Aripiprazole 30 mg
versus placebo
1 145 Mean Difference (IV, Random, 95% CI) -1.3 [-1.71, -0.89]
12 CGI-Bipolar Version:
improvement (mania)-mean
change at three weeks
5 1529 Mean Difference (IV, Random, 95% CI) -0.41 [-0.62, -0.21]
12.1 Aripiprazole variable
dose versus placebo
4 1143 Mean Difference (IV, Random, 95% CI) -0.52 [-0.70, -0.34]
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12.2 Aripiprazole 15 mg
versus placebo
1 192 Mean Difference (IV, Random, 95% CI) -0.06 [-0.52, 0.40]
12.3 Aripiprazole 30 mg
versus placebo
1 194 Mean Difference (IV, Random, 95% CI) -0.06 [-0.50, 0.38]
13 CGI-Bipolar Version: severity
(depression)-mean change at
three weeks
6 1905 Mean Difference (IV, Random, 95% CI) -0.09 [-0.18, 0.01]
13.1 Aripiprazole variable dose
versus placebo as monotherapy
3 878 Mean Difference (IV, Random, 95% CI) 0.06 [-0.13, 0.24]
13.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 142 Mean Difference (IV, Random, 95% CI) -0.30 [-0.70, 0.10]
13.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 190 Mean Difference (IV, Random, 95% CI) -0.12 [-0.42, 0.18]
13.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 338 Mean Difference (IV, Random, 95% CI) -0.25 [-0.49, -0.01]
13.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 357 Mean Difference (IV, Random, 95% CI) -0.08 [-0.22, 0.06]
14 CGI-Bipolar Version: severity
(depression)-mean change at
four weeks
1 287 Mean Difference (IV, Random, 95% CI) -0.30 [-0.61, 0.01]
14.1 Aripiprazole 10 mg
versus placebo
1 142 Mean Difference (IV, Random, 95% CI) -0.30 [-0.74, 0.14]
14.2 Aripiprazole 30 mg
versus placebo
1 145 Mean Difference (IV, Random, 95% CI) -0.30 [-0.74, 0.14]
15 CGI-Bipolar Version:
improvement
(depression)-mean change at
three weeks
2 632 Mean Difference (IV, Random, 95% CI) -0.19 [-0.45, 0.07]
15.1 Aripiprazole variable dose
versus placebo as monotherapy
1 246 Mean Difference (IV, Random, 95% CI) -0.40 [-0.71, -0.09]
15.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 192 Mean Difference (IV, Random, 95% CI) 0.05 [-0.31, 0.41]
15.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 194 Mean Difference (IV, Random, 95% CI) -0.18 [-0.55, 0.19]
16 CGI-Bipolar Version: severity
(overall)-mean change at three
weeks
5 1549 Mean Difference (IV, Random, 95% CI) -0.52 [-0.75, -0.29]
16.1 Aripiprazole variable dose
versus placebo as monotherapy
3 879 Mean Difference (IV, Random, 95% CI) -0.44 [-0.61, -0.26]
16.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 142 Mean Difference (IV, Random, 95% CI) -0.7 [-1.05, -0.35]
16.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 190 Mean Difference (IV, Random, 95% CI) -0.24 [-0.65, 0.17]
16.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 338 Mean Difference (IV, Random, 95% CI) -0.65 [-1.55, 0.26]
17 CGI-Bipolar Version: severity
(overall)-mean change at six
weeks
2 419 Mean Difference (IV, Random, 95% CI) -0.08 [-0.72, 0.56]
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17.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 376 Mean Difference (IV, Random, 95% CI) -0.3 [-0.56, -0.04]
17.2 Aripiprazole variable dose
versus placebo as monotherapy
1 43 Mean Difference (IV, Random, 95% CI) 0.41 [-0.49, 1.31]
18 CGI-Bipolar Version:
improvement (overall)-mean
change at three weeks
2 633 Mean Difference (IV, Random, 95% CI) -0.37 [-0.82, 0.08]
18.1 Aripiprazole variable dose
versus placebo as monotherapy
1 247 Mean Difference (IV, Random, 95% CI) -0.80 [-1.20, -0.40]
18.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 192 Mean Difference (IV, Random, 95% CI) -0.11 [-0.57, 0.35]
18.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 194 Mean Difference (IV, Random, 95% CI) -0.17 [-0.61, 0.27]
19 Mean change in MADRS from
baseline to week three
2 635 Mean Difference (IV, Random, 95% CI) -0.43 [-2.08, 1.22]
19.1 Aripiprazole variable dose
versus placebo as monotherapy
2 635 Mean Difference (IV, Random, 95% CI) -0.43 [-2.08, 1.22]
20 Mean change in PANSS total
score at week three
3 863 Mean Difference (IV, Random, 95% CI) -3.22 [-5.26, -1.19]
20.1 Aripiprazole 15 mg
versus placebo
1 145 Mean Difference (IV, Random, 95% CI) 0.56 [-4.00, 7.12]
20.2 Aripiprazole 30 mg
versus placebo
1 137 Mean Difference (IV, Random, 95% CI) -1.45 [-8.16, 5.26]
20.3 Aripiprazole variable dose
versus placebo as monotherapy
2 581 Mean Difference (IV, Random, 95% CI) -3.87 [-6.13, -1.62]
21 Mean change in
PANSS-hostility subscale score
at week three
3 827 Mean Difference (IV, Random, 95% CI) -1.17 [-1.68, -0.66]
21.1 Aripiprazole variable
dose versus placebo
1 246 Mean Difference (IV, Random, 95% CI) -1.39 [-2.41, -0.37]
21.2 Aripiprazole variable dose
versus placebo as monotherapy
2 581 Mean Difference (IV, Random, 95% CI) -1.10 [-1.69, -0.51]
22 Mean change in PANSS
cognitive subscale score at week
three
3 863 Mean Difference (IV, Random, 95% CI) -0.77 [-1.38, -0.15]
22.1 Aripiprazole 15 mg
versus placebo
1 145 Mean Difference (IV, Random, 95% CI) 0.58 [-1.19, 2.35]
22.2 Aripiprazole 30 mg
versus placebo
1 137 Mean Difference (IV, Random, 95% CI) -0.45 [-4.61, 3.71]
22.3 Aripiprazole variable dose
versus placebo as monotherapy
2 581 Mean Difference (IV, Random, 95% CI) -0.97 [-1.63, -0.30]
23 Requirement for
anticholinergics
2 730 Risk Ratio (M-H, Random, 95% CI) 3.28 [1.82, 5.91]
23.1 Aripiprazole variable
dose versus placebo
1 384 Risk Ratio (M-H, Random, 95% CI) 2.70 [1.37, 5.34]
23.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.65, 12.18]
23.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 8.5 [2.02, 35.82]
24 Requirement for lorazepam 2 638 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.12]
60Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
25 Numbers completing
double-blind treatment
8 2216 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.95, 1.12]
25.1 Aripiprazole variable dose
versus placebo as monotherapy
5 1217 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.94, 1.29]
25.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 147 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.93, 1.31]
25.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 98 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.81, 1.24]
25.4 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 754 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.87, 1.02]
26 Failure to complete
treatment-dropouts: adverse
drug reaction
8 2621 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.97, 1.63]
26.1 Aripiprazole variable dose
versus placebo as monotherapy
4 1174 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.83, 1.74]
26.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 147 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.23, 17.42]
26.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 197 Risk Ratio (M-H, Random, 95% CI) 2.52 [0.90, 7.07]
26.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 349 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.53, 3.90]
26.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 754 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.69, 2.00]
27 Failure to complete
treatment-dropouts: lack of
efficacy
8 2609 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.44, 0.84]
27.1 Aripiprazole variable dose
versus placebo as monotherapy
4 1174 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.30, 0.77]
27.2 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 754 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.53, 1.85]
27.3 Aripiprazole 10 mg
versus placebo as monotherapy
1 147 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.05, 1.32]
27.4 Aripiprazole 15 mg
versus placebo as monotherapy
1 192 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.40, 1.20]
27.5 Aripiprazole 30 mg
versus placebo as monotherapy
2 342 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.18, 2.12]
28 Participants meeting criteria for
treatment as outpatients
2 534 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.19, 2.34]
29 Simpson Angus Scale 4 1233 Mean Difference (IV, Random, 95% CI) 0.75 [0.20, 1.30]
29.1 Aripiprazole variable dose
versus placebo as monotherapy
2 561 Mean Difference (IV, Random, 95% CI) 0.07 [-0.77, 0.90]
29.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 141 Mean Difference (IV, Random, 95% CI) 0.66 [0.18, 1.14]
29.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 192 Mean Difference (IV, Random, 95% CI) 0.86 [0.09, 1.63]
29.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 339 Mean Difference (IV, Random, 95% CI) 1.51 [0.86, 2.15]
30 Barnes Akathisia Scale 5 1498 Mean Difference (IV, Random, 95% CI) 0.20 [0.09, 0.31]
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30.1 Aripiprazole variable dose
versus placebo as monotherapy
3 825 Mean Difference (IV, Random, 95% CI) 0.27 [0.08, 0.46]
30.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 142 Mean Difference (IV, Random, 95% CI) 0.02 [-0.19, 0.23]
30.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 192 Mean Difference (IV, Random, 95% CI) 0.35 [0.02, 0.68]
30.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 339 Mean Difference (IV, Random, 95% CI) 0.15 [-0.04, 0.35]
31 Abnormal Involuntary
Movement Scale
4 1068 Mean Difference (IV, Random, 95% CI) 0.02 [-0.10, 0.15]
31.1 Aripiprazole variable dose
versus placebo as monotherapy
2 494 Mean Difference (IV, Random, 95% CI) 0.04 [-0.15, 0.24]
31.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 142 Mean Difference (IV, Random, 95% CI) 0.0 [-0.25, 0.25]
31.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 147 Mean Difference (IV, Random, 95% CI) -0.17 [-0.78, 0.44]
31.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 285 Mean Difference (IV, Random, 95% CI) 0.05 [-0.19, 0.29]
32 Manic reaction 2 663 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.40, 2.78]
32.1 Aripiprazole variable dose
versus placebo as monotherapy
1 262 Risk Ratio (M-H, Random, 95% CI) 7.11 [0.37, 136.24]
32.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.26, 3.96]
32.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.15, 2.85]
33 Hypertension 2 663 Risk Ratio (M-H, Random, 95% CI) 3.17 [0.83, 12.14]
33.1 Aripiprazole variable dose
versus placebo as monotherapy
1 262 Risk Ratio (M-H, Random, 95% CI) 3.05 [0.13, 74.09]
33.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 4.09 [0.52, 32.04]
33.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 2.46 [0.29, 20.67]
34 Headache 7 2305 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.87, 1.21]
34.1 Aripiprazole variable dose
versus placebo as monotherapy
3 854 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.85, 1.30]
34.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.46, 2.01]
34.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.73, 1.86]
34.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 352 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.68, 1.51]
34.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 753 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.36, 1.31]
35 Anxiety 3 935 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.86, 1.71]
35.1 Aripiprazole variable dose
versus placebo as monotherapy
2 534 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.86, 2.05]
35.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.46, 2.27]
35.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.48, 2.30]
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36 Insomnia 4 1416 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.82, 1.55]
36.1 Aripiprazole variable dose
versus placebo as monotherapy
1 262 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.77, 2.54]
36.2 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 753 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.72, 2.46]
36.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.50, 1.90]
36.4 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.40, 1.61]
37 Light-headedness 3 932 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.74, 1.57]
37.1 Aripiprazole variable dose
versus placebo as monotherapy
2 534 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.62, 1.91]
37.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 197 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.47, 2.92]
37.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 201 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.35, 2.32]
38 Akathisia 7 2305 Risk Ratio (M-H, Random, 95% CI) 3.16 [2.25, 4.43]
38.1 Aripiprazole variable dose
versus placebo as monotherapy
3 854 Risk Ratio (M-H, Random, 95% CI) 2.75 [1.72, 4.41]
38.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 2.04 [0.45, 9.25]
38.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 9.21 [1.26, 67.48]
38.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 352 Risk Ratio (M-H, Random, 95% CI) 3.91 [1.20, 12.77]
38.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 753 Risk Ratio (M-H, Random, 95% CI) 3.62 [2.00, 6.55]
39 Nausea 7 2305 Risk Ratio (M-H, Random, 95% CI) 1.50 [1.20, 1.88]
39.1 Aripiprazole variable dose
versus placebo as monotherapy
3 854 Risk Ratio (M-H, Random, 95% CI) 1.56 [1.17, 2.08]
39.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.43, 5.40]
39.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.64, 2.66]
39.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 352 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.63, 2.26]
39.5 Aripiprazole versus
placebo as add-on to lithium or
valproate
2 753 Risk Ratio (M-H, Random, 95% CI) 1.74 [0.91, 3.34]
40 Dyspepsia 3 930 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.89, 1.92]
40.1 Aripiprazole variable dose
versus placebo as monotherapy
2 534 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.17, 2.68]
40.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.50, 1.90]
40.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.42, 1.67]
41 Vomiting 4 1232 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.87, 2.48]
41.1 Aripiprazole variable dose
versus placebo as monotherapy
2 534 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.04, 2.76]
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41.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.28, 2.37]
41.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 7.16 [0.96, 53.29]
41.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 352 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.27, 5.61]
42 Constipation 4 1255 Risk Ratio (M-H, Random, 95% CI) 1.75 [1.23, 2.49]
42.1 Aripiprazole variable dose
versus placebo as monotherapy
3 854 Risk Ratio (M-H, Random, 95% CI) 1.72 [1.14, 2.61]
42.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.76, 4.98]
42.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 1.68 [0.65, 4.35]
43 Diarrhoea 4 1319 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.17]
43.1 Aripiprazole variable dose
versus placebo as monotherapy
2 534 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.57, 1.55]
43.2 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 384 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.29, 1.73]
43.3 Aripiprazole 15mg versus
placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.36, 1.91]
43.4 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.25, 1.49]
44 Pain extremity 2 673 Risk Ratio (M-H, Random, 95% CI) 2.01 [1.07, 3.78]
44.1 Aripiprazole variable dose
versus placebo as monotherapy
1 272 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.74, 3.62]
44.2 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 2.56 [0.58, 11.34]
44.3 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 3.20 [0.74, 13.78]
45 Somnolence 3 970 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.94, 3.65]
45.1 Aripiprazole variable dose
versus placebo as monotherapy
1 272 Risk Ratio (M-H, Random, 95% CI) 1.72 [0.98, 3.04]
45.2 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 4.85 [1.18, 19.99]
45.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.32, 2.24]
45.4 Aripiprazole 30 mg
versus placebo as monotherapy
2 352 Risk Ratio (M-H, Random, 95% CI) 2.38 [0.34, 16.79]
46 Tremor 3 1105 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.89, 2.34]
46.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 384 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.68, 3.24]
46.2 Aripiprazole variable dose
versus placebo as monotherapy
1 320 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.62, 3.27]
46.3 Aripiprazole 15 mg
versus placebo as monotherapy
1 198 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.43, 5.48]
46.4 Aripiprazole 30 mg
versus placebo as monotherapy
1 203 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.36, 4.79]
47 EPS 3 1001 Risk Ratio (M-H, Random, 95% CI) 2.24 [1.47, 3.42]
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47.1 Aripiprazole versus
placebo as add-on to lithium or
valproate
1 384 Risk Ratio (M-H, Random, 95% CI) 1.93 [1.22, 3.07]
47.2 Aripiprazole variable dose
versus placebo as monotherapy
1 320 Risk Ratio (M-H, Random, 95% CI) 1.82 [1.12, 2.98]
47.3 Aripiprazole 10 mg
versus placebo as monotherapy
1 148 Risk Ratio (M-H, Random, 95% CI) 5.87 [1.44, 23.89]
47.4 Aripiprazole 30 mg
versus placebo as monotherapy
1 149 Risk Ratio (M-H, Random, 95% CI) 5.05 [1.23, 20.75]
48 Weight gain (≥ 7% increase
from baseline)
5 1596 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.47, 1.10]
48.1 Aripiprazole variable dose
versus placebo as monotherapy
3 854 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.36, 1.03]
48.2 Aripiprazole variable
dose versus placebo as add-on
to lithium or valproate
2 742 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.48, 2.00]
Comparison 2. Aripiprazole versus other drug treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in YMRS from
baseline at week three
3 972 Mean Difference (IV, Random, 95% CI) 0.07 [-1.24, 1.37]
1.1 Versus haloperidol 2 663 Mean Difference (IV, Random, 95% CI) 0.42 [-1.19, 2.03]
1.2 Versus lithium 1 309 Mean Difference (IV, Random, 95% CI) -0.61 [-2.83, 1.61]
2 Mean change in YMRS from
baseline at week 12
2 645 Mean Difference (IV, Random, 95% CI) -1.75 [-3.60, 0.11]
2.1 Versus haloperidol 1 336 Mean Difference (IV, Random, 95% CI) -1.71 [-4.48, 1.06]
2.2 Versus lithium 1 309 Mean Difference (IV, Random, 95% CI) -1.78 [-4.27, 0.71]
3 Response ≥ 50% decrease in
YMRS from baseline at week
three
3 990 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.77, 1.63]
3.1 Versus haloperidol 2 675 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.73, 2.16]
3.2 Versus lithium 1 315 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.64, 1.25]
4 CGI-Bipolar Version: severity
(mania)-mean change at week
three
3 971 Mean Difference (IV, Random, 95% CI) -0.04 [-0.20, 0.13]
4.1 Versus haloperidol 2 664 Mean Difference (IV, Random, 95% CI) 0.02 [-0.19, 0.24]
4.2 Versus lithium 1 307 Mean Difference (IV, Random, 95% CI) -0.14 [-0.42, 0.14]
5 CGI-Bipolar Version: severity
(mania)-mean change at week
12
2 644 Mean Difference (IV, Random, 95% CI) -0.22 [-0.44, -0.00]
5.1 Versus haloperidol 1 337 Mean Difference (IV, Random, 95% CI) -0.31 [-0.67, 0.05]
5.2 Versus lithium 1 307 Mean Difference (IV, Random, 95% CI) -0.17 [-0.45, 0.11]
6 CGI-Bipolar Version: severity
(depression)-mean change at
week 12
2 644 Mean Difference (IV, Random, 95% CI) -0.08 [-0.25, 0.09]
6.1 Versus haloperidol 1 337 Mean Difference (IV, Random, 95% CI) -0.07 [-0.28, 0.14]
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6.2 Versus lithium 1 307 Mean Difference (IV, Random, 95% CI) -0.10 [-0.38, 0.18]
7 CGI-Bipolar Version: severity
(overall)-mean change at week
12
2 644 Mean Difference (IV, Random, 95% CI) -0.29 [-0.50, -0.07]
7.1 Versus haloperidol 1 337 Mean Difference (IV, Random, 95% CI) -0.41 [-0.74, -0.08]
7.2 Versus lithium 1 307 Mean Difference (IV, Random, 95% CI) -0.20 [-0.48, 0.08]
8 CGI-Bipolar Version:
improvement (mania)-mean
change at week three
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Versus haloperidol 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Versus lithium 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Mean change in MADRS from
baseline at week three
3 971 Mean Difference (IV, Random, 95% CI) -0.55 [-2.03, 0.92]
9.1 Versus haloperidol 2 662 Mean Difference (IV, Random, 95% CI) -0.39 [-2.59, 1.82]
9.2 Versus lithium 1 309 Mean Difference (IV, Random, 95% CI) -1.0 [-2.66, 0.66]
10 Mean change in MADRS from
baseline at week 12
2 644 Mean Difference (IV, Random, 95% CI) -1.05 [-2.39, 0.30]
10.1 Versus haloperidol 1 335 Mean Difference (IV, Random, 95% CI) -1.25 [-2.94, 0.44]
10.2 Versus lithium 1 309 Mean Difference (IV, Random, 95% CI) -0.7 [-2.92, 1.52]
11 Mean change in PANSS-total
at week three
2 582 Mean Difference (IV, Random, 95% CI) -0.64 [-3.62, 2.34]
11.1 Versus haloperidol 1 314 Mean Difference (IV, Random, 95% CI) 0.60 [-2.17, 3.37]
11.2 Versus lithium 1 268 Mean Difference (IV, Random, 95% CI) -2.5 [-6.38, 1.38]
12 Mean change in
PANSS-cognitive subscale
score at week three
2 582 Mean Difference (IV, Random, 95% CI) -0.08 [-0.75, 0.59]
12.1 Versus haloperidol 1 314 Mean Difference (IV, Random, 95% CI) 0.10 [-0.73, 0.93]
12.2 Versus lithium 1 268 Mean Difference (IV, Random, 95% CI) -0.40 [-1.51, 0.71]
13 Mean change in
PANSS-hostility subscale score
at week three
2 582 Mean Difference (IV, Random, 95% CI) -0.10 [-0.88, 0.68]
13.1 Versus haloperidol 1 314 Mean Difference (IV, Random, 95% CI) 0.30 [-0.53, 1.13]
13.2 Versus lithium 1 268 Mean Difference (IV, Random, 95% CI) -0.5 [-1.33, 0.33]
14 Simpson Angus Scale LOCF at
week 12
2 646 Mean Difference (IV, Random, 95% CI) -2.09 [-7.11, 2.93]
14.1 Versus haloperidol 1 333 Mean Difference (IV, Random, 95% CI) -4.68 [-5.87, -3.49]
14.2 Versus lithium 1 313 Mean Difference (IV, Random, 95% CI) 0.44 [-0.09, 0.97]
15 Barnes Akathisia Scale LOCF
at week 12
2 646 Mean Difference (IV, Random, 95% CI) -0.17 [-0.76, 0.41]
15.1 Versus haloperidol 1 333 Mean Difference (IV, Random, 95% CI) -0.48 [-0.73, -0.23]
15.2 Versus lithium 1 313 Mean Difference (IV, Random, 95% CI) 0.12 [-0.07, 0.31]
16 Abnormal Involuntary
Movement Scale LOCF at
week 12
2 634 Mean Difference (IV, Random, 95% CI) -0.31 [-0.97, 0.36]
16.1 Versus haloperidol 1 321 Mean Difference (IV, Random, 95% CI) -0.67 [-1.07, -0.27]
16.2 Versus lithium 1 313 Mean Difference (IV, Random, 95% CI) 0.01 [-0.17, 0.19]
17 Akathisia 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
17.1 Versus haloperidol (over
12 weeks)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Versus lithium (over 12
weeks)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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18 Headache 2 657 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.72, 1.42]
18.1 Versus haloperidol (over
12 weeks)
1 344 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.51, 1.66]
18.2 Versus lithium (over 12
weeks)
1 313 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.71, 1.60]
19 Tremor 2 657 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.41, 1.09]
19.1 Versus haloperidol (over
12 weeks)
1 344 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.34, 1.38]
19.2 Versus lithium (over 12
weeks)
1 313 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.33, 1.30]
20 Numbers completing at end of
week three
3 994 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.90, 1.39]
20.1 Versus haloperidol 2 679 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.88, 1.60]
20.2 Versus lithium 1 315 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.22]
21 Numbers completing the trial
(at end of week 12)
3 994 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.73, 1.71]
21.1 Versus haloperidol 2 679 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.74, 2.31]
21.2 Versus lithium 1 315 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.57, 1.13]
22 Failure to complete treatment:
dropouts-lack of efficacy at
three weeks
2 647 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.19, 1.40]
22.1 Versus haloperidol (over
three weeks)
1 332 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.35, 2.23]
22.2 Versus lithium (over
three weeks)
1 315 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.14, 0.70]
23 Failure to complete treatment:
dropouts-adverse event at end
of three weeks
3 994 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.22, 2.76]
23.1 Versus haloperidol (over
three weeks)
2 679 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.09, 4.56]
23.2 Versus lithium (over
three weeks)
1 315 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.64, 2.32]
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Analysis 1.1. Comparison 1 Aripiprazole versus placebo, Outcome 1 Mean change in YMRS from baseline at
three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 1 Mean change in YMRS from baseline at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 123 -8.2 (13.5) 120 -3.4 (13.7) 10.8 % -4.80 [ -8.22, -1.38 ]
Keck 2009 154 -12.64 (9.93) 163 -9.01 (10.21) 15.1 % -3.63 [ -5.85, -1.41 ]
Sachs 2006 136 -12.52 (12.24) 132 -7.19 (12.29) 12.4 % -5.33 [ -8.27, -2.39 ]
Young 2009 166 -11.98 (10.31) 152 -9.7 (10.23) 15.0 % -2.28 [ -4.54, -0.02 ]
Subtotal (95% CI) 579 567 53.4 % -3.69 [ -5.01, -2.38 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 3.10, df = 3 (P = 0.38); I2 =3%
Test for overall effect: Z = 5.51 (P < 0.00001)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -13.9 (9.29) 46 -8.1 (8.51) 11.9 % -5.80 [ -8.88, -2.72 ]
Subtotal (95% CI) 96 46 11.9 % -5.80 [ -8.88, -2.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00023)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 127 -10.01 (11.01) 65 -10.12 (10.95) 11.3 % 0.11 [ -3.17, 3.39 ]
Subtotal (95% CI) 127 65 11.3 % 0.11 [ -3.17, 3.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 -10.8 (11.04) 65 -10.12 (10.95) 11.3 % -0.68 [ -3.95, 2.59 ]
Findling 2009 99 -15 (9.07) 46 -8.1 (8.51) 12.1 % -6.90 [ -9.94, -3.86 ]
Subtotal (95% CI) 228 111 23.4 % -3.82 [ -9.92, 2.27 ]
Heterogeneity: Tau2 = 16.75; Chi2 = 7.45, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 1030 789 100.0 % -3.66 [ -5.28, -2.05 ]
Heterogeneity: Tau2 = 3.20; Chi2 = 17.57, df = 7 (P = 0.01); I2 =60%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.89, df = 3 (P = 0.08), I2 =56%
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Analysis 1.2. Comparison 1 Aripiprazole versus placebo, Outcome 2 Mean change in YMRS from baseline at
day four.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 2 Mean change in YMRS from baseline at day four
Study or subgroup Aripiprazole Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 123 -5.7 (15.49) 120 -2.8 (7.97) 30.0 % -2.90 [ -5.99, 0.19 ]
Sachs 2006 135 -8.17 (8.36) 132 -5.37 (8.5) 70.0 % -2.80 [ -4.82, -0.78 ]
Total (95% CI) 258 252 100.0 % -2.83 [ -4.52, -1.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Aripiprazole versus placebo, Outcome 3 Mean change in YMRS from baseline
week four.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 3 Mean change in YMRS from baseline week four
Study or subgroup Aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -14.2 (9.33) 46 -8.2 (9.17) 49.5 % -6.00 [ -9.24, -2.76 ]
Subtotal (95% CI) 96 46 49.5 % -6.00 [ -9.24, -2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.00029)
2 Aripiprazole 30 mg versus placebo as monotherapy
Findling 2009 99 -16.5 (9.18) 46 -8.2 (9.17) 50.5 % -8.30 [ -11.51, -5.09 ]
Subtotal (95% CI) 99 46 50.5 % -8.30 [ -11.51, -5.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.07 (P < 0.00001)
Total (95% CI) 195 92 100.0 % -7.16 [ -9.44, -4.88 ]
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 6.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.4. Comparison 1 Aripiprazole versus placebo, Outcome 4 Mean change in YMRS from baseline at
week six.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 4 Mean change in YMRS from baseline at week six
Study or subgroup Aripiprazole Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 247 -13.31 (7.9) 130 -10.7 (7.6) 65.3 % -2.61 [ -4.25, -0.97 ]
Subtotal (95% CI) 247 130 65.3 % -2.61 [ -4.25, -0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
2 Aripiprazole versus placebo as monotherapy
Tramontina 2009 18 -27.22 (9.02) 25 -19.52 (10.12) 34.7 % -7.70 [ -13.45, -1.95 ]
Subtotal (95% CI) 18 25 34.7 % -7.70 [ -13.45, -1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
Total (95% CI) 265 155 100.0 % -4.38 [ -9.13, 0.37 ]
Heterogeneity: Tau2 = 8.30; Chi2 = 2.78, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 1.81 (P = 0.071)
Test for subgroup differences: Chi2 = 2.78, df = 1 (P = 0.10), I2 =64%
-10 -5 0 5 10
Favours aripiprazole Favours placebo
71Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Aripiprazole versus placebo, Outcome 5 Mean change in YMRS from baseline
to week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 5 Mean change in YMRS from baseline to week 12
Study or subgroup Aripiprazole Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 176 -13.57 (10.35) 186 -11.54 (10.64) -2.03 [ -4.19, 0.13 ]
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Analysis 1.6. Comparison 1 Aripiprazole versus placebo, Outcome 6 Response (≥ 50% decrease in total
YMRS from baseline) at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 6 Response (≥ 50% decrease in total YMRS from baseline) at three weeks
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo
Keck 2003 49/130 23/132 17.3 % 2.16 [ 1.40, 3.33 ]
Sachs 2006 72/137 42/135 20.8 % 1.69 [ 1.25, 2.27 ]
Subtotal (95% CI) 267 267 38.2 % 1.83 [ 1.43, 2.34 ]
Total events: 121 (Aripiprazole), 65 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 4.83 (P < 0.00001)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 39/98 8/49 11.8 % 2.44 [ 1.24, 4.81 ]
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(. . . Continued)
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 98 49 11.8 % 2.44 [ 1.24, 4.81 ]
Total events: 39 (Aripiprazole), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
3 Aripiprazole 15 mg versus placebo
CN138-007 52/131 25/67 18.8 % 1.06 [ 0.73, 1.55 ]
Subtotal (95% CI) 131 67 18.8 % 1.06 [ 0.73, 1.55 ]
Total events: 52 (Aripiprazole), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 Aripiprazole 30 mg versus placebo
CN138-007 58/136 25/67 19.0 % 1.14 [ 0.79, 1.65 ]
Findling 2009 53/99 8/49 12.2 % 3.28 [ 1.69, 6.34 ]
Subtotal (95% CI) 235 116 31.2 % 1.87 [ 0.64, 5.45 ]
Total events: 111 (Aripiprazole), 33 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 8.07, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 731 499 100.0 % 1.70 [ 1.23, 2.34 ]
Total events: 323 (Aripiprazole), 131 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.23, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Chi2 = 7.22, df = 3 (P = 0.07), I2 =58%
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Analysis 1.7. Comparison 1 Aripiprazole versus placebo, Outcome 7 Response (≥ 50% decrease in total
YMRS from baseline) at four weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 7 Response (≥ 50% decrease in total YMRS from baseline) at four weeks
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole 10 mg versus placebo
Findling 2009 43/98 12/49 47.5 % 1.79 [ 1.04, 3.08 ]
Subtotal (95% CI) 98 49 47.5 % 1.79 [ 1.04, 3.08 ]
Total events: 43 (Aripiprazole), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 Aripiprazole 30 mg versus placebo
Findling 2009 63/99 12/49 52.5 % 2.60 [ 1.55, 4.34 ]
Subtotal (95% CI) 99 49 52.5 % 2.60 [ 1.55, 4.34 ]
Total events: 63 (Aripiprazole), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.64 (P = 0.00027)
Total (95% CI) 197 98 100.0 % 2.18 [ 1.50, 3.16 ]
Total events: 106 (Aripiprazole), 24 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000042)
Test for subgroup differences: Chi2 = 0.96, df = 1 (P = 0.33), I2 =0.0%
0.2 0.5 1 2 5
Favours placebo Favours aripiprazole
74Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Aripiprazole versus placebo, Outcome 8 Response (≥ 50% decrease in total
YMRS from baseline) at six weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 8 Response (≥ 50% decrease in total YMRS from baseline) at six weeks
Study or subgroup aripirpazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 155/247 63/130 71.1 % 1.29 [ 1.06, 1.58 ]
Subtotal (95% CI) 247 130 71.1 % 1.29 [ 1.06, 1.58 ]
Total events: 155 (aripirpazole), 63 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
2 Aripiprazole versus placebo as monotherapy
Tramontina 2009 16/18 13/25 28.9 % 1.71 [ 1.13, 2.58 ]
Subtotal (95% CI) 18 25 28.9 % 1.71 [ 1.13, 2.58 ]
Total events: 16 (aripirpazole), 13 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 265 155 100.0 % 1.40 [ 1.09, 1.80 ]
Total events: 171 (aripirpazole), 76 (placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =29%
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Analysis 1.9. Comparison 1 Aripiprazole versus placebo, Outcome 9 Remission (YMRS total score ≤ 12) at
six weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 9 Remission (YMRS total score ≤ 12) at six weeks
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole versus placebo as monotherapy
Tramontina 2009 13/18 8/25 13.7 % 2.26 [ 1.19, 4.28 ]
Subtotal (95% CI) 18 25 13.7 % 2.26 [ 1.19, 4.28 ]
Total events: 13 (Aripiprazole), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.013)
2 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 91/176 91/186 42.5 % 1.06 [ 0.86, 1.30 ]
Vieta 2008 163/247 66/130 43.8 % 1.30 [ 1.07, 1.57 ]
Subtotal (95% CI) 423 316 86.3 % 1.18 [ 0.96, 1.44 ]
Total events: 254 (Aripiprazole), 157 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 441 341 100.0 % 1.28 [ 0.98, 1.69 ]
Total events: 267 (Aripiprazole), 165 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.86, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Chi2 = 3.63, df = 1 (P = 0.06), I2 =72%
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Analysis 1.10. Comparison 1 Aripiprazole versus placebo, Outcome 10 CGI-Bipolar Version: severity
(mania)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 10 CGI-Bipolar Version: severity (mania) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 124 -1 (1.7) 122 -0.4 (1.7) 10.2 % -0.60 [ -1.02, -0.18 ]
Keck 2009 153 -1.48 (1.24) 162 -1.06 (1.27) 12.2 % -0.42 [ -0.70, -0.14 ]
Sachs 2006 135 -1.59 (1.62) 129 -1.12 (1.7) 10.5 % -0.47 [ -0.87, -0.07 ]
Young 2009 166 -1.44 (1.29) 151 -1.17 (2.09) 10.7 % -0.27 [ -0.66, 0.12 ]
Subtotal (95% CI) 578 564 43.6 % -0.43 [ -0.61, -0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -1.4 (1.23) 92 -0.8 (1.03) 11.6 % -0.60 [ -0.92, -0.28 ]
Subtotal (95% CI) 96 92 11.6 % -0.60 [ -0.92, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.00028)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 125 -1.29 (1.43) 65 -1.17 (1.42) 10.1 % -0.12 [ -0.55, 0.31 ]
Subtotal (95% CI) 125 65 10.1 % -0.12 [ -0.55, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 -1.33 (1.45) 65 -1.17 (1.42) 10.1 % -0.16 [ -0.59, 0.27 ]
Findling 2009 99 -1.9 (1.28) 92 -0.8 (1.03) 11.5 % -1.10 [ -1.43, -0.77 ]
Subtotal (95% CI) 228 157 21.7 % -0.64 [ -1.56, 0.28 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 11.72, df = 1 (P = 0.00062); I2 =91%
Test for overall effect: Z = 1.36 (P = 0.17)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 174 -0.93 (1.06) 183 -0.97 (1.08) 13.0 % 0.04 [ -0.18, 0.26 ]
Subtotal (95% CI) 174 183 13.0 % 0.04 [ -0.18, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 1201 1061 100.0 % -0.41 [ -0.66, -0.16 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 38.01, df = 8 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Chi2 = 15.53, df = 4 (P = 0.00), I2 =74%
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Analysis 1.11. Comparison 1 Aripiprazole versus placebo, Outcome 11 CGI-Bipolar Version: severity
(mania)-mean change at four weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 11 CGI-Bipolar Version: severity (mania) mean change at four weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole 10 mg versus placebo
Findling 2009 96 -1.6 (1.3) 46 -0.8 (1.11) 49.8 % -0.80 [ -1.21, -0.39 ]
Subtotal (95% CI) 96 46 49.8 % -0.80 [ -1.21, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00015)
2 Aripiprazole 30 mg versus placebo
Findling 2009 99 -2.1 (1.29) 46 -0.8 (1.11) 50.2 % -1.30 [ -1.71, -0.89 ]
Subtotal (95% CI) 99 46 50.2 % -1.30 [ -1.71, -0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.23 (P < 0.00001)
Total (95% CI) 195 92 100.0 % -1.05 [ -1.54, -0.56 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 2.84, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 4.20 (P = 0.000026)
Test for subgroup differences: Chi2 = 2.84, df = 1 (P = 0.09), I2 =65%
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Analysis 1.12. Comparison 1 Aripiprazole versus placebo, Outcome 12 CGI-Bipolar Version: improvement
(mania)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 12 CGI-Bipolar Version: improvement (mania) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo
Keck 2003 124 3.3 (1.7) 123 4.1 (1.7) 14.0 % -0.80 [ -1.22, -0.38 ]
Keck 2009 153 2.53 (1.24) 162 3.06 (1.27) 21.2 % -0.53 [ -0.81, -0.25 ]
Sachs 2006 135 2.62 (1.36) 129 3.21 (1.47) 17.7 % -0.59 [ -0.93, -0.25 ]
Young 2009 166 2.66 (1.29) 151 2.98 (1.23) 21.2 % -0.32 [ -0.60, -0.04 ]
Subtotal (95% CI) 578 565 74.0 % -0.52 [ -0.70, -0.34 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.83, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 5.65 (P < 0.00001)
2 Aripiprazole 15 mg versus placebo
CN138-007 127 3.2 (1.69) 65 3.26 (1.48) 12.5 % -0.06 [ -0.52, 0.40 ]
Subtotal (95% CI) 127 65 12.5 % -0.06 [ -0.52, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
3 Aripiprazole 30 mg versus placebo
CN138-007 129 3.2 (1.47) 65 3.26 (1.48) 13.4 % -0.06 [ -0.50, 0.38 ]
Subtotal (95% CI) 129 65 13.4 % -0.06 [ -0.50, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 834 695 100.0 % -0.41 [ -0.62, -0.21 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 10.01, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 3.91 (P = 0.000094)
Test for subgroup differences: Chi2 = 6.05, df = 2 (P = 0.05), I2 =67%
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Analysis 1.13. Comparison 1 Aripiprazole versus placebo, Outcome 13 CGI-Bipolar Version: severity
(depression)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 13 CGI-Bipolar Version: severity (depression) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 124 -0.2 (3.1) 122 0.1 (1.1) 2.6 % -0.30 [ -0.88, 0.28 ]
Keck 2009 153 -0.1 (1.24) 162 -0.2 (1.27) 11.3 % 0.10 [ -0.18, 0.38 ]
Young 2009 166 -0.1 (1.29) 151 -0.2 (1.23) 11.3 % 0.10 [ -0.18, 0.38 ]
Subtotal (95% CI) 443 435 25.2 % 0.06 [ -0.13, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -0.9 (1.21) 46 -0.6 (1.1) 5.4 % -0.30 [ -0.70, 0.10 ]
Subtotal (95% CI) 96 46 5.4 % -0.30 [ -0.70, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 125 -0.43 (1.02) 65 -0.31 (1.01) 9.4 % -0.12 [ -0.42, 0.18 ]
Subtotal (95% CI) 125 65 9.4 % -0.12 [ -0.42, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 128 -0.53 (1.01) 65 -0.31 (1.01) 9.6 % -0.22 [ -0.52, 0.08 ]
Findling 2009 99 -0.9 (1.22) 46 -0.6 (1.1) 5.5 % -0.30 [ -0.70, 0.10 ]
Subtotal (95% CI) 227 111 15.0 % -0.25 [ -0.49, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 174 -0.09 (0.66) 183 -0.01 (0.68) 44.9 % -0.08 [ -0.22, 0.06 ]
Subtotal (95% CI) 174 183 44.9 % -0.08 [ -0.22, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 1065 840 100.0 % -0.09 [ -0.18, 0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.00, df = 7 (P = 0.43); I2 =0%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Chi2 = 5.26, df = 4 (P = 0.26), I2 =24%
-0.5 -0.25 0 0.25 0.5
Favours aripiprazole Favours placebo
80Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.14. Comparison 1 Aripiprazole versus placebo, Outcome 14 CGI-Bipolar Version: severity
(depression)-mean change at four weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 14 CGI-Bipolar Version: severity (depression) mean change at four weeks
Study or subgroup Aripiprazole Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole 10 mg versus placebo
Findling 2009 96 -0.9 (1.37) 46 -0.6 (1.21) 49.0 % -0.30 [ -0.74, 0.14 ]
Subtotal (95% CI) 96 46 49.0 % -0.30 [ -0.74, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Aripiprazole 30 mg versus placebo
Findling 2009 99 -0.9 (1.32) 46 -0.6 (1.21) 51.0 % -0.30 [ -0.74, 0.14 ]
Subtotal (95% CI) 99 46 51.0 % -0.30 [ -0.74, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 195 92 100.0 % -0.30 [ -0.61, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 1.15. Comparison 1 Aripiprazole versus placebo, Outcome 15 CGI-Bipolar Version: improvement
(depression)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 15 CGI-Bipolar Version: improvement (depression) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 124 3.6 (1.3) 122 4 (1.2) 37.5 % -0.40 [ -0.71, -0.09 ]
Subtotal (95% CI) 124 122 37.5 % -0.40 [ -0.71, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 127 3.56 (1.12) 65 3.51 (1.25) 31.8 % 0.05 [ -0.31, 0.41 ]
Subtotal (95% CI) 127 65 31.8 % 0.05 [ -0.31, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 3.33 (1.24) 65 3.51 (1.25) 30.7 % -0.18 [ -0.55, 0.19 ]
Subtotal (95% CI) 129 65 30.7 % -0.18 [ -0.55, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 380 252 100.0 % -0.19 [ -0.45, 0.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.43, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 3.43, df = 2 (P = 0.18), I2 =42%
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Analysis 1.16. Comparison 1 Aripiprazole versus placebo, Outcome 16 CGI-Bipolar Version: severity
(overall)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 16 CGI-Bipolar Version: severity (overall) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 124 -1 (1.7) 123 -0.4 (1.7) 12.5 % -0.60 [ -1.02, -0.18 ]
Keck 2009 153 -1.4 (1.24) 162 -0.9 (1.27) 16.5 % -0.50 [ -0.78, -0.22 ]
Young 2009 166 -1.4 (1.29) 151 -1.1 (1.23) 16.5 % -0.30 [ -0.58, -0.02 ]
Subtotal (95% CI) 443 436 45.5 % -0.44 [ -0.61, -0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -1.4 (1.18) 46 -0.7 (0.91) 14.3 % -0.70 [ -1.05, -0.35 ]
Subtotal (95% CI) 96 46 14.3 % -0.70 [ -1.05, -0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.88 (P = 0.00010)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 125 -1.3 (1.34) 65 -1.06 (1.36) 13.0 % -0.24 [ -0.65, 0.17 ]
Subtotal (95% CI) 125 65 13.0 % -0.24 [ -0.65, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 128 -1.24 (1.35) 65 -1.06 (1.36) 13.0 % -0.18 [ -0.58, 0.22 ]
Findling 2009 99 -1.8 (1.22) 46 -0.7 (0.91) 14.3 % -1.10 [ -1.46, -0.74 ]
Subtotal (95% CI) 227 111 27.2 % -0.65 [ -1.55, 0.26 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 11.18, df = 1 (P = 0.00083); I2 =91%
Test for overall effect: Z = 1.40 (P = 0.16)
Total (95% CI) 891 658 100.0 % -0.52 [ -0.75, -0.29 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 18.28, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Chi2 = 3.14, df = 3 (P = 0.37), I2 =4%
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Analysis 1.17. Comparison 1 Aripiprazole versus placebo, Outcome 17 CGI-Bipolar Version: severity
(overall)-mean change at six weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 17 CGI-Bipolar Version: severity (overall) mean change at six weeks
Study or subgroup Aripiprazole Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 246 -1.6 (1.3) 130 -1.3 (1.2) 69.0 % -0.30 [ -0.56, -0.04 ]
Subtotal (95% CI) 246 130 69.0 % -0.30 [ -0.56, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
2 Aripiprazole variable dose versus placebo as monotherapy
Tramontina 2009 18 2.05 (1.6) 25 1.64 (1.3) 31.0 % 0.41 [ -0.49, 1.31 ]
Subtotal (95% CI) 18 25 31.0 % 0.41 [ -0.49, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 264 155 100.0 % -0.08 [ -0.72, 0.56 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 2.21, df = 1 (P = 0.14), I2 =55%
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Analysis 1.18. Comparison 1 Aripiprazole versus placebo, Outcome 18 CGI-Bipolar Version: improvement
(overall)-mean change at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 18 CGI-Bipolar Version: improvement (overall) mean change at three weeks
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 124 3.4 (1.6) 123 4.2 (1.6) 35.0 % -0.80 [ -1.20, -0.40 ]
Subtotal (95% CI) 124 123 35.0 % -0.80 [ -1.20, -0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000085)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 127 3.24 (1.69) 65 3.35 (1.48) 31.9 % -0.11 [ -0.57, 0.35 ]
Subtotal (95% CI) 127 65 31.9 % -0.11 [ -0.57, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 3.18 (1.47) 65 3.35 (1.48) 33.1 % -0.17 [ -0.61, 0.27 ]
Subtotal (95% CI) 129 65 33.1 % -0.17 [ -0.61, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 380 253 100.0 % -0.37 [ -0.82, 0.08 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 6.40, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 6.40, df = 2 (P = 0.04), I2 =69%
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Analysis 1.19. Comparison 1 Aripiprazole versus placebo, Outcome 19 Mean change in MADRS from
baseline to week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 19 Mean change in MADRS from baseline to week three
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 154 -2.1 (7.45) 163 -0.7 (7.66) 43.1 % -1.40 [ -3.06, 0.26 ]
Young 2009 166 -1.8 (5.15) 152 -2.1 (4.93) 56.9 % 0.30 [ -0.81, 1.41 ]
Total (95% CI) 320 315 100.0 % -0.43 [ -2.08, 1.22 ]
Heterogeneity: Tau2 = 0.92; Chi2 = 2.78, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Aripiprazole versus placebo, Outcome 20 Mean change in PANSS total score
at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 20 Mean change in PANSS total score at week three
Study or subgroup Aripiprazole Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole 15 mg versus placebo
CN138-007 101 -9.56 (18.63) 44 -10.12 (18.48) 9.6 % 0.56 [ -6.00, 7.12 ]
Subtotal (95% CI) 101 44 9.6 % 0.56 [ -6.00, 7.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
2 Aripiprazole 30 mg versus placebo
CN138-007 93 -11.57 (19.16) 44 -10.12 (18.48) 9.2 % -1.45 [ -8.16, 5.26 ]
Subtotal (95% CI) 93 44 9.2 % -1.45 [ -8.16, 5.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
3 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 130 -9.5 (15.96) 142 -4.9 (16.68) 27.4 % -4.60 [ -8.48, -0.72 ]
Young 2009 166 -8.2 (12.88) 143 -4.7 (11.96) 53.8 % -3.50 [ -6.27, -0.73 ]
Subtotal (95% CI) 296 285 81.2 % -3.87 [ -6.13, -1.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00077)
Total (95% CI) 490 373 100.0 % -3.22 [ -5.26, -1.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.07, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Chi2 = 1.86, df = 2 (P = 0.39), I2 =0.0%
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Analysis 1.21. Comparison 1 Aripiprazole versus placebo, Outcome 21 Mean change in PANSS-hostility
subscale score at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 21 Mean change in PANSS-hostility subscale score at week three
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo
Sachs 2006 124 -2.21 (4.12) 122 -0.82 (4.08) 24.8 % -1.39 [ -2.41, -0.37 ]
Subtotal (95% CI) 124 122 24.8 % -1.39 [ -2.41, -0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
2 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 130 -2.1 (3.42) 142 -1 (3.57) 37.7 % -1.10 [ -1.93, -0.27 ]
Young 2009 166 -2.3 (3.87) 143 -1.2 (3.59) 37.5 % -1.10 [ -1.93, -0.27 ]
Subtotal (95% CI) 296 285 75.2 % -1.10 [ -1.69, -0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00025)
Total (95% CI) 420 407 100.0 % -1.17 [ -1.68, -0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 1.22. Comparison 1 Aripiprazole versus placebo, Outcome 22 Mean change in PANSS cognitive
subscale score at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 22 Mean change in PANSS cognitive subscale score at week three
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole 15 mg versus placebo
CN138-007 101 -2.11 (5.02) 44 -2.69 (4.99) 12.1 % 0.58 [ -1.19, 2.35 ]
Subtotal (95% CI) 101 44 12.1 % 0.58 [ -1.19, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Aripiprazole 30 mg versus placebo
CN138-007 93 -3.14 (19.16) 44 -2.69 (4.99) 2.2 % -0.45 [ -4.61, 3.71 ]
Subtotal (95% CI) 93 44 2.2 % -0.45 [ -4.61, 3.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
3 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 130 -2 (4.56) 142 -0.9 (4.77) 30.9 % -1.10 [ -2.21, 0.01 ]
Young 2009 166 -2.4 (3.87) 143 -1.51 (3.59) 54.8 % -0.89 [ -1.72, -0.06 ]
Subtotal (95% CI) 296 285 85.7 % -0.97 [ -1.63, -0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
Total (95% CI) 490 373 100.0 % -0.77 [ -1.38, -0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.68, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 2.59, df = 2 (P = 0.27), I2 =23%
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Analysis 1.23. Comparison 1 Aripiprazole versus placebo, Outcome 23 Requirement for anticholinergics.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 23 Requirement for anticholinergics
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo
Vieta 2008 47/253 9/131 67.9 % 2.70 [ 1.37, 5.34 ]
Subtotal (95% CI) 253 131 67.9 % 2.70 [ 1.37, 5.34 ]
Total events: 47 (Aripiprazole), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 11/98 2/50 15.7 % 2.81 [ 0.65, 12.18 ]
Subtotal (95% CI) 98 50 15.7 % 2.81 [ 0.65, 12.18 ]
Total events: 11 (Aripiprazole), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Aripiprazole 30 mg versus placebo as monotherapy
Findling 2009 17/99 2/99 16.4 % 8.50 [ 2.02, 35.82 ]
Subtotal (95% CI) 99 99 16.4 % 8.50 [ 2.02, 35.82 ]
Total events: 17 (Aripiprazole), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
Total (95% CI) 450 280 100.0 % 3.28 [ 1.82, 5.91 ]
Total events: 75 (Aripiprazole), 13 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.07, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 3.96 (P = 0.000075)
Test for subgroup differences: Chi2 = 2.03, df = 2 (P = 0.36), I2 =2%
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Analysis 1.24. Comparison 1 Aripiprazole versus placebo, Outcome 24 Requirement for lorazepam.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 24 Requirement for lorazepam
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keck 2003 109/127 108/127 90.9 % 1.01 [ 0.91, 1.12 ]
Vieta 2008 53/253 32/131 9.1 % 0.86 [ 0.58, 1.26 ]
Total (95% CI) 380 258 100.0 % 0.99 [ 0.88, 1.12 ]
Total events: 162 (aripiprazole), 140 (placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Aripiprazole versus placebo, Outcome 25 Numbers completing double-blind
treatment.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 25 Numbers completing double-blind treatment
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 54/130 28/132 3.9 % 1.96 [ 1.33, 2.88 ]
Keck 2009 73/155 78/165 8.2 % 1.00 [ 0.79, 1.26 ]
Sachs 2006 75/137 70/135 8.7 % 1.06 [ 0.84, 1.32 ]
Tramontina 2009 17/18 24/25 13.8 % 0.98 [ 0.86, 1.13 ]
Young 2009 126/167 109/153 14.2 % 1.06 [ 0.93, 1.21 ]
Subtotal (95% CI) 607 610 48.7 % 1.10 [ 0.94, 1.29 ]
Total events: 345 (Aripiprazole), 309 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 13.29, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 84/98 38/49 11.5 % 1.11 [ 0.93, 1.31 ]
Subtotal (95% CI) 98 49 11.5 % 1.11 [ 0.93, 1.31 ]
Total events: 84 (Aripiprazole), 38 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
3 Aripiprazole 30 mg versus placebo as monotherapy
Findling 2009 38/49 38/49 9.1 % 1.00 [ 0.81, 1.24 ]
Subtotal (95% CI) 49 49 9.1 % 1.00 [ 0.81, 1.24 ]
Total events: 38 (Aripiprazole), 38 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 122/181 131/189 13.7 % 0.97 [ 0.85, 1.12 ]
Vieta 2008 199/253 111/131 16.9 % 0.93 [ 0.84, 1.02 ]
Subtotal (95% CI) 434 320 30.6 % 0.94 [ 0.87, 1.02 ]
Total events: 321 (Aripiprazole), 242 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Total (95% CI) 1188 1028 100.0 % 1.03 [ 0.95, 1.12 ]
Total events: 788 (Aripiprazole), 627 (Placebo)
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(. . . Continued)
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.01; Chi2 = 18.08, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 4.70, df = 3 (P = 0.19), I2 =36%
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Analysis 1.26. Comparison 1 Aripiprazole versus placebo, Outcome 26 Failure to complete treatment-
dropouts: adverse drug reaction.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 26 Failure to complete treatment dropouts: adverse drug reaction
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 14/130 13/132 12.8 % 1.09 [ 0.53, 2.24 ]
Keck 2009 23/155 13/165 15.8 % 1.88 [ 0.99, 3.59 ]
Sachs 2006 12/137 10/135 10.1 % 1.18 [ 0.53, 2.64 ]
Young 2009 14/167 16/153 14.0 % 0.80 [ 0.40, 1.59 ]
Subtotal (95% CI) 589 585 52.7 % 1.20 [ 0.83, 1.74 ]
Total events: 63 (Aripiprazole), 52 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.97 (P = 0.33)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 4/98 1/49 1.4 % 2.00 [ 0.23, 17.42 ]
Subtotal (95% CI) 98 49 1.4 % 2.00 [ 0.23, 17.42 ]
Total events: 4 (Aripiprazole), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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(. . . Continued)
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 20/131 4/66 6.1 % 2.52 [ 0.90, 7.07 ]
Subtotal (95% CI) 131 66 6.1 % 2.52 [ 0.90, 7.07 ]
Total events: 20 (Aripiprazole), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.079)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 9/135 4/66 5.0 % 1.10 [ 0.35, 3.44 ]
Findling 2009 7/99 1/49 1.5 % 3.46 [ 0.44, 27.38 ]
Subtotal (95% CI) 234 115 6.6 % 1.44 [ 0.53, 3.90 ]
Total events: 16 (Aripiprazole), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 23/181 25/189 23.4 % 0.96 [ 0.57, 1.63 ]
Vieta 2008 23/253 7/131 9.7 % 1.70 [ 0.75, 3.86 ]
Subtotal (95% CI) 434 320 33.2 % 1.17 [ 0.69, 2.00 ]
Total events: 46 (Aripiprazole), 32 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 1486 1135 100.0 % 1.26 [ 0.97, 1.63 ]
Total events: 149 (Aripiprazole), 94 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.82, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 2.09, df = 4 (P = 0.72), I2 =0.0%
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Analysis 1.27. Comparison 1 Aripiprazole versus placebo, Outcome 27 Failure to complete treatment-
dropouts: lack of efficacy.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 27 Failure to complete treatment dropouts: lack of efficacy
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 13/130 16/132 11.7 % 0.83 [ 0.41, 1.65 ]
Keck 2009 9/155 36/165 11.6 % 0.27 [ 0.13, 0.53 ]
Sachs 2006 12/137 28/135 12.9 % 0.42 [ 0.22, 0.80 ]
Young 2009 9/167 14/153 9.7 % 0.59 [ 0.26, 1.32 ]
Subtotal (95% CI) 589 585 46.0 % 0.48 [ 0.30, 0.77 ]
Total events: 43 (Aripiprazole), 94 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.55, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 10/181 11/189 9.4 % 0.95 [ 0.41, 2.18 ]
Vieta 2008 12/253 6/131 7.8 % 1.04 [ 0.40, 2.70 ]
Subtotal (95% CI) 434 320 17.2 % 0.99 [ 0.53, 1.85 ]
Total events: 22 (Aripiprazole), 17 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
3 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 2/98 4/49 3.2 % 0.25 [ 0.05, 1.32 ]
Subtotal (95% CI) 98 49 3.2 % 0.25 [ 0.05, 1.32 ]
Total events: 2 (Aripiprazole), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
4 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 23/127 17/65 14.7 % 0.69 [ 0.40, 1.20 ]
Subtotal (95% CI) 127 65 14.7 % 0.69 [ 0.40, 1.20 ]
Total events: 23 (Aripiprazole), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
5 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 32/129 17/65 15.8 % 0.95 [ 0.57, 1.57 ]
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(. . . Continued)
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Findling 2009 2/99 4/49 3.2 % 0.25 [ 0.05, 1.30 ]
Subtotal (95% CI) 228 114 19.0 % 0.62 [ 0.18, 2.12 ]
Total events: 34 (Aripiprazole), 21 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 1476 1133 100.0 % 0.61 [ 0.44, 0.84 ]
Total events: 124 (Aripiprazole), 153 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 15.18, df = 9 (P = 0.09); I2 =41%
Test for overall effect: Z = 3.04 (P = 0.0024)
Test for subgroup differences: Chi2 = 4.52, df = 4 (P = 0.34), I2 =11%
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Analysis 1.28. Comparison 1 Aripiprazole versus placebo, Outcome 28 Participants meeting criteria for
treatment as outpatients.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 28 Participants meeting criteria for treatment as outpatients
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keck 2003 54/130 28/132 54.1 % 1.96 [ 1.33, 2.88 ]
Sachs 2006 38/137 27/135 45.9 % 1.39 [ 0.90, 2.14 ]
Total (95% CI) 267 267 100.0 % 1.67 [ 1.19, 2.34 ]
Total events: 92 (Aripiprazole), 55 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Aripiprazole versus placebo, Outcome 29 Simpson Angus Scale.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 29 Simpson Angus Scale
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 123 -0.48 (2.62) 120 -0.1 (1.79) 17.1 % -0.38 [ -0.94, 0.18 ]
Keck 2009 154 0.62 (1.98) 164 0.15 (1.92) 18.5 % 0.47 [ 0.04, 0.90 ]
Subtotal (95% CI) 277 284 35.6 % 0.07 [ -0.77, 0.90 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 5.54, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 95 0.61 (2.24) 46 -0.05 (0.58) 18.0 % 0.66 [ 0.18, 1.14 ]
Subtotal (95% CI) 95 46 18.0 % 0.66 [ 0.18, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0071)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 127 0.77 (2.56) 65 -0.09 (2.56) 14.8 % 0.86 [ 0.09, 1.63 ]
Subtotal (95% CI) 127 65 14.8 % 0.86 [ 0.09, 1.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 1.79 (2.57) 65 -0.09 (2.56) 14.9 % 1.88 [ 1.12, 2.64 ]
Findling 2009 99 1.17 (2.91) 46 -0.05 (0.58) 16.7 % 1.22 [ 0.62, 1.82 ]
Subtotal (95% CI) 228 111 31.6 % 1.51 [ 0.86, 2.15 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 4.60 (P < 0.00001)
Total (95% CI) 727 506 100.0 % 0.75 [ 0.20, 1.30 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 27.27, df = 5 (P = 0.00005); I2 =82%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Chi2 = 7.99, df = 3 (P = 0.05), I2 =62%
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Analysis 1.30. Comparison 1 Aripiprazole versus placebo, Outcome 30 Barnes Akathisia Scale.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 30 Barnes Akathisia Scale
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 123 0.33 (1.17) 120 -0.11 (0.7) 15.8 % 0.44 [ 0.20, 0.68 ]
Keck 2009 154 0.21 (0.74) 164 0.04 (0.76) 25.4 % 0.17 [ 0.01, 0.33 ]
Sachs 2006 135 0.25 (2.9) 129 0.05 (0.56) 4.8 % 0.20 [ -0.30, 0.70 ]
Subtotal (95% CI) 412 413 46.0 % 0.27 [ 0.08, 0.46 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 2.75 (P = 0.0059)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -0.03 (0.55) 46 -0.05 (0.62) 19.1 % 0.02 [ -0.19, 0.23 ]
Subtotal (95% CI) 96 46 19.1 % 0.02 [ -0.19, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 127 0.24 (1.1) 65 -0.11 (1.1) 9.8 % 0.35 [ 0.02, 0.68 ]
Subtotal (95% CI) 127 65 9.8 % 0.35 [ 0.02, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 129 0.14 (1.11) 65 -0.11 (1.1) 9.8 % 0.25 [ -0.08, 0.58 ]
Findling 2009 99 0.05 (0.87) 46 -0.05 (0.62) 15.2 % 0.10 [ -0.15, 0.35 ]
Subtotal (95% CI) 228 111 25.1 % 0.15 [ -0.04, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 863 635 100.0 % 0.20 [ 0.09, 0.31 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.22, df = 6 (P = 0.22); I2 =27%
Test for overall effect: Z = 3.44 (P = 0.00057)
Test for subgroup differences: Chi2 = 4.16, df = 3 (P = 0.24), I2 =28%
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Analysis 1.31. Comparison 1 Aripiprazole versus placebo, Outcome 31 Abnormal Involuntary Movement
Scale.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 31 Abnormal Involuntary Movement Scale
Study or subgroup aripiprazole placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 99 0.01 (1.09) 77 -0.16 (1.08) 15.5 % 0.17 [ -0.15, 0.49 ]
Keck 2009 154 0.07 (1.11) 164 0.1 (1.15) 26.3 % -0.03 [ -0.28, 0.22 ]
Subtotal (95% CI) 253 241 41.8 % 0.04 [ -0.15, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 96 -0.02 (0.56) 46 -0.02 (0.78) 25.6 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 96 46 25.6 % 0.0 [ -0.25, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 102 -0.51 (1.74) 45 -0.34 (1.75) 4.3 % -0.17 [ -0.78, 0.44 ]
Subtotal (95% CI) 102 45 4.3 % -0.17 [ -0.78, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 95 -0.3 (1.79) 45 -0.34 (1.75) 4.1 % 0.04 [ -0.59, 0.67 ]
Findling 2009 99 0.03 (0.65) 46 -0.02 (0.78) 24.1 % 0.05 [ -0.21, 0.31 ]
Subtotal (95% CI) 194 91 28.3 % 0.05 [ -0.19, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 645 423 100.0 % 0.02 [ -0.10, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 0.50, df = 3 (P = 0.92), I2 =0.0%
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Analysis 1.32. Comparison 1 Aripiprazole versus placebo, Outcome 32 Manic reaction.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 32 Manic reaction
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 3/130 0/132 10.7 % 7.11 [ 0.37, 136.24 ]
Subtotal (95% CI) 130 132 10.7 % 7.11 [ 0.37, 136.24 ]
Total events: 3 (aripiprazole), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 6/131 3/67 48.0 % 1.02 [ 0.26, 3.96 ]
Subtotal (95% CI) 131 67 48.0 % 1.02 [ 0.26, 3.96 ]
Total events: 6 (aripiprazole), 3 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 4/136 3/67 41.3 % 0.66 [ 0.15, 2.85 ]
Subtotal (95% CI) 136 67 41.3 % 0.66 [ 0.15, 2.85 ]
Total events: 4 (aripiprazole), 3 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 397 266 100.0 % 1.05 [ 0.40, 2.78 ]
Total events: 13 (aripiprazole), 6 (placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 2.00, df = 2 (P = 0.37), I2 =0%
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Analysis 1.33. Comparison 1 Aripiprazole versus placebo, Outcome 33 Hypertension.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 33 Hypertension
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 1/130 0/132 17.7 % 3.05 [ 0.13, 74.09 ]
Subtotal (95% CI) 130 132 17.7 % 3.05 [ 0.13, 74.09 ]
Total events: 1 (Aripiprazole), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 8/131 1/67 42.5 % 4.09 [ 0.52, 32.04 ]
Subtotal (95% CI) 131 67 42.5 % 4.09 [ 0.52, 32.04 ]
Total events: 8 (Aripiprazole), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 5/136 1/67 39.8 % 2.46 [ 0.29, 20.67 ]
Subtotal (95% CI) 136 67 39.8 % 2.46 [ 0.29, 20.67 ]
Total events: 5 (Aripiprazole), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 397 266 100.0 % 3.17 [ 0.83, 12.14 ]
Total events: 14 (Aripiprazole), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
Test for subgroup differences: Chi2 = 0.11, df = 2 (P = 0.94), I2 =0.0%
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Analysis 1.34. Comparison 1 Aripiprazole versus placebo, Outcome 34 Headache.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 34 Headache
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 49/130 45/132 25.7 % 1.11 [ 0.80, 1.53 ]
Keck 2009 37/155 38/165 17.2 % 1.04 [ 0.70, 1.54 ]
Sachs 2006 35/137 35/135 16.6 % 0.99 [ 0.66, 1.48 ]
Subtotal (95% CI) 422 432 59.4 % 1.05 [ 0.85, 1.30 ]
Total events: 121 (aripiprazole), 118 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 17/98 9/50 5.0 % 0.96 [ 0.46, 2.01 ]
Subtotal (95% CI) 98 50 5.0 % 0.96 [ 0.46, 2.01 ]
Total events: 17 (aripiprazole), 9 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 41/131 18/67 12.2 % 1.16 [ 0.73, 1.86 ]
Subtotal (95% CI) 131 67 12.2 % 1.16 [ 0.73, 1.86 ]
Total events: 41 (aripiprazole), 18 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 36/136 18/67 11.5 % 0.99 [ 0.61, 1.60 ]
Findling 2009 19/99 9/50 5.3 % 1.07 [ 0.52, 2.18 ]
Subtotal (95% CI) 235 117 16.8 % 1.01 [ 0.68, 1.51 ]
Total events: 55 (aripiprazole), 27 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 5/180 10/189 2.4 % 0.53 [ 0.18, 1.51 ]
Vieta 2008 14/253 9/131 4.1 % 0.81 [ 0.36, 1.81 ]
Subtotal (95% CI) 433 320 6.5 % 0.69 [ 0.36, 1.31 ]
Total events: 19 (aripiprazole), 19 (placebo)
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(. . . Continued)
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 1319 986 100.0 % 1.02 [ 0.87, 1.21 ]
Total events: 253 (aripiprazole), 191 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 8 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 1.86, df = 4 (P = 0.76), I2 =0.0%
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Analysis 1.35. Comparison 1 Aripiprazole versus placebo, Outcome 35 Anxiety.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 35 Anxiety
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 26/130 18/132 38.8 % 1.47 [ 0.85, 2.54 ]
Sachs 2006 15/137 13/135 23.7 % 1.14 [ 0.56, 2.30 ]
Subtotal (95% CI) 267 267 62.5 % 1.33 [ 0.86, 2.05 ]
Total events: 41 (aripiprazole), 31 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 16/131 8/67 18.5 % 1.02 [ 0.46, 2.27 ]
Subtotal (95% CI) 131 67 18.5 % 1.02 [ 0.46, 2.27 ]
Total events: 16 (aripiprazole), 8 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
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(. . . Continued)
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 17/136 8/67 18.9 % 1.05 [ 0.48, 2.30 ]
Subtotal (95% CI) 136 67 18.9 % 1.05 [ 0.48, 2.30 ]
Total events: 17 (aripiprazole), 8 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 534 401 100.0 % 1.21 [ 0.86, 1.71 ]
Total events: 74 (aripiprazole), 47 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
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Analysis 1.36. Comparison 1 Aripiprazole versus placebo, Outcome 36 Insomnia.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 36 Insomnia
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 22/130 16/132 28.7 % 1.40 [ 0.77, 2.54 ]
Subtotal (95% CI) 130 132 28.7 % 1.40 [ 0.77, 2.54 ]
Total events: 22 (aripiprazole), 16 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 10/180 10/189 14.1 % 1.05 [ 0.45, 2.46 ]
Vieta 2008 20/253 6/131 13.0 % 1.73 [ 0.71, 4.19 ]
Subtotal (95% CI) 433 320 27.0 % 1.33 [ 0.72, 2.46 ]
Total events: 30 (aripiprazole), 16 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 21/131 11/67 22.9 % 0.98 [ 0.50, 1.90 ]
Subtotal (95% CI) 131 67 22.9 % 0.98 [ 0.50, 1.90 ]
Total events: 21 (aripiprazole), 11 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 18/136 11/67 21.4 % 0.81 [ 0.40, 1.61 ]
Subtotal (95% CI) 136 67 21.4 % 0.81 [ 0.40, 1.61 ]
Total events: 18 (aripiprazole), 11 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 830 586 100.0 % 1.13 [ 0.82, 1.55 ]
Total events: 91 (aripiprazole), 54 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.50, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Chi2 = 1.86, df = 3 (P = 0.60), I2 =0.0%
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Analysis 1.37. Comparison 1 Aripiprazole versus placebo, Outcome 37 Light-headedness.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 37 Light-headedness
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 21/130 15/132 37.4 % 1.42 [ 0.77, 2.63 ]
Sachs 2006 13/137 16/135 29.7 % 0.80 [ 0.40, 1.60 ]
Subtotal (95% CI) 267 267 67.1 % 1.09 [ 0.62, 1.91 ]
Total events: 34 (aripiprazole), 31 (placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.30 (P = 0.76)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 14/131 6/66 17.2 % 1.18 [ 0.47, 2.92 ]
Subtotal (95% CI) 131 66 17.2 % 1.18 [ 0.47, 2.92 ]
Total events: 14 (aripiprazole), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 11/135 6/66 15.7 % 0.90 [ 0.35, 2.32 ]
Subtotal (95% CI) 135 66 15.7 % 0.90 [ 0.35, 2.32 ]
Total events: 11 (aripiprazole), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 533 399 100.0 % 1.08 [ 0.74, 1.57 ]
Total events: 59 (aripiprazole), 43 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
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Analysis 1.38. Comparison 1 Aripiprazole versus placebo, Outcome 38 Akathisia.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 38 Akathisia
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 17/130 8/132 17.6 % 2.16 [ 0.96, 4.82 ]
Keck 2009 18/155 6/165 14.2 % 3.19 [ 1.30, 7.84 ]
Sachs 2006 25/137 8/135 19.8 % 3.08 [ 1.44, 6.58 ]
Subtotal (95% CI) 422 432 51.6 % 2.75 [ 1.72, 4.41 ]
Total events: 60 (aripiprazole), 22 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 8/98 2/50 5.0 % 2.04 [ 0.45, 9.25 ]
Subtotal (95% CI) 98 50 5.0 % 2.04 [ 0.45, 9.25 ]
Total events: 8 (aripiprazole), 2 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.35)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 18/131 1/67 2.9 % 9.21 [ 1.26, 67.48 ]
Subtotal (95% CI) 131 67 2.9 % 9.21 [ 1.26, 67.48 ]
Total events: 18 (aripiprazole), 1 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 15/136 1/67 2.8 % 7.39 [ 1.00, 54.77 ]
Findling 2009 11/99 2/50 5.3 % 2.78 [ 0.64, 12.05 ]
Subtotal (95% CI) 235 117 8.1 % 3.91 [ 1.20, 12.77 ]
Total events: 26 (aripiprazole), 3 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 20/180 4/189 10.3 % 5.25 [ 1.83, 15.06 ]
Vieta 2008 47/253 8/131 22.1 % 3.04 [ 1.48, 6.25 ]
Subtotal (95% CI) 433 320 32.4 % 3.62 [ 2.00, 6.55 ]
Total events: 67 (aripiprazole), 12 (placebo)
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(. . . Continued)
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 4.24 (P = 0.000022)
Total (95% CI) 1319 986 100.0 % 3.16 [ 2.25, 4.43 ]
Total events: 179 (aripiprazole), 40 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.03, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 6.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.08, df = 4 (P = 0.72), I2 =0.0%
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Analysis 1.39. Comparison 1 Aripiprazole versus placebo, Outcome 39 Nausea.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 39 Nausea
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 32/130 18/132 18.5 % 1.81 [ 1.07, 3.05 ]
Keck 2009 36/155 23/165 22.5 % 1.67 [ 1.04, 2.68 ]
Sachs 2006 30/137 23/135 21.3 % 1.29 [ 0.79, 2.09 ]
Subtotal (95% CI) 422 432 62.3 % 1.56 [ 1.17, 2.08 ]
Total events: 98 (aripiprazole), 64 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 9/98 3/50 3.2 % 1.53 [ 0.43, 5.40 ]
Subtotal (95% CI) 98 50 3.2 % 1.53 [ 0.43, 5.40 ]
Total events: 9 (aripiprazole), 3 (placebo)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.66 (P = 0.51)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 23/131 9/67 10.0 % 1.31 [ 0.64, 2.66 ]
Subtotal (95% CI) 131 67 10.0 % 1.31 [ 0.64, 2.66 ]
Total events: 23 (aripiprazole), 9 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 18/136 9/67 9.2 % 0.99 [ 0.47, 2.07 ]
Findling 2009 12/99 3/50 3.4 % 2.02 [ 0.60, 6.83 ]
Subtotal (95% CI) 235 117 12.6 % 1.20 [ 0.63, 2.26 ]
Total events: 30 (aripiprazole), 12 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
5 Aripiprazole versus placebo as add-on to lithium or valproate
NCT00665366 10/180 5/189 4.6 % 2.10 [ 0.73, 6.02 ]
Vieta 2008 21/253 7/131 7.4 % 1.55 [ 0.68, 3.56 ]
Subtotal (95% CI) 433 320 12.0 % 1.74 [ 0.91, 3.34 ]
Total events: 31 (aripiprazole), 12 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 1319 986 100.0 % 1.50 [ 1.20, 1.88 ]
Total events: 191 (aripiprazole), 100 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.05, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Chi2 = 0.91, df = 4 (P = 0.92), I2 =0.0%
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Analysis 1.40. Comparison 1 Aripiprazole versus placebo, Outcome 40 Dyspepsia.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 40 Dyspepsia
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 31/130 18/132 31.4 % 1.75 [ 1.03, 2.96 ]
Sachs 2006 22/137 12/135 23.4 % 1.81 [ 0.93, 3.50 ]
Subtotal (95% CI) 267 267 54.8 % 1.77 [ 1.17, 2.68 ]
Total events: 53 (aripiprazole), 30 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0066)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 21/131 11/67 23.1 % 0.98 [ 0.50, 1.90 ]
Subtotal (95% CI) 131 67 23.1 % 0.98 [ 0.50, 1.90 ]
Total events: 21 (aripiprazole), 11 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 18/131 11/67 22.1 % 0.84 [ 0.42, 1.67 ]
Subtotal (95% CI) 131 67 22.1 % 0.84 [ 0.42, 1.67 ]
Total events: 18 (aripiprazole), 11 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 529 401 100.0 % 1.31 [ 0.89, 1.92 ]
Total events: 92 (aripiprazole), 52 (placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.41, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 4.40, df = 2 (P = 0.11), I2 =55%
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Analysis 1.41. Comparison 1 Aripiprazole versus placebo, Outcome 41 Vomiting.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 41 Vomiting
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 23/130 11/132 28.5 % 2.12 [ 1.08, 4.18 ]
Sachs 2006 16/137 12/135 27.2 % 1.31 [ 0.65, 2.67 ]
Subtotal (95% CI) 267 267 55.6 % 1.69 [ 1.04, 2.76 ]
Total events: 39 (aripiprazole), 23 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 8/98 5/50 16.7 % 0.82 [ 0.28, 2.37 ]
Subtotal (95% CI) 98 50 16.7 % 0.82 [ 0.28, 2.37 ]
Total events: 8 (aripiprazole), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 14/131 1/67 6.0 % 7.16 [ 0.96, 53.29 ]
Subtotal (95% CI) 131 67 6.0 % 7.16 [ 0.96, 53.29 ]
Total events: 14 (aripiprazole), 1 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 7/136 1/67 5.7 % 3.45 [ 0.43, 27.46 ]
Findling 2009 7/99 5/50 16.0 % 0.71 [ 0.24, 2.12 ]
Subtotal (95% CI) 235 117 21.7 % 1.23 [ 0.27, 5.61 ]
Total events: 14 (aripiprazole), 6 (placebo)
Heterogeneity: Tau2 = 0.61; Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 731 501 100.0 % 1.47 [ 0.87, 2.48 ]
Total events: 75 (aripiprazole), 35 (placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 7.37, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Chi2 = 3.83, df = 3 (P = 0.28), I2 =22%
0.02 0.1 1 10 50
Favours aripiprazole Favours placebo
111Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.42. Comparison 1 Aripiprazole versus placebo, Outcome 42 Constipation.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 42 Constipation
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 20/130 12/132 27.5 % 1.69 [ 0.86, 3.32 ]
Keck 2009 17/155 11/165 23.7 % 1.65 [ 0.80, 3.40 ]
Sachs 2006 17/137 9/135 20.9 % 1.86 [ 0.86, 4.03 ]
Subtotal (95% CI) 422 432 72.1 % 1.72 [ 1.14, 2.61 ]
Total events: 54 (aripiprazole), 32 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 19/131 5/67 14.1 % 1.94 [ 0.76, 4.98 ]
Subtotal (95% CI) 131 67 14.1 % 1.94 [ 0.76, 4.98 ]
Total events: 19 (aripiprazole), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 17/136 5/67 13.7 % 1.68 [ 0.65, 4.35 ]
Subtotal (95% CI) 136 67 13.7 % 1.68 [ 0.65, 4.35 ]
Total events: 17 (aripiprazole), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 689 566 100.0 % 1.75 [ 1.23, 2.49 ]
Total events: 90 (aripiprazole), 42 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.06, df = 2 (P = 0.97), I2 =0.0%
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Analysis 1.43. Comparison 1 Aripiprazole versus placebo, Outcome 43 Diarrhoea.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 43 Diarrhoea
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 18/130 16/132 31.5 % 1.14 [ 0.61, 2.14 ]
Sachs 2006 9/137 13/135 18.7 % 0.68 [ 0.30, 1.54 ]
Subtotal (95% CI) 267 267 50.2 % 0.94 [ 0.57, 1.55 ]
Total events: 27 (aripiprazole), 29 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 11/253 8/131 15.8 % 0.71 [ 0.29, 1.73 ]
Subtotal (95% CI) 253 131 15.8 % 0.71 [ 0.29, 1.73 ]
Total events: 11 (aripiprazole), 8 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 Aripiprazole 15mg versus placebo as monotherapy
CN138-007 13/131 8/67 18.0 % 0.83 [ 0.36, 1.91 ]
Subtotal (95% CI) 131 67 18.0 % 0.83 [ 0.36, 1.91 ]
Total events: 13 (aripiprazole), 8 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 10/136 8/67 16.0 % 0.62 [ 0.25, 1.49 ]
Subtotal (95% CI) 136 67 16.0 % 0.62 [ 0.25, 1.49 ]
Total events: 10 (aripiprazole), 8 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 787 532 100.0 % 0.82 [ 0.58, 1.17 ]
Total events: 61 (aripiprazole), 53 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.77, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 0.80, df = 3 (P = 0.85), I2 =0.0%
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Analysis 1.44. Comparison 1 Aripiprazole versus placebo, Outcome 44 Pain extremity.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 44 Pain extremity
Study or subgroup aripiprazole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Sachs 2006 15/137 9/135 63.4 % 1.64 [ 0.74, 3.62 ]
Subtotal (95% CI) 137 135 63.4 % 1.64 [ 0.74, 3.62 ]
Total events: 15 (aripiprazole), 9 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 10/131 2/67 17.9 % 2.56 [ 0.58, 11.34 ]
Subtotal (95% CI) 131 67 17.9 % 2.56 [ 0.58, 11.34 ]
Total events: 10 (aripiprazole), 2 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
3 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 13/136 2/67 18.7 % 3.20 [ 0.74, 13.78 ]
Subtotal (95% CI) 136 67 18.7 % 3.20 [ 0.74, 13.78 ]
Total events: 13 (aripiprazole), 2 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 404 269 100.0 % 2.01 [ 1.07, 3.78 ]
Total events: 38 (aripiprazole), 13 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.030)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.45. Comparison 1 Aripiprazole versus placebo, Outcome 45 Somnolence.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 45 Somnolence
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Sachs 2006 28/137 16/135 29.1 % 1.72 [ 0.98, 3.04 ]
Subtotal (95% CI) 137 135 29.1 % 1.72 [ 0.98, 3.04 ]
Total events: 28 (Aripiprazole), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
2 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 19/98 2/50 14.1 % 4.85 [ 1.18, 19.99 ]
Subtotal (95% CI) 98 50 14.1 % 4.85 [ 1.18, 19.99 ]
Total events: 19 (Aripiprazole), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 10/131 6/67 20.9 % 0.85 [ 0.32, 2.24 ]
Subtotal (95% CI) 131 67 20.9 % 0.85 [ 0.32, 2.24 ]
Total events: 10 (Aripiprazole), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 12/136 6/67 21.6 % 0.99 [ 0.39, 2.51 ]
Findling 2009 26/99 2/50 14.3 % 6.57 [ 1.62, 26.56 ]
Subtotal (95% CI) 235 117 35.9 % 2.38 [ 0.34, 16.79 ]
Total events: 38 (Aripiprazole), 8 (Placebo)
Heterogeneity: Tau2 = 1.63; Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 601 369 100.0 % 1.85 [ 0.94, 3.65 ]
Total events: 95 (Aripiprazole), 32 (Placebo)
Heterogeneity: Tau2 = 0.33; Chi2 = 9.50, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Chi2 = 4.16, df = 3 (P = 0.24), I2 =28%
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Analysis 1.46. Comparison 1 Aripiprazole versus placebo, Outcome 46 Tremor.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 46 Tremor
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 23/253 8/131 38.5 % 1.49 [ 0.68, 3.24 ]
Subtotal (95% CI) 253 131 38.5 % 1.49 [ 0.68, 3.24 ]
Total events: 23 (Aripiprazole), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 12/155 9/165 33.2 % 1.42 [ 0.62, 3.27 ]
Subtotal (95% CI) 155 165 33.2 % 1.42 [ 0.62, 3.27 ]
Total events: 12 (Aripiprazole), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
3 Aripiprazole 15 mg versus placebo as monotherapy
CN138-007 9/131 3/67 14.3 % 1.53 [ 0.43, 5.48 ]
Subtotal (95% CI) 131 67 14.3 % 1.53 [ 0.43, 5.48 ]
Total events: 9 (Aripiprazole), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
4 Aripiprazole 30 mg versus placebo as monotherapy
CN138-007 8/136 3/67 13.9 % 1.31 [ 0.36, 4.79 ]
Subtotal (95% CI) 136 67 13.9 % 1.31 [ 0.36, 4.79 ]
Total events: 8 (Aripiprazole), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 675 430 100.0 % 1.45 [ 0.89, 2.34 ]
Total events: 52 (Aripiprazole), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.04, df = 3 (P = 1.00), I2 =0.0%
0.2 0.5 1 2 5
Favours aripiprazole Favours placebo
116Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.47. Comparison 1 Aripiprazole versus placebo, Outcome 47 EPS.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 47 EPS
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole versus placebo as add-on to lithium or valproate
Vieta 2008 71/253 19/131 43.3 % 1.93 [ 1.22, 3.07 ]
Subtotal (95% CI) 253 131 43.3 % 1.93 [ 1.22, 3.07 ]
Total events: 71 (Aripiprazole), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
2 Aripiprazole variable dose versus placebo as monotherapy
Keck 2009 36/155 21/165 40.4 % 1.82 [ 1.12, 2.98 ]
Subtotal (95% CI) 155 165 40.4 % 1.82 [ 1.12, 2.98 ]
Total events: 36 (Aripiprazole), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
3 Aripiprazole 10 mg versus placebo as monotherapy
Findling 2009 23/98 2/50 8.2 % 5.87 [ 1.44, 23.89 ]
Subtotal (95% CI) 98 50 8.2 % 5.87 [ 1.44, 23.89 ]
Total events: 23 (Aripiprazole), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.014)
4 Aripiprazole 30 mg versus placebo as monotherapy
Findling 2009 20/99 2/50 8.2 % 5.05 [ 1.23, 20.75 ]
Subtotal (95% CI) 99 50 8.2 % 5.05 [ 1.23, 20.75 ]
Total events: 20 (Aripiprazole), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Total (95% CI) 605 396 100.0 % 2.24 [ 1.47, 3.42 ]
Total events: 150 (Aripiprazole), 44 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.18, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.73 (P = 0.00019)
Test for subgroup differences: Chi2 = 3.97, df = 3 (P = 0.26), I2 =24%
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Analysis 1.48. Comparison 1 Aripiprazole versus placebo, Outcome 48 Weight gain (≥ 7% increase from
baseline).
Review: Aripiprazole alone or in combination for acute mania
Comparison: 1 Aripiprazole versus placebo
Outcome: 48 Weight gain (≥ 7% increase from baseline)
Study or subgroup Aripiprazole Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aripiprazole variable dose versus placebo as monotherapy
Keck 2003 5/130 5/132 12.3 % 1.02 [ 0.30, 3.42 ]
Sachs 2006 2/137 6/135 7.2 % 0.33 [ 0.07, 1.60 ]
Young 2009 14/167 22/153 45.2 % 0.58 [ 0.31, 1.10 ]
Subtotal (95% CI) 434 420 64.8 % 0.61 [ 0.36, 1.03 ]
Total events: 21 (Aripiprazole), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
2 Aripiprazole variable dose versus placebo as add-on to lithium or valproate
NCT00665366 9/174 8/184 21.0 % 1.19 [ 0.47, 3.01 ]
Vieta 2008 7/253 5/131 14.3 % 0.72 [ 0.23, 2.24 ]
Subtotal (95% CI) 427 315 35.2 % 0.97 [ 0.48, 2.00 ]
Total events: 16 (Aripiprazole), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 861 735 100.0 % 0.72 [ 0.47, 1.10 ]
Total events: 37 (Aripiprazole), 46 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.80, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 1.08, df = 1 (P = 0.30), I2 =7%
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Analysis 2.1. Comparison 2 Aripiprazole versus other drug treatment, Outcome 1 Mean change in YMRS
from baseline at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 1 Mean change in YMRS from baseline at week three
Study or subgroup Aripiprazole
Other
drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 174 -15.7 (10.94) 162 -15.65 (10.94) 31.0 % -0.05 [ -2.39, 2.29 ]
Young 2009 166 -11.98 (10.31) 161 -12.83 (10.15) 34.5 % 0.85 [ -1.37, 3.07 ]
Subtotal (95% CI) 340 323 65.5 % 0.42 [ -1.19, 2.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
2 Versus lithium
Keck 2009 154 -12.64 (9.93) 155 -12.03 (9.96) 34.5 % -0.61 [ -2.83, 1.61 ]
Subtotal (95% CI) 154 155 34.5 % -0.61 [ -2.83, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 494 478 100.0 % 0.07 [ -1.24, 1.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 2.2. Comparison 2 Aripiprazole versus other drug treatment, Outcome 2 Mean change in YMRS
from baseline at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 2 Mean change in YMRS from baseline at week 12
Study or subgroup Aripiprazole
Other
drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 174 -19.93 (12.92) 162 -18.22 (12.98) 44.8 % -1.71 [ -4.48, 1.06 ]
Subtotal (95% CI) 174 162 44.8 % -1.71 [ -4.48, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Versus lithium
Keck 2009 154 -14.48 (11.17) 155 -12.7 (11.2) 55.2 % -1.78 [ -4.27, 0.71 ]
Subtotal (95% CI) 154 155 55.2 % -1.78 [ -4.27, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Total (95% CI) 328 317 100.0 % -1.75 [ -3.60, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 2.3. Comparison 2 Aripiprazole versus other drug treatment, Outcome 3 Response ≥ 50%
decrease in YMRS from baseline at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 3 Response≥ 50% decrease in YMRS from baseline at week three
Study or subgroup aripiprazole
other drug
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol
Vieta 2005 68/175 40/172 32.3 % 1.67 [ 1.20, 2.32 ]
Young 2009 67/167 67/161 35.7 % 0.96 [ 0.74, 1.25 ]
Subtotal (95% CI) 342 333 68.1 % 1.26 [ 0.73, 2.16 ]
Total events: 135 (aripiprazole), 107 (other drug treatment)
Heterogeneity: Tau2 = 0.13; Chi2 = 6.68, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Versus lithium
Keck 2009 44/155 51/160 31.9 % 0.89 [ 0.64, 1.25 ]
Subtotal (95% CI) 155 160 31.9 % 0.89 [ 0.64, 1.25 ]
Total events: 44 (aripiprazole), 51 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 497 493 100.0 % 1.12 [ 0.77, 1.63 ]
Total events: 179 (aripiprazole), 158 (other drug treatment)
Heterogeneity: Tau2 = 0.08; Chi2 = 8.73, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 1.12, df = 1 (P = 0.29), I2 =11%
0.5 0.7 1 1.5 2
Favours other treatment Favours aripiprazole
121Aripiprazole alone or in combination for acute mania (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Aripiprazole versus other drug treatment, Outcome 4 CGI-Bipolar Version:
severity (mania)-mean change at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 4 CGI-Bipolar Version: severity (mania) mean change at week three
Study or subgroup Aripiprazole
Other
drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 -2 (1.78) 164 -1.9 (1.12) 27.8 % -0.10 [ -0.42, 0.22 ]
Young 2009 166 -1.44 (1.29) 161 -1.56 (1.27) 36.1 % 0.12 [ -0.16, 0.40 ]
Subtotal (95% CI) 339 325 63.9 % 0.02 [ -0.19, 0.24 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 0.21 (P = 0.83)
2 Versus lithium
Keck 2009 153 -1.48 (1.24) 154 -1.34 (1.24) 36.1 % -0.14 [ -0.42, 0.14 ]
Subtotal (95% CI) 153 154 36.1 % -0.14 [ -0.42, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 492 479 100.0 % -0.04 [ -0.20, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.84, df = 1 (P = 0.36), I2 =0.0%
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Analysis 2.5. Comparison 2 Aripiprazole versus other drug treatment, Outcome 5 CGI-Bipolar Version:
severity (mania)-mean change at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 5 CGI-Bipolar Version: severity (mania) mean change at week 12
Study or subgroup Aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 -2.58 (1.7) 164 -2.27 (1.66) 37.4 % -0.31 [ -0.67, 0.05 ]
Subtotal (95% CI) 173 164 37.4 % -0.31 [ -0.67, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
2 Versus lithium
Keck 2009 153 -1.7 (1.24) 154 -1.53 (1.24) 62.6 % -0.17 [ -0.45, 0.11 ]
Subtotal (95% CI) 153 154 62.6 % -0.17 [ -0.45, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 326 318 100.0 % -0.22 [ -0.44, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.55), I2 =0.0%
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Analysis 2.6. Comparison 2 Aripiprazole versus other drug treatment, Outcome 6 CGI-Bipolar Version:
severity (depression)-mean change at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 6 CGI-Bipolar Version: severity (depression) mean change at week 12
Study or subgroup Aripiprazole
Other
drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 0.2 (0.92) 164 0.27 (1.02) 64.1 % -0.07 [ -0.28, 0.14 ]
Subtotal (95% CI) 173 164 64.1 % -0.07 [ -0.28, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Versus lithium
Keck 2009 153 -0.2 (1.24) 154 -0.1 (1.24) 35.9 % -0.10 [ -0.38, 0.18 ]
Subtotal (95% CI) 153 154 35.9 % -0.10 [ -0.38, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 326 318 100.0 % -0.08 [ -0.25, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 2.7. Comparison 2 Aripiprazole versus other drug treatment, Outcome 7 CGI-Bipolar Version:
severity (overall)-mean change at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 7 CGI-Bipolar Version: severity (overall) mean change at week 12
Study or subgroup Aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 -2.01 (1.58) 164 -1.6 (1.53) 41.1 % -0.41 [ -0.74, -0.08 ]
Subtotal (95% CI) 173 164 41.1 % -0.41 [ -0.74, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
2 Versus lithium
Keck 2009 153 -1.5 (1.24) 154 -1.3 (1.24) 58.9 % -0.20 [ -0.48, 0.08 ]
Subtotal (95% CI) 153 154 58.9 % -0.20 [ -0.48, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 326 318 100.0 % -0.29 [ -0.50, -0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 2.8. Comparison 2 Aripiprazole versus other drug treatment, Outcome 8 CGI-Bipolar Version:
improvement (mania)-mean change at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 8 CGI-Bipolar Version: improvement (mania) mean change at week three
Study or subgroup aripiprazole
other drug
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Versus haloperidol
Young 2009 166 2.66 (1.29) 161 2.56 (1.27) 0.10 [ -0.18, 0.38 ]
2 Versus lithium
Keck 2009 153 2.53 (1.24) 154 2.87 (1.24) -0.34 [ -0.62, -0.06 ]
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Analysis 2.9. Comparison 2 Aripiprazole versus other drug treatment, Outcome 9 Mean change in MADRS
from baseline at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 9 Mean change in MADRS from baseline at week three
Study or subgroup aripirpazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 -3.12 (6.44) 162 -1.57 (6.36) 33.4 % -1.55 [ -2.92, -0.18 ]
Young 2009 166 -1.8 (5.15) 161 -2.5 (5.08) 37.2 % 0.70 [ -0.41, 1.81 ]
Subtotal (95% CI) 339 323 70.6 % -0.39 [ -2.59, 1.82 ]
Heterogeneity: Tau2 = 2.13; Chi2 = 6.25, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Versus lithium
Keck 2009 154 -2.1 (7.45) 155 -1.1 (7.47) 29.4 % -1.00 [ -2.66, 0.66 ]
Subtotal (95% CI) 154 155 29.4 % -1.00 [ -2.66, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 493 478 100.0 % -0.55 [ -2.03, 0.92 ]
Heterogeneity: Tau2 = 1.20; Chi2 = 6.97, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 2.10. Comparison 2 Aripiprazole versus other drug treatment, Outcome 10 Mean change in
MADRS from baseline at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 10 Mean change in MADRS from baseline at week 12
Study or subgroup Aripiprazole
Other
drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 -1.96 (7.89) 162 -0.71 (7.89) 63.2 % -1.25 [ -2.94, 0.44 ]
Subtotal (95% CI) 173 162 63.2 % -1.25 [ -2.94, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 Versus lithium
Keck 2009 154 -0.9 (9.93) 155 -0.2 (9.96) 36.8 % -0.70 [ -2.92, 1.52 ]
Subtotal (95% CI) 154 155 36.8 % -0.70 [ -2.92, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 327 317 100.0 % -1.05 [ -2.39, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 2.11. Comparison 2 Aripiprazole versus other drug treatment, Outcome 11 Mean change in
PANSS-total at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 11 Mean change in PANSS-total at week three
Study or subgroup aripripazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Young 2009 166 -8.2 (12.88) 148 -8.8 (12.17) 60.0 % 0.60 [ -2.17, 3.37 ]
Subtotal (95% CI) 166 148 60.0 % 0.60 [ -2.17, 3.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 Versus lithium
Keck 2009 130 -9.5 (15.96) 138 -7 (16.44) 40.0 % -2.50 [ -6.38, 1.38 ]
Subtotal (95% CI) 130 138 40.0 % -2.50 [ -6.38, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 296 286 100.0 % -0.64 [ -3.62, 2.34 ]
Heterogeneity: Tau2 = 1.85; Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 1.62, df = 1 (P = 0.20), I2 =38%
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Analysis 2.12. Comparison 2 Aripiprazole versus other drug treatment, Outcome 12 Mean change in
PANSS-cognitive subscale score at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 12 Mean change in PANSS-cognitive subscale score at week three
Study or subgroup aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Young 2009 166 -2.4 (3.87) 148 -2.5 (3.65) 64.0 % 0.10 [ -0.73, 0.93 ]
Subtotal (95% CI) 166 148 64.0 % 0.10 [ -0.73, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Versus lithium
Keck 2009 130 -2 (4.56) 138 -1.6 (4.7) 36.0 % -0.40 [ -1.51, 0.71 ]
Subtotal (95% CI) 130 138 36.0 % -0.40 [ -1.51, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 296 286 100.0 % -0.08 [ -0.75, 0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.13. Comparison 2 Aripiprazole versus other drug treatment, Outcome 13 Mean change in
PANSS-hostility subscale score at week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 13 Mean change in PANSS-hostility subscale score at week three
Study or subgroup aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Young 2009 166 -2.3 (3.87) 148 -2.6 (3.65) 50.0 % 0.30 [ -0.53, 1.13 ]
Subtotal (95% CI) 166 148 50.0 % 0.30 [ -0.53, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 Versus lithium
Keck 2009 130 -2.1 (3.42) 138 -1.6 (3.52) 50.0 % -0.50 [ -1.33, 0.33 ]
Subtotal (95% CI) 130 138 50.0 % -0.50 [ -1.33, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 296 286 100.0 % -0.10 [ -0.88, 0.68 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 1.78, df = 1 (P = 0.18), I2 =44%
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Analysis 2.14. Comparison 2 Aripiprazole versus other drug treatment, Outcome 14 Simpson Angus Scale
LOCF at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 14 Simpson Angus Scale LOCF at week 12
Study or subgroup aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 1.02 (5.52) 160 5.7 (5.57) 49.4 % -4.68 [ -5.87, -3.49 ]
Subtotal (95% CI) 173 160 49.4 % -4.68 [ -5.87, -3.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.69 (P < 0.00001)
2 Versus lithium
Keck 2009 154 0.62 (2.35) 159 0.18 (2.39) 50.6 % 0.44 [ -0.09, 0.97 ]
Subtotal (95% CI) 154 159 50.6 % 0.44 [ -0.09, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 327 319 100.0 % -2.09 [ -7.11, 2.93 ]
Heterogeneity: Tau2 = 12.89; Chi2 = 59.33, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 59.33, df = 1 (P = 0.00), I2 =98%
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Analysis 2.15. Comparison 2 Aripiprazole versus other drug treatment, Outcome 15 Barnes Akathisia
Scale LOCF at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 15 Barnes Akathisia Scale LOCF at week 12
Study or subgroup Aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 173 0.32 (1.18) 160 0.8 (1.14) 49.1 % -0.48 [ -0.73, -0.23 ]
Subtotal (95% CI) 173 160 49.1 % -0.48 [ -0.73, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
2 Versus lithium
Keck 2009 154 0.18 (0.86) 159 0.06 (0.88) 50.9 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 154 159 50.9 % 0.12 [ -0.07, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 327 319 100.0 % -0.17 [ -0.76, 0.41 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 13.93, df = 1 (P = 0.00019); I2 =93%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 13.93, df = 1 (P = 0.00), I2 =93%
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Analysis 2.16. Comparison 2 Aripiprazole versus other drug treatment, Outcome 16 Abnormal Involuntary
Movement Scale LOCF at week 12.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 16 Abnormal Involuntary Movement Scale LOCF at week 12
Study or subgroup aripiprazole
other drug
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Versus haloperidol
Vieta 2005 167 0.14 (1.81) 154 0.81 (1.86) 46.4 % -0.67 [ -1.07, -0.27 ]
Subtotal (95% CI) 167 154 46.4 % -0.67 [ -1.07, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
2 Versus lithium
Keck 2009 154 -0.05 (0.86) 159 -0.06 (0.75) 53.6 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 154 159 53.6 % 0.01 [ -0.17, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 321 313 100.0 % -0.31 [ -0.97, 0.36 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 9.17, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 9.17, df = 1 (P = 0.00), I2 =89%
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Analysis 2.17. Comparison 2 Aripiprazole versus other drug treatment, Outcome 17 Akathisia.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 17 Akathisia
Study or subgroup Aripiprazole
other drug
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Versus haloperidol (over 12 weeks)
Vieta 2005 20/175 39/169 0.50 [ 0.30, 0.81 ]
2 Versus lithium (over 12 weeks)
Keck 2009 23/154 8/159 2.97 [ 1.37, 6.43 ]
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Analysis 2.18. Comparison 2 Aripiprazole versus other drug treatment, Outcome 18 Headache.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 18 Headache
Study or subgroup Aripiprazole
other drug
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol (over 12 weeks)
Vieta 2005 19/175 20/169 32.4 % 0.92 [ 0.51, 1.66 ]
Subtotal (95% CI) 175 169 32.4 % 0.92 [ 0.51, 1.66 ]
Total events: 19 (Aripiprazole), 20 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.78)
2 Versus lithium (over 12 weeks)
Keck 2009 36/154 35/159 67.6 % 1.06 [ 0.71, 1.60 ]
Subtotal (95% CI) 154 159 67.6 % 1.06 [ 0.71, 1.60 ]
Total events: 36 (Aripiprazole), 35 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 329 328 100.0 % 1.01 [ 0.72, 1.42 ]
Total events: 55 (Aripiprazole), 55 (other drug treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.19. Comparison 2 Aripiprazole versus other drug treatment, Outcome 19 Tremor.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 19 Tremor
Study or subgroup Aripiprazole
other drug
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol (over 12 weeks)
Vieta 2005 12/175 17/169 48.6 % 0.68 [ 0.34, 1.38 ]
Subtotal (95% CI) 175 169 48.6 % 0.68 [ 0.34, 1.38 ]
Total events: 12 (Aripiprazole), 17 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 Versus lithium (over 12 weeks)
Keck 2009 12/154 19/159 51.4 % 0.65 [ 0.33, 1.30 ]
Subtotal (95% CI) 154 159 51.4 % 0.65 [ 0.33, 1.30 ]
Total events: 12 (Aripiprazole), 19 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 329 328 100.0 % 0.67 [ 0.41, 1.09 ]
Total events: 24 (Aripiprazole), 36 (other drug treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 2.20. Comparison 2 Aripiprazole versus other drug treatment, Outcome 20 Numbers completing
at end of week three.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 20 Numbers completing at end of week three
Study or subgroup Aripiprazole
other drug
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol
Vieta 2005 134/175 95/172 34.5 % 1.39 [ 1.18, 1.62 ]
Young 2009 126/167 121/165 36.8 % 1.03 [ 0.91, 1.17 ]
Subtotal (95% CI) 342 337 71.3 % 1.19 [ 0.88, 1.60 ]
Total events: 260 (Aripiprazole), 216 (other drug treatment)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.64, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Versus lithium
Keck 2009 73/155 78/160 28.7 % 0.97 [ 0.77, 1.22 ]
Subtotal (95% CI) 155 160 28.7 % 0.97 [ 0.77, 1.22 ]
Total events: 73 (Aripiprazole), 78 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 497 497 100.0 % 1.12 [ 0.90, 1.39 ]
Total events: 333 (Aripiprazole), 294 (other drug treatment)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.36, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.18, df = 1 (P = 0.28), I2 =15%
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Analysis 2.21. Comparison 2 Aripiprazole versus other drug treatment, Outcome 21 Numbers completing
the trial (at end of week 12).
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 21 Numbers completing the trial (at end of week 12)
Study or subgroup Aripiprazole
other drug
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol
Vieta 2005 89/175 50/172 33.1 % 1.75 [ 1.33, 2.30 ]
Young 2009 95/167 95/165 35.9 % 0.99 [ 0.82, 1.19 ]
Subtotal (95% CI) 342 337 69.0 % 1.30 [ 0.74, 2.31 ]
Total events: 184 (Aripiprazole), 145 (other drug treatment)
Heterogeneity: Tau2 = 0.16; Chi2 = 11.89, df = 1 (P = 0.00056); I2 =92%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Versus lithium
Keck 2009 42/155 54/160 31.0 % 0.80 [ 0.57, 1.13 ]
Subtotal (95% CI) 155 160 31.0 % 0.80 [ 0.57, 1.13 ]
Total events: 42 (Aripiprazole), 54 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 497 497 100.0 % 1.12 [ 0.73, 1.71 ]
Total events: 226 (Aripiprazole), 199 (other drug treatment)
Heterogeneity: Tau2 = 0.12; Chi2 = 15.65, df = 2 (P = 0.00040); I2 =87%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 2.04, df = 1 (P = 0.15), I2 =51%
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Analysis 2.22. Comparison 2 Aripiprazole versus other drug treatment, Outcome 22 Failure to complete
treatment: dropouts-lack of efficacy at three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 22 Failure to complete treatment: dropouts lack of efficacy at three weeks
Study or subgroup aripiprazole
other drug
treatment Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol (over three weeks)
Young 2009 9/167 10/165 47.1 % 0.88 [ 0.35, 2.23 ]
Subtotal (95% CI) 167 165 47.1 % 0.88 [ 0.35, 2.23 ]
Total events: 9 (aripiprazole), 10 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
2 Versus lithium (over three weeks)
Keck 2009 9/155 26/160 52.9 % 0.32 [ 0.14, 0.70 ]
Subtotal (95% CI) 155 160 52.9 % 0.32 [ 0.14, 0.70 ]
Total events: 9 (aripiprazole), 26 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Total (95% CI) 322 325 100.0 % 0.51 [ 0.19, 1.40 ]
Total events: 18 (aripiprazole), 36 (other drug treatment)
Heterogeneity: Tau2 = 0.33; Chi2 = 2.70, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 2.69, df = 1 (P = 0.10), I2 =63%
0.01 0.1 1 10 100
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Analysis 2.23. Comparison 2 Aripiprazole versus other drug treatment, Outcome 23 Failure to complete
treatment: dropouts-adverse event at end of three weeks.
Review: Aripiprazole alone or in combination for acute mania
Comparison: 2 Aripiprazole versus other drug treatment
Outcome: 23 Failure to complete treatment: dropouts adverse event at end of three weeks
Study or subgroup aripiprazole
other drug
treatment Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Versus haloperidol (over three weeks)
Vieta 2005 17/175 53/172 34.5 % 0.24 [ 0.13, 0.44 ]
Young 2009 14/167 8/165 31.4 % 1.80 [ 0.73, 4.40 ]
Subtotal (95% CI) 342 337 65.9 % 0.64 [ 0.09, 4.56 ]
Total events: 31 (aripiprazole), 61 (other drug treatment)
Heterogeneity: Tau2 = 1.86; Chi2 = 13.34, df = 1 (P = 0.00026); I2 =93%
Test for overall effect: Z = 0.45 (P = 0.66)
2 Versus lithium (over three weeks)
Keck 2009 23/155 20/160 34.1 % 1.22 [ 0.64, 2.32 ]
Subtotal (95% CI) 155 160 34.1 % 1.22 [ 0.64, 2.32 ]
Total events: 23 (aripiprazole), 20 (other drug treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 497 497 100.0 % 0.79 [ 0.22, 2.76 ]
Total events: 54 (aripiprazole), 81 (other drug treatment)
Heterogeneity: Tau2 = 1.09; Chi2 = 19.23, df = 2 (P = 0.00007); I2 =90%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Adverse effects
Control drug Body system Side effects N of compari-
son
N of partici-
pants
Adverse event
rate (%) in arip-
iprazole group
Ad-
verse event rate
(%) in compar-
ison group
Versus placebo Cardiovascular QTc interval ≥
450 msec and
1 262 0 0.8
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Table 1. Adverse effects (Continued)
≥ 10% increase
from baseline
Chest
discomfort
1 262 0 0.8
Syncope 1 262 0 0.8
Dermatological Urticaria 1 262 0 0.8
Neuropsychi-
atric
Agitation 1 262 0 0.8
Dizziness 1 296 5.0 3.0
Fatigue 1 296 11.1 6.0
Asthenia 1 401 11.9 7.5
Dystonia 1 296 2.5 2.0
Depression 1 370 7.8 2.7
Endocrine Prolactin below
normal (< 2 ng/
mL)male adoles-
cents
1 159 50.4 19.6
Prolactin below
normal (< 3 ng/
mL) female ado-
lescents
1 139 27.0 11.6
Other Overdose of
sedatives
1 262 0.8 0
Accidental
injury
1 262 13.8 6.1
Blurred vision 1 296 8.1 2.0
Salivary
hypersecretion
1 296 5.5 2.0
Increased
appetite
1 296 3.5 5.0
Decreased
appetite
1 296 4.5 5.0
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Table 1. Adverse effects (Continued)
Upper abdomi-
nal pain
1 296 4.5 5.0
Versus
haloperidol
Cardiovascular QTc interval ≥
450 msec and
≥ 10% increase
from baseline
1 347 2.3 4.7
Neuropsychi-
atric
Treatment-
emergent
depression mea-
sured by CGI-
BP depression
subscore worsen-
ing by ≥ two
points
1 347 12.0 21.5
Insomnia 1 347 13.7 8.7
Depression 1 347 11.4 15.7
Extrapyramidal
syndrome
1 347 9.1 36.6
Versus lithium Gastrointestinal Constipation 1 315 11.0 11.3
Nausea 1 315 23.2 23.8
Neuropsychi-
atric
Akathisia 1 315 11.6 5.6
Headache 1 315 23.9 20.6
Tremor 1 315 7.7 10.6
Sedation 1 315 12.3 7.5
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A P P E N D I C E S
Appendix 1. MEDLINE search terms
Subject heading “bipolar disorder” (exploded)
Text words: “manic depressive psychosis”, “bipolar disorder*”, “bipolar depress*”, “manic depress*”, “aripiprazole”, “abilify”, “abilitat”,
and “OPC-14597”, and the CAS-registry number “129722-19-9”.
Appendix 2. EMBASE search terms
Subject headings: “bipolar disorder” (exploded) and “aripiprazole”
Text words: “manic depressive psychosis”, “bipolar disorder*”, “bipolar depress*”, “manic depress*”, “aripiprazole”, “abilify”, “abilitat”,
and “OPC-14597”, and the CAS-registry number “129722-19-9”.
Appendix 3. PsycINFO search terms
Subject headings: “bipolar disorder” (exploded) and “aripiprazole”
Text words: “manic depressive psychosis”, “bipolar disorder*”, “bipolar depress*”, “manic depress*”, “aripiprazole”, “abilify”, “abilitat”,
and “OPC-14597”, and the CAS-registry number “129722-19-9”.
Appendix 4. CINAHL search terms
Subject headings: “bipolar disorder” (exploded) and “aripiprazole”
Text words: “manic depressive psychosis”, “bipolar disorder*”, “bipolar depress*”, “manic depress*”, “aripiprazole”, “abilify”, “abilitat”,
and “OPC-14597”, and the CAS-registry number “129722-19-9”.
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D E C L A R A T I O N S O F I N T E R E S T
RB is a mental health pharmacist for Oxford Health NHS Foundation Trust and has attended educational meetings and conferences
sponsored by various drug manufacturers, including the manufacturers of aripiprazole.
MJT has attended educational meetings sponsored by the manufacturers of aripiprazole and by manufacturers of competing products.
JG has received research funding and support from Sanofi-Aventis, GlaxoSmithKline and Lilly UK.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Psychiatry, University of Oxford, UK.
• Oxford Health NHS Foundation Trust, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Authorship: Heather Wilder was listed as an author of the protocol.
Search strategy: We also searched the World Health Organization trials portal (http://apps.who.int/trialsearch/default.aspx).
Methods, primary outcomes: We specified the change in YMRS at three weeks as the primary outcome and this measure at all other
timeframes as secondary outcomes.
Methods: Mortality (as measured by deaths during the study) was added to the types of outcome measure in the Methods section.
Data synthesis: We routinely conducted random-effects analyses and presented these in the effects of intervention section. For our
primary analyses only (not the exploratory analyses), we also conducted fixed-effect analyses.
Background: The Background section has been updated to include details of other reviews and meta-analyses that include aripiprazole
for the treatment of mania.
Bias: We did not examine publication bias using funnel plots, as the studies were too few. With only 10 studies, the power of the tests
is too low to distinguish chance from real asymmetry.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimanic Agents [therapeutic use]; Antipsychotic Agents [adverse effects; ∗therapeutic use]; Bipolar Disorder [drug therapy]; Drug
Therapy, Combination [methods]; Dyskinesia, Drug-Induced [etiology]; Haloperidol [therapeutic use]; Lithium Compounds [ther-
apeutic use]; Piperazines [adverse effects; ∗therapeutic use]; Quinolones [adverse effects; ∗therapeutic use]; Randomized Controlled
Trials as Topic; Valproic Acid [therapeutic use]
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MeSH check words
Adolescent; Adult; Child; Humans
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